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Abbreviations and symbols
ARCON accelerated rad io therapy  w ith carbogen and nicotinam ide
BSA bovine serum  album ine
BOLD blood oxygen level dependence
BrdUrd brom odeoxyuridine
BRU 2-nitroim idazole agent
11C carbon-11
11C-ACE 1-11C-acetate
11C-MET L-methyl-11C-methionine
CA-IX carbonic anhydrase IX
CCD charge-coupled device
CCI-103F hexafluorom isonidazole
CI confidence interval
CT com puted tom ography
CTV clinical ta rg e t volume
60Cu copper-60
60Cu-ATSM 60Cu(H)-diacetyl-bis(W4-m ethylthiosem icarbazone)
DAB diam inobenzidine
DCE-CT dynam ic con trast enhanced CT
DCE-MRI dynam ic con trast enhanced MRI
DSC Dice Similarity Coefficient
EF5 2-(2-nitro-1H-im idazol-1-yl)-N -(2,2,3,3,3-pentafluoropropyl)-acetam ide
EGFR epiderm al grow th factor receptor
f female
9F1 ra t monoclonal to m ouse endothelium
18F fluorine-18
18FAZA 18F-fluoroazomycin arabinoside
18FETNIM 18F-fluoroerythronitrom idazole
18F-EF3 18F-2-(2-nitroim idazol-1-yl)-N -(3,3,3-trifluoropropyl)-acetam ide
18F-FDG 18F-fluorodeoxyglucose
18F-FET O-2-18F-fluoroethyl-L-tyrosine
18F-FLT 3'-deoxy-3’-18F-fluorothym idine
18F-FMISO 18F-fluoromisonidazole
fCA-IX fraction positive for CA-IX
Fig figure
FN false negative
FP false positive
fPIMO fraction positive for pim onidazole
G250 antibody against CA-IX
GC germ inal center
GLUT-1 glucose tran sp o rte r 1
GTV gross tum or volume
GTV5o% GTV based on 50% isocontour
GTV8o% GTV based on 80%  isocontour
G T V sbr GTV based on SBR
Gy Gray [J-kg-1]
H&E hem atoxylin and eosin
HF hypoxic fraction
HIF-1a hypoxia-induced factor 1 alpha
HPV hum an papillom avirus
111In indium -111
IdUrd iododeoxyuridine
IHC im m unohistochem istry
IMRT intensity-m odulated radiation therapy
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Abbreviations and symbols
ITLC instan t thin-layer chrom atography
i.p. in traperitoneal
i.v. intravenous
Ki-67 endogenous proliferation m arker, protein  encoded by MKI67 gene
kV kilo Volt
LI labeling index
LN lymph node
LT lym phoid tissue
M m olarity [mol-L-1]
m male
mAB monoclonal antibody
mAs milliAmpere second
MBq megaBecquerel
MET m etastases
MRI m agnetic resonance imaging
MRND modified radical neck dissection
MRS m agnetic resonance spectroscopy
n.a. not available
n .p. not perform ed
n.r. not represen tative
NS node sam pling
n.s. not significant
15O oxygen-15
15O-H2O 15O-labeled w ater
OR odds ratio
OSEM ordered  subset expectation maximization
PAD prim ary antibody diluent
PBS phosphate buffered saline
PCNA proliferating cell nuclear antigen
PET positron em ission tom ography
PIMO pim onidazole
pim onidazole 1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroim idazole hydrochlori
pO2 arterial partial p ressu re  of oxygen
PTV planning target volume
PPI phosphor imaging system
RCHT rad io therapy  + chem otherapy
RGB red-green-blue
RND radical neck dissection
RTL relative-threshold  level
SD standard  deviation
SEM standard  e rro r of the m ean
SBR signal-to-background ratio
SIB sim ultaneous in tegrated  boost
SND selective neck dissection
SPECT single photon em ission com puted tom ography
SPET single photon em ission tom ography
SUV standardized uptake value
SUVmax maximum SUV
SUVmean m ean SUV
99mTc technecium -99m
TE tum or excision
TK-1 thym idine kinase 1
TLE total laryngectom ie
TN true  negative
TP true  positive
US ultrasound
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Introduction and outline
Chapter 1
1.1 Treatment of head and neck carcinomas
W orldw ide, approx im ate ly  850,000 p a tien ts  annually  p re se n t w ith  squam ous cell 
carcinom as of th e  head  and  neck, and  in the  N etherlands th e  incidence is 2,400 
(w w w .oncoline.nl x). As such, head  and  neck  cancer is ranked  as th e  fifth m o st com m on 
m alignancy in m en and eighth  in w om en. In w este rn  countries, p a tien ts  typically  have a 
h is to ry  of alcohol and  nicotine abuse, a lthough increasing  evidence on th e  ro le  of the  
hum an papillom a v irus em erges in relatively  young  non-sm oking  oropharyngeal cancer 
p a tien ts  2-5. In Asia and  p a rts  of Africa, infection w ith  th e  Epstein-B arr v irus and  betel 
quid chew ing play an im p o rtan t ro le  in th e  developm en t of nasopharyngeal and  oral 
cancer, respectively  4,6. As p a tien ts ’ com plaints are  often ra th e r  vague vary ing  from  
th ro a t ache and  difficulties w ith  sw allow ing to  otalgia, they  often p re se n t w ith  advanced 
stage disease: large, bulky p rim ary  tum ors and frequen tly  uni- o r b ila tera l cervical 
lym ph node m etastases. Generally, head  and  neck cancer firs t poses a loco-regional 
problem , how ever, th e  ra te  of d is tan t (pu lm onary) m etastases  depends on th e  p rim ary  
tu m o r site and  stage. Therefore, m ulti-m odality  tre a tm e n t p rim arily  focuses on loco- 
regional control by surgical resection  of th e  tu m o r and  cervical lym ph node levels, 
rad io th e rap y  of th e  tu m o r and  (potentially) affected lym ph nodes, chem otherapy  for 
enhanced  rad ia tion  efficacy, o r a com bination  of these  7-13. Due to  an increasing  
p reference for organ  p rese rv a tio n  strateg ies, rad io th e rap y  is th e  p rim e m odality  in 
m o st cases 12,14.
1.2 Resistance mechanisms in head and neck tumors
T hree m ajor tu m o r characteristics are  know n th a t adversely  influence rad io th erap y  
outcom e and  prognosis: tu m o r cell hypoxia, clonogenic p ro lifera tion  and  in trinsic  
rad iosensitiv ity  (Fig. 1.1).
In trinsic  rad iosensitiv ity  of squam ous cell carcinom as is generally  classified as 
“in te rm ed ia te” albeit w ith  b ro ad  in te rtu m o r varia tions 15. Factors such as DNA single- 
and  doub le -strand  rep a ir  capacity, and  apop to tic  po ten tia l influence resis tance  to 
rad io th e rap y  16.
A ccelerated tu m o r cell p ro lifera tion  is induced as response  to  cell loss during  
rad io th e rap y  17,18. It is affected by several factors, such as d ifferentiation  of th e  tum or, 
cell-cycle gene regulation , and  m icroenvironm ental factors, including oxygen and 
n u tr ie n t availability. R etrospective analyses of rad ia tion  dose and  tim e re la tions in head 
and  neck cancer have revealed  a decrease in local tu m o r contro l w ith  increasing  overall 
tre a tm e n t tim e 19,20.
Hypoxia ap pears  to  be p re se n t in th e  m ajority  of solid hum an tum ors, including 
squam ous cell carcinom as of th e  head  and  neck. Traditionally , tw o m ajor form s of 
hypoxia are  recognized: “chronic” o r “diffusion-lim ited”, and  “acu te” o r “perfusion- 
lim ited”. T um ors are  vascu larized  by a chaotic ne tw o rk  of blood vessels w ith  changing
12
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vessel d iam eters, leaky vessel w alls and  a rte rio -venous shun ts  21. Chronic hypoxia is 
caused by an exceeding of th e  m axim um  diffusion capacity be tw een  th e  tu m o r cells and 
th e  supply ing  blood vessel leading to  a dep letion  of n u trien ts  and  oxygen 22. The 
underly ing  m echanism  for acute  hypoxia is th e  tra n s ie n t opening  and  closure of 
m alform ed blood vessels resu ltin g  in fluctuations of b lood perfusion  to tu m o r regions 
and  te m p o ra ry  changes in oxygen tensions 23. Often th e  tw o types of hypoxia co-exist, 
w hile dom inance of one type o r the  o th e r m ay vary  over tim e. T here is am ple evidence 
th a t th e  tu m o r oxygenation sta tu s  p red ic ts  th e  p rognosis of head  and  neck and  cervical 
cancer p a tien ts  undergo ing  rad io th e rap y  24-28. H ypoxia-induced genom e and  p ro teom e 
changes m ay p rom ote  tu m o r p rog ression  via various m echanism s. These a lte ra tions  
enable cells to  overcom e oxygen and  n u tr ie n t deprivation , help cells to  escape from  
hostile  env iro n m en t and  favor u n res tric ted  grow th. Cells th u s  change to  a clinically 
m ore aggressive pheno type w ith  increased  p o ten tia l for local invasive grow th , perifocal 
tu m o r cell sp read ing  and  form ation  of regional and  d is tan t m etastases, all negatively 
affecting prognosis 29.
1.3 Treatment modifications counteracting tumor cell hypoxia 
and accelerated proliferation
Shortening  of th e  overall tre a tm e n t tim e is an estab lished  m ethod  to  co u n te rac t tu m o r 
cell repopu la tion  20. “A ccelerated rad io th e rap y ” reduces th e  overall tre a tm e n t tim e by 
delivering m ore than  one fraction  p e r day, a n d /o r  by continuing  tre a tm e n t during  the  
w eekends. W ith acceptable acute toxicity, th e  overall tre a tm e n t tim e can be reduced  up 
to  tw o w eeks w h ils t m ain tain ing  the  sam e to ta l rad ia tion  dose. Several random ized  
tria ls  and  one m eta-analysis have d em o n stra ted  th e  effectiveness of th is approach  30,31.
N um erous s tra teg ies to  overcom e tu m o r cell hypoxia have been  clinically te s ted  32. A 
large m eta-analysis including 86 random ized  clinical tria ls  on various p rim ary  tu m o r 
sites, including 31 tria ls  on head  and  neck  cancer, has show n th a t rad io th erap y  w ith  
oxygenation m odifying tre a tm e n t resu lted  in im proved  loco-regional control [odds ratio  
(OR) 0.77; 95%  confidence in terval (CI), 0.71 to  0.86] and  survival (OR 0.87; 95%  CI,
0.80 to  0.95) com pared  to  rad io th e rap y  alone 33. This study  included tria ls  w ith  
hyperbaric  oxygen, no rm obaric  oxygen, carbogen, hypoxic cell rad iosensitizers, o r a 
com bination  of hyperbaric  oxygen w ith  hypoxic sensitizer 34-38.
A large phase II tria l on a p a tien t co h o rt w ith  advanced  stage head  and  neck cancer w as 
conducted  applying A ccelerated R ad io therapy  w ith  CarbOgen b rea th in g  and 
N icotinam ide (ARCON). In th is clinical study, accelera ted  rad io th e rap y  w as given to 
co u n te rac t accelera ted  tu m o r cell repopu la tion  occurring  during  th e  course of 
trea tm en t. P atien ts b rea th ed  carbogen  (98%  O2 and  2%  CO2) in o rd e r to  raise  the  
a rte ria l partia l p ressu re  of oxygen (pO 2) and  th u s  decrease diffusion-lim ited (chronic) 
hypoxia. The th ird  com ponent, nicotinam ide, w as orally  adm in is te red  in o rd e r to
13
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decrease perfusion-lim ited  (acute) hypoxia by p reven ting  in te rm itte n t vascular 
shu tdow n. N icotinam ide p robab ly  also influences m etabolic processes, including 
oxidative m etabolism  and glycolysis, th a t sh ift th e  oxygen consum ption  ra te  and  acid- 
base balance, and  secondarily  affect tu m o r blood flow and pO 2 . In th is study, th is 
approach  resu lted  in high local and  regional contro l ra tes, especially  for advanced  stage 
laryngeal and  oropharyngeal cancer (actuarial 3 -year contro l ra te s  for th e  p rim ary  
tum or: 80%  and 88% , and  for th e  cervical lym ph nodes: 95%  and 85% , respectively) 37. 
T herefore, a large phase  III clinical tria l add ressing  th e  value of ARCON including 345 
laryngeal cancer p a tien ts  w as in itia ted  and  recen tly  com pleted. Results are  expected to 
be com m unicated  in th e  y ea r 2010.
1.4 Selection of patients
A lthough the  long-term  figures regard ing  th e rap eu tic  outcom e afte r tre a tm e n t 
m odification are  encouraging, n o t all p a tien ts  benefit. P atien ts m ay p re se n t w ith  tum ors  
th a t are  barely  hypoxic o r do n o t develop accelera ted  rep opu la tion  during  irrad iation . 
Intensified tre a tm e n t is associated  w ith  increased  (acute) toxicity: p ro longed  rad ia tion  
induced  m ucositis of increased  severity, and  longer dependence on tem p o ra ry  feeding 
by nasogastric  tube  o r percu tan eo u s gastro stom y  37. T herefore, it is m an d a to ry  to  select 
those  p a tien ts  w ho are  m o st likely to  p ro fit from  tre a tm e n t m odification p rio r to 
tre a tm e n t and  possib ly  also to  ad ju st th e  tre a tm e n t in an early  phase in case of 
insufficient response. This req u ires  pred ic tive assays th a t reliably  assess tu m o r cell 
hypoxia and  p ro lifera tion  p rio r to  and  during  trea tm en t.
The po larograph ic needle e lectrode (Eppendorf™ ) d irectly  m easures pO 2 in accessible 
p rim ary  tu m o rs  and  cervical lym ph node m etastases  24,39,40. The d isadvan tages of th is 
m ethod  include: insufficient coverage of the  en tire  tu m o r o r lym ph node, and 
lim itations regard ing  repetitive  read ings w hen  th e  p ro ced u re  m u st be perfo rm ed  u n d er 
general anesthesia . The m o st im p o rtan t lim itations, how ever, are  th a t th is  m ethod  
canno t d istinguish  necrosis w ith  very  low  pO 2 read ings from  severe hypoxia in viable 
tu m o r areas, and  th a t it does n o t p rov ide in form ation  on th e  re la tion  of hypoxia to  the  
histological a rch itec tu re  and  th e  m icroenv ironm en t of th e  tum or.
T um or cell hypoxia and  p ro lifera tion  can also be assessed  in tu m o r b iopsies ob ta ined  
u n d er local o r general anesthesia  (Fig. 1.2). In travenously  ad m in iste red  b io-reductive 
chem ical m arkers, such as th e  n itro im idazoles pim onidazole, CCI-103F and  EF5, are 
reduced  u n d e r hypoxic conditions and  subsequen tly  sta in  hypoxic tu m o r areas 41,42. 
E ndogenous hypoxia-re lated  m arkers are  physiologically involved in th e  tu m o r cell 
response  to  hypoxia. These include p ro te in s such as hypoxia-inducible factor 1 a  (HIF- 
1a), glucose tra n sp o r te r  1 (Glut-1) and  carbonic anhydrase  IX (CA-IX) 43-46. Clonogenic 
repopu la tion  can be assessed  using th e  exogenous S-phase specific thym id ine analogues
14
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brom odeoxyurid ine  and  iododeoxyurid ine (IdUrd) o r by stain ing  endogenous p ro te in s 
involved in th e  cell cycle, e.g., Ki-67 and  p ro liferating  cell nuc lear an tigen  47-50.
These m ethods, again, have dow nsides: tu m o r b iopsies are  only ob ta ined  from  the 
accessible p a r t  of th e  tu m o r and  m ay n o t alw ays be rep resen ta tiv e  of th e  in tra -tu m o r 
heterogeneity . F urtherm ore , im m unohistochem ical sta in ing  is typically perfo rm ed  on 
tu m o r sections of 5 [im thickness, cu t from  th e  tu m o r biopsy, and  thus again lim its the 
spatial in form ation . Finally, repe titive  tu m o r assessm en t is ham pered  and  only feasible 
in accessible squam ous cell carcinom as of th e  oral cavity o r oropharynx, due to  the  
invasive n a tu re  of b iopsy  acquisition  and  th e  req u ire m en t of general anesthesia  in m ost 
of th e  patien ts.
In conclusion, th e  lim itations of m ethods discussed above call for non-invasive 
anatom ical a n d /o r  functional im aging techniques.
1.5 Non-invasive imaging modalities for tumor characterization 
and response assessment
1.5.1 Anatomical imaging
N on-invasive anatom ical im aging m odalities have th e  advantage of depicting  th e  en tire  
tum or, po ten tially  a t num erous tim e-points. For tu m o rs  of the  larynx and  hypopharynx, 
com puted  tom ography  (CT) w ith  in travenous iodine co n tra s t agen t is th e  im aging 
m odality  of choice. It enables localization and  delineation  of th e  p rim ary  tum or, 
(m etastatic) lym ph nodes, and  su rro u n d in g  tissues th a t are  possib ly  invaded  by the  
p rim ary  tum or, such as th e  th y ro id  cartilage. M agnetic resonance im aging (MRI) w ith  
in travenous ad m in istra tion  of gadolin ium  is the  p re fe rred  m odality  for tum ors of the 
oral cavity and  oropharynx. MRI delivers suprem e soft tissue  c o n tra s t facilitating, for 
exam ple, th e  d ifferen tiation  be tw een  deep tongue m uscu latu re  and  infiltrative tu m o r 
tissue. Along w ith  a tho rough  clinical exam ination of th e  head  and  neck region, CT and 
MRI form  the  co rners tones  for p rim ary  tu m o r staging and  delineation  
(w w w .oncoline.nl). A natom ical im aging m odalities such as CT and  MRI have been  used  
for tu m o r response  evaluation  during  and  afte r tre a tm e n t 51,52. H owever, tu m o r 
shrinkage during  tre a tm e n t occurs relatively  slow, a t a m edian  ra te  of approx im ately  
2%  p er day 51. F u rtherm ore , CT and  MRI are  bo th  h am p ered  by anatom ical changes 
occurring  during  trea tm en t, e.g ., edem a o r developm ent of necrosis, and  by post- 
th e rap eu tic  d is to rted  anatom y caused by tu m o r regression . Functional im aging based  
on CT, MRI, o r p o sitron  em ission tom ography  (PET) m ay n o t only assis t th e  p re ­
tre a tm e n t localization and  delineation  of the  tum or, b u t m ay also define biological 
response  profiles.
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1.5.2 Functional imaging
T here are  d ifferen t types of functional im aging m odalities, som e of w hich have been  
developed based  on anatom ical im aging techniques. Dynamic co n tra s t enhanced  CT 
(DCE-CT) p rovides in form ation  ab o u t blood flow, b lood volum e, capillary perm eability  
and  m icro-vessel density  53,54. T um or perfusion  assessed  by DCE-CT w as show n to be an 
in d ep en d en t p red ic to r for local failure in a large panel of head  and  neck  tu m o rs  54. From  
dynam ic co n tra s t enhanced  MRI (DCE-MRI) and blood oxygen level dependence (BOLD) 
MRI, data  on tissue  perfusion  and  tu m o r oxygenation can be ex tracted  55,56. Diffusion- 
w eigh ted  MRI relies on th e rm al m otion  of w a te r  m olecules occurring  during  cell 
swelling, tu m o r lysis and  necrosis. M agnetic resonance  spectroscopy  (MRS) p rovides 
chem ical in form ation  ab o u t tissue m etabo lites  57,58. The advan tages of th ese  im aging 
m odalities are: b ro ad  availability, high reso lu tion  (DCE-CT and DCE-MRI), possib ility  of 
quantification  and  repetitive  im aging before o r during  the  course of trea tm en t, and  
in co rpo ra tion  in adaptive rad io th erap y  techniques. The d isadvantages include the  
in d irec t n a tu re  of th e  m easurem en ts, th e  lack of m etabolic in fo rm ation  (CT, MRI) and  a 
p o o r reso lu tion  in case of MRS.
PET is a highly sensitive im aging m odality  w ith  a relatively  good tem poral, b u t in ferior 
spatial reso lu tion . The adm in iste red  rad ionuclide em its positrons  th a t annih ila te  w ith  
e lectrons p roducing  tw o pho tons sim ultaneously  traveling  in opposite  d irections. These 
pho tons are  subsequen tly  detected  on a ring  of crystals a rran g ed  a ro u n d  th e  volum e of 
in terest. Coincidental events re su lt in a “sinogram ” th a t is finally reco n stru c ted  for 
im age display. PET enables in vivo  im aging of biologically active m olecules, such as 
peptides, horm ones, m etabolites, and  pharm aceuticals. A varie ty  of tu m o r 
characteristics, i.e ., glucose m etabolism , hypoxia, p ro lifera tion  and  recep to r expression 
can be non-invasively  v isualized w ith  PET using  specific rad iopharm aceu ticals. 
F urtherm ore , PET m ay su p p o rt th e  localization and  delineation  of th e  p rim ary  tu m o r 
and  possib ly  of th e  m etasta tic  cervical lym ph nodes. A dditionally, th e  PET signal m ay 
hold im p o rtan t in fo rm ation  on overall tra c e r  up take w ith in  th e  lesion and  on its intra- 
tu m ora l heterogeneity . The in troduction  of in teg ra ted  PET-CT scanners has fu rth e r 
b ro ad en ed  th e  possib ilities for accurate  tu m o r localization and  characterization .
18F-fluorodeoxyglucose (18FDG) is th e  m o st w idely used  PET trac e r  in oncology, applied 
for tu m o r detection, staging, and  tre a tm e n t resp o n se  m onito ring  59. In th is e ra  of high- 
precision  rad io therapy , 18FDG-PET can provide im p o rtan t com plem entary  inform ation  
for tre a tm e n t p lanning  in head  and  neck tum ors, facilitating norm al tissue sparing  and  
dose escalation to  re s is ta n t tu m o r subvolum es 60-62. However, p rim ary  squam ous cell 
carcinom as of th e  head  and  neck are  often ulcerative lesions accom panied by reactive 
cervical lym ph nodes. Glucose consum ption  of in flam m atory  cells resu lts  in false- 
positive 18FDG-PET read ings and  lim its th e  value of th is trac e r for th is tu m o r entity. 
O ther PET trace rs  are  available th a t m ore  specifically im age featu res of the  tu m o r th a t 
are  re la ted  to  rad ia tion  tre a tm e n t response.
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INTRINSIC
RADIO-
Figure 1.1 Immunohistochemical staining o f a head and neck squamous cell carcinoma. A: Tumor cell 
proliferation (red) and hypoxia (green) relative to blood vessels (yellow). B: Radiation-induced DNA double­
strand breaks (red/yellow) as a measure o f intrinsic radiosensitivity; hypoxia is shown in green, vasculature 
in blue.
Figure 1.2 A: Pseudo-colored image o f a biopsy obtained from  a laryngeal carcinoma 
immunohistochemically stained for vessels (blue), tumor cell hypoxia (pimonidazole, green) and 
proliferation (iododeoxyuridine, red). B: The enlarged detail illustrates the typical distribution o f cells, with 
proliferating tumor cells lining the vasculature, tumor cell hypoxia at a certain distance from the vessels 
(typically 150 ¡im), and finally necrosis (N).
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18F-fluorom isonidazole (18FMISO) is a n itro im idazo le w idely  used  for im aging tu m o r 
cell hypoxia in squam ous cell carcinom as of the  head  and  neck 63,64. It w as show n to 
have bo th  p rognostic  and  p red ic tive value in th is tu m o r en tity  65. F urtherm ore , dose 
escalation stud ies d irec ted  against 18FMISO positive subvolum es o r pixels have 
d em o n stra ted  technical feasibility  64,66,67.
T um or cell p ro liferation  can be non-invasively im aged using 3’-deoxy-3’-18F- 
fluoro thym idine (18FLT) PET. This rad ionuclide reflects th e  activity  of thym id ine kinase 
1 (TK-1), a principal enzym e in th e  salvage pa thw ay  of DNA synthesis 68. Only one study  
had  applied  th is tra c e r  to  head  and  neck squam ous cell carcinom as before w e in itia ted  
ou r clinical stud ies 69. This study  investigated  th e  po ten tia l of 18FLT-PET for tu m o r 
detection, b u t did n o t fu rth er explore th e  functional in fo rm ation  ob ta ined  w ith  18FLT.
1.6 Outline of the thesis
This thesis deals w ith  th e  non-invasive charac teriza tion  of squam ous cell carcinom as of 
th e  head  and  neck using PET, w ith  em phasis on tu m o r cell hypoxia and  proliferation. 
V alidation of these  PET trac e rs  against histopathology, using xenograft tu m o r m odels or 
hum an tu m o r resection  specim en, is a p re-requ isite  before th e ir  w ide clinical 
in troduction . Next, p a tien t selection  for tre a tm e n t m odification based  on these  PET 
findings w ill be th e  aim  of clinical stud ies. F u rth er investigations w ill explore th e  ro le  of 
specific PET trace rs  for response  m on ito ring  and tre a tm e n t adap tation .
In c h a p te r  2 an in tro d u c to ry  overview  regard ing  th e  ro le of PET in rad ia tion  th e rap y  
p lann ing  for head  and  neck tu m o rs  is given. 18FDG-PET can be used  for staging 
purposes, for gross tu m o r volum e delineation, and  for dose escalation to  tu m o r 
subvolum es w ith  high trac e r  uptake. A dditionally, several PET trace rs  are  available th a t 
non-invasively im age biological tu m o r characteristics reflecting rad ia tion  resistance  
m echanism s and  th u s  offer p o ten tia l for ta ilo red  rad ia tion  therapy.
T um or cell hypoxia is one of th e  th ree  m ajor resis tance  m echanism s in head  and  neck 
carcinom as. N on-invasive im aging m odalities depicting  endogenous hypoxia-related  
m arkers, such as carbonic anhydrase  IX (CA-IX), are  being developed. H owever, before 
these  trace rs  can be used  for PET imaging, pre-clinical te sting  using b iod istribu tion  and 
au to rad iog raphy  is com pulsory. In c h a p te r  3, w e exam ined th e  rad ioactively  labeled 
m onoclonal an tibody  against CA-IX, 111In-G250, in a panel of squam ous cell carcinom a 
xenograft lines. B iodistribu tion  of th is rad ioactive tra c e r  and  CA-IX 
im m unoh istochem istry  w ere  com pared  to  hypoxia detected  by  p im onidazole 
im m unohistochem istry . The u ltim ate  aim  w as to  develop and  te s t  th is  tra c e r  for 
applicability  in clinical PET.
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18FMISO is th e  m o st w idely  used  PET tra c e r  for th e  detection  of hypoxia in head  and 
neck tu m o rs  63-67,70,7i. H owever, in co n tra s t to  p im onidazole im m unohistochem istry , 
little w as know n ab o u t th e  m icroregional d istribu tion  of 18FMISO. C h a p te r  4  describes 
a validation  study  of 18FMISO au to rad iog raphy  against p im onidazole 
im m unoh istochem istry  in ten  head  and  neck squam ous cell carcinom a xenograft lines.
A su b seq u en t s tudy  w as conducted  to  assess w h e th e r changes in oxygenation sta tu s  
w ere  also accurately  de tected  by 18FMISO au torad iography . This is described  in 
c h a p te r  5. In th ree  hum an xenograft lines (head  and  neck squam ous cell carcinom a and 
glioblastom a), a lte ra tions  in trac e r  up take a fte r increasing  and  decreasing  th e  hypoxic 
tu m o r sta te  w ere  assessed , com paring  p im onidazole im m unoh istochem istry  and 
18FMISO au torad iography .
P rio r to  assessing  th e  p o ten tia l ro le  of 18FLT-PET for m on ito ring  tu m o r cell p ro lifera tion  
in head  and  neck cancer, a clinical validation  study  w as perfo rm ed  (c h a p te r  6). 
Seventeen p a tien ts  w ith  oral cavity tu m o rs  u n d e rw en t 18FLT-PET before surgical tu m o r 
resection. The exogenous S-phase m ark e r IdUrd w as ad m in iste red  p rio r  to  surgery, and 
tu m o r sam ples w ere  im m unohistochem ically  stained  for IdUrd and  TK-1.
Based on ten  p a tien ts  undergo ing  selective o r (m odified) radical neck dissection, w e 
assessed  th e  value of 18FLT-PET for the  detection  of cervical lym ph node m etastases. 
Results of th is  s tudy  are  p resen ted  in c h a p te r  7.
Finally, c h a p te r  8 show s the  findings of a s tudy  on ten  o ropharyngeal cancer pa tien ts  
undergo ing  th ree  consecutive 18FLT-PET-CT scans, one p rio r  to  and  tw o during  the 
course of rad io th erap y  w ith  o r w ith o u t concom itan t chem otherapy.
C h a p te r  9 p rovides a general d iscussion including fu tu re  perspectives. A sum m ary  of 
th e  w o rk  is given in c h a p te r  10.
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Chapter 2
Abstract
Modern radiotherapy techniques heavily rely on high quality medical imaging. Positron 
emission tomography (PET] provides biological information about the tumor, complementary 
to anatomical imaging. Integrated PET-CT has found its way into the practice of radiation 
oncology and 18F-fluorodeoxyglucose (18FDG) PET is being introduced for radiotherapy 
planning. The functional information possibly augments accurate delineation and treatm ent of 
the tum or and its extensions while reducing the dose to surrounding healthy tissues. In addition 
to 18FDG, other PET tracers are available for imaging specific biological tumor characteristics 
determining radiation resistance. For head and neck cancer, the potential gains of PET imaging 
are increasingly being recognized. This review describes the current role and future 
perspectives of PET for selection and delineation of radiotherapy target volumes and for 
biological tum or characterization in this tumor entity. Furthermore, the potential role of PET for 
early response monitoring, treatm ent modification and patient selection is addressed in this 
review.
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2.1 Innovations in radiotherapy for head and neck tumors
The field of rad ia tion  oncology changed dram atically  w ith  th e  w ide in troduction  of 
com puter optim ized in tensity -m odu lated  rad ia tion  th e ra p y  (IMRT) in th e  1 9 9 0 ‘s. IMRT 
is based  on th e  use of num ero u s rad ia tion  beam s w ith  optim ized non-uniform  
in tensities resu lting  from  inverse tre a tm e n t planning. The algorithm  for beam  fluence 
calculations is guided by dose-volum e objectives for th e  ta rg e t volum e and  organs a t 
risk  delineated  by th e  rad ia tio n  oncologist. IMRT can th u s  achieve m uch b e tte r  dose 
conform ity  th an  conventional rad io th e rap y  techniques. W ith th is technique, d ifferen t 
dose p rescrip tio n s  to  m ultip le ta rg e t sites can be delivered. It also facilitates boosting  of 
th e  p rim ary  tu m o r to high rad ia tion  doses w hile reducing  th e  dose to  rad ia tion  sensitive 
tissues ad jacen t to  th e  tu m o r 1,2. Due to  th e  highly conform al dose d is tribu tion  and  steep 
dose g rad ien ts  used  in IMRT, know ledge ab o u t th e  localization and  boundaries  of the  
p rim ary  tu m o r and  of the  cervical lym ph node m etastases is crucial. For th is purpose, 
biological im aging using p o sitron  em ission tom ography  (PET) m ay augm ent trad itional 
im aging m ethods such as com puted  tom ography  (CT) and  m agnetic resonance im aging 
(MRI) (Fig. 2.1).
2.2 PET for highly accurate radiation treatment planning
2.2.1 Identification of radiotherapy targets based on 18FDG-PET
In a rece n t issue of th is journal, F letcher e t  al. rev iew ed th e  available lite ra tu re  and  a 
m ultid isc ip linary  ex p ert panel developed  recom m endations on th e  use of 18FDG-PET in 
oncology practice 3. These recom m endations on th e  use of 18FDG-PET for th e  detection  
and  staging of head  and  neck tu m o rs  are  briefly  sum m arized  here.
The expert panel concluded th a t 18FDG-PET should  no t be added  to  conventional 
anatom ical im aging in th e  rou tine  d iagnostic w ork-up  of p rim ary  head  and  neck 
tu m o rs  3. This conclusion w as d raw n  as the  available data  w ere  too  u ncerta in  as to 
w h e th e r 18FDG-PET can de term ine  the  anatom ic ex ten t of th e  p rim ary  tu m o r m ore 
accurately  th an  CT o r MRI.
R egarding th e  detection  of cervical lym ph node m etastases, F letcher e t  al. concluded 
th a t 18FDG-PET has a h igher sensitivity, specificity, positive pred ic tive value and 
negative pred ic tive value com pared  to  CT and  MRI. T herefore, its use in ro u tin e  local 
staging w as recom m ended  3. However, th is  recom m endation  did n o t inco rpo ra te  the  
findings of the  m eta-analysis by Kyzas e t  al. th a t w as pub lished  sho rtly  th e re a fte r  4. This 
m eta-analysis rev iew ed 35 stud ies using 18FDG-PET for the  p re tre a tm e n t evaluation  of 
th e  lym ph node status. The au th o rs  concluded th a t th e re  w as no solid evidence to 
su p p o rt th e  rou tine  application  of 18FDG-PET, as th e  sensitiv ity  and  specificity only 
im proved  by 5-7%  com pared  to  conventional im aging m odalities. In th e  su b se t of 
stud ies only enro lling  p a tien ts  w ith o u t clinically a p p a re n t cervical lym ph node
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m etastases, th e  sensitiv ity  w as only 50%  and n o t b e tte r  th an  conventional im aging 
m ethods, specifically u ltraso u n d  w ith  fine needle cytology. From  these  con trad ic to ry  
recom m endations it is clear th a t th is  is an un reso lved  issue th a t req u ires  fu rth e r study.
For th e  detection  of d is tan t m etastases, th e  n e t benefit of using 18FDG-PET w as rep o rte d  
to  be still u ncerta in  3. Functional im aging m ight be beneficial in p a tien ts  w ith  advanced- 
stage disease, in w hom  th e  odds of having d istan t m etastases  are  g rea te r 3. In these  
patien ts, th e  18FDG-PET findings m ay a lte r the  tre a tm e n t in ten tion  from  curative to 
palliative and  th u s  im pact on th e  to ta l dose and  fractionation  schem e. A dditionally, it 
m ay reduce trea tm e n t-re la ted  side-effects in th o se  patien ts, as th e  selected  tre a tm e n t 
volum e is often confined to  the  p rim ary  tu m o r a n d /o r  m etasta tic  lym ph nodes causing 
discom fort or pain. The ro le  of 18FDG-PET(-CT) for th e  early  de tection  of recu rren t 
d isease is add ressed  elsew here  3,5,6.
It can be concluded th a t th e re  is only a m odest ro le  for 18FDG-PET in th e  rou tine  
d iagnostic w orkup  and staging of head  and  neck cancer patien ts. H owever, th is  does n o t 
disqualify 18FDG-PET as a po ten tia lly  useful and  com plem en tary  too l for accurate  
rad io th e rap y  ta rg e t volum e delineation  and  custom ized dose delivery.
Figure 2.1 18FLT-PET-CT scan for image-guided high-precision radiation treatment planning in an
oropharynx carcinoma
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Figure 2.2 (legend on page 30)
Figure 2.3 (legend on page 30)
29
Chapter 2
Figure 2.2 A: CT (left column), 18FDG-PET (middle column) and fused 18FDG-PET-CT (right column)
images o f a patient with a T4N2M0 carcinoma o f the oral cavity. Indicated are gross tumor volume (GTV) 
delineated on CT (G TV ct; red) and PET-based GTVs obtained by visual interpretation (GTVvis; green), 
applying an isocontour o f a standardized uptake value (SUV) o f 2.5 (GTVsuv2.s; orange), using a fixed 
threshold o f 40% (GTV4 0%; yellow) and 50% (GTVsq%; dark blue) o f the maximum signal intensity, applying 
an adaptive threshold based on the signal-to-background ratio (SBR; GTVsbr; light blue). Absolute volumes 
are G T V ct = 47.5 cm3, GTVvis = 43.8 cm3, GTV40% = 20.1 cm3, GTVsq% = 14.9 cm3, GTVsuv2.5 = 32.6 cm3 and 
GTVsbr = 15.7 cm3. B: Same for a patient with a T4N2M0 carcinoma o f the base o f tongue. Absolute volumes 
are G T V ct = 16.9 cm3, GTVvis = 6.9 cm3, GTV4 0% = 15.5 cm3, GTV50% = 7.1 cm3, and GTVsbr = 6.8 cm3. GTVsuv2.5 
was unsuccessful in this patient because o f inclusion o f large areas with normal background signal.
Figure 2.3 Planning CT scan (A), corresponding 18FDG-PET fusion image (B, C) and calculated dose
distribution (D) o f a patient with a T3N2M0 hypopharyngeal carcinoma. Indicated are gross tumor volume 
(GTV) delineated on CT (G TV ct; red) and on 18FDG-PET using an adaptive threshold based on the signal-to- 
background ratio (SBR; GTVsbr; light blue). Absolute volumes are G T V ct = 39.0 cm3 and GTVsbr = 13.1 cm3. 
Also illustrated are the planning target volume (PTV) to 50.3 Gy (pink), to 68.0 Gy (dark blue) and to 72.0 Gy 
(light blue). An additional dose o f 4.0 Gy is directed to the GTVsbr using IMRT with an integrated boost 
technique in an accelerated scheme. A subvolume o f the G T V c t thus receives a total dose o f 72.0 Gy.
2.2.2 18FDG-PET for delineation of the radiation therapy target volume
In th is era  of h igh-precision  rad io therapy , accu ra te  tu m o r volum e delineation  w ith  
respect to  tu m o r boundaries, shape and  volum e is crucial. Target volum e delineation  is 
p rim arily  based  on anatom ical in fo rm ation  of th e  tu m o r and  affected lym ph nodes. A 
tho rough  physical exam ination  of th e  head  and  neck form s th e  basis for assessm en t of 
tu m o r extensions, especially for superficially  sp read ing  m ucosal tum ors. A natom ical 
im aging using CT a n d /o r  MRI prov ides im p o rtan t com plim entary  inform ation  by 
depicting  d is to rted  anatom y and reg ions of abno rm al con trast enhancem ent. For oral 
cavity and  oropharyngeal carcinom as, MRI is th e  p re fe rred  im aging m odality  as it 
achieves a b e tte r  soft-tissue contrast.
T here are  a nu m b er of p o ten tia l advan tages of using 18FDG-PET for ta rg e t volum e 
delineation. 18FDG-PET m ay reduce the  in te ro b se rv e r variab ility  in gross tu m o r volum e 
(GTV) delineation, reduce th e  size of th e  GTV, identify  tu m o r areas o r lym ph nodes 
m issed by CT o r MRI, and  it m ay identify  p arts  of th e  GTV poten tially  requ irin g  an 
add itional rad ia tion  dose. H owever, th e  use of 18FDG-PET also bears  som e 
d isadvantages: th e  lim ited  spatial reso lu tion , th e  lack of a s tand ard ized  m ethod  for 
signal segm entation , and  false-positive 18FDG-PET read ings caused by inflam m ation.
A reduction  of th e  in te ro b se rv e r variab ility  has been  d em o n stra ted  for non-sm all cell 
lung cancer w hen  18FDG-PET w as inco rp o ra ted  in GTV delineation  7,8. In head  and  neck 
cancer patien ts, th is  finding has been  less consisten t. C iernik e t  a l. investigated  th e  value 
of 18FDG-PET in 39 p a tien ts  w ith  various solid tu m o rs  of w hich 12 w ere  head  and  neck 
cancer p a tien ts  9. They found bo th  increases (> 25% ) and  decreases (< 25% ) in half of 
th e  p a tien ts  w hen  GTV delineation  based  on CT alone w as com pared  w ith  18FDG-PET- 
CT. W hen com paring  th e  GTV delineation  be tw een  tw o experienced  rad ia tion  
oncologists, th e  m ean volum e difference of 26.6 cm 3 by CT alone w as reduced  to 9.1 cm 3 
w ith  18FDG-PET-CT 9. Riegel e t  a l. found conflicting resu lts  w hen tw o experienced
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rad ia tion  oncologists and  tw o neu ro rad io log ists  delineated  16 head  and  neck cancer 
p a tien ts  10. On average, th e  GTVs based  on 18FDG-PET-CT w ere  la rger th an  the  
co rrespond ing  CT-based volum es. F u rtherm ore , th e  au th o rs  observed  a large 
d iscrepancy  be tw een  th e  GTV delineation  of th e  tw o rad ia tion  oncologists, one 
delineating  la rger volum es on CT, the  o th e r one on 18FDG-PET-CT 10. One im p o rtan t 
difference be tw een  th e se  tw o stud ies re la tes  to  th resh o ld in g  of th e  18FDG-PET signal: 
C iernik e t  al. chose a fixed th resho ld-level of 50%  of th e  m axim um  signal intensity , 
w hereas Riegel e t  al. used  a d iscre tionary  w indow -level se tting  9,10. The issue of 
segm en tation  of th e  18FDG-PET signal from  background will be add ressed  in one of the  
nex t paragraphs.
A reduction  of th e  GTV using 18FDG-PET has been  d em o n stra ted  in a lan d m ark  study  
including laryngeal cancer p a tien ts  11. The au th o rs  investigated  th e  ro le  of co-registered  
CT, MRI and  18FDG-PET in GTV delineation  of p a tien ts  undergo ing  laryngectom y. 
C om pared to  the  reference surgical specim en, 18FDG-PET w as closest to  dep ic t th e  tru e  
tu m o r volum e. All m odalities overestim ated  th e  extension of th e  tum or, 18FDG-PET w ith  
an average of 29% , CT w ith  65% , and  MRI w ith  89% . H owever, all th ree  im aging 
m odalities, including 18FDG-PET, failed to  identify  a sm all fraction of th e  m acroscopic 
tu m o r (approxim ately  10% ), m ainly consisting of superficial m ucosal extensions.
Before PET-based GTVs can reliab ly  and  rep roducib ly  be inco rp o ra ted  into high- 
precision  rad io th erap y  planning, o p e ra to r-in d ep en d en t segm en tation  tools have to  be 
developed and  validated. Simple v isual in te rp re ta tio n  of the  PET signal is m ost 
com m only applied  b u t highly o p e ra to r dependen t, as it is very  susceptib le to  the  
w indow -level settings of th e  im ages and  in te rp re ta tio n  differences 10,12,13. This is w hy 
research  g roups have explored  m ore  objective m ethods, such as isocon touring  based  on 
a fixed s tan d ard ized  up take value (SUV), e.g., of 2.5, o r th resh o ld s  acqu ired  th rough  
phan tom  experim ents such as a fixed th resh o ld  of th e  m axim um  tu m o r signal in tensity  
(40%  or 50% ) 9,14,15. Daisne e t  al. used  a variab le  th resh o ld  adaptive to  th e  signal-to- 
background  ra tio  (SBR m ethod) in th e ir  s tudy  on laryngeal cancer p a tien ts  16. Recently, 
th e  sam e group  published  a new  g rad ien t-based  segm en tation  tool based  on w ate rsh ed  
tran sfo rm  and h ierarch ical c luster analysis and  validated  th is in an adaptive biological 
im age-guided p lanning  study  17,18. Shortly  thereafte r, van  Dalen e t  al. pub lished  an 
itera tive  b ackg round-sub trac ted  re la tive-th resho ld  level (RTL) m ethod  validated  in 
p a tien ts  w ith  liver m etastases 19. The optim al RTL th e reb y  depends on th e  lesion size, 
b u t n o t on the  signal-to-background ratio. A rece n t study  in 78 head-and-neck  cancer 
p a tien ts  com pared  five com m only used  m ethods of 18FDG-PET signal segm entation  
(visual in te rp re ta tio n , 40%  and 50%  of th e  m axim um  tu m o r signal intensity , fixed SUV 
of 2.5 and  th e  SBR m ethod; Fig. 2.2 and  Table 2.1) 20. The resu lts  show ed  th a t the  
volum e and  th e  shape of th e  re su ltin g  GTV w ere  heavily influenced by th e  choice of the  
segm en tation  tool.
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Figure 2.4 (legend on page 33)
Figure 2.5 (legend on page 33)
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Figure 2.4 Left column: grey-value images obtained after immunohistochemical staining o f the
nitroimidazole hypoxia marker pimonidazole in three xenografted human squamous cell carcinomas o f the 
head and neck (A: SCCNij3, B: SCCNij153, C: SCCNij86). Right column: 18FMISO autoradiography images o f 
the same xenograft tumor sections. Note corresponding staining patterns and signal intensities for  
pimonidazole and 18FMISO in SCCNij3 and SCCNij153 (A and B), but not in SCCNij86 (C).
Figure 2.5 Early response monitoring using 18FLT-PET-CT in a T3N0M0 oropharyngeal carcinoma.
A: CT (left column), 18FLT-PET (middle column) and fused 18FLT-PET-CT (right column) scan prior to 
radiation therapy, indicating the gross tumor volume (GTV) based on CT (G T V ct; red). B: Corresponding CT, 
18FLT-PET and fused 18FLT-PET-CT scan after 8 fractions o f 2 Gy. Note already a significant reduction o f the 
18FLT-PETsignal intensity, while there is only a modest decrease o f the G T V ct at this dose level.
Visual in te rp re ta tio n  of th e  PET signal y ielded volum es close to  those  of CT-based GTV 
delineation, w hereas all au to m ated  segm en tation  m ethods resu lted  in significantly 
sm aller GTVs th an  th e  GTVs based  on clinical in form ation  and  CT alone 20. F urtherm ore , 
in a large percen tage of p a tien ts  (be tw een  29%  and 64% , depend ing  on the  
segm en tation  tool used) m ore th an  20%  of th e  18FDG-PET-based GTV w as located 
ou tside th e  GTV based  on clinical in fo rm ation  and CT. This suggests th a t tu m o r could be 
identified  by 18FDG-PET th a t w as m issed  using th e  s tan d a rd  m ethods of GTV 
delineation. H owever, in th e  absence of histological validation  it is unknow n in w h a t 
percen tage of cases th is w as caused by p e ritu m o ra l inflam m ation, resu lting  in a false- 
positive read ing  of th e  18FDG-PET signal.
Most of th e  d iscussed data  are  based  on theo re tica l delineation  stud ies using operato r- 
d ep en d en t o r -in d ep en d en t segm en tation  tools. Only th e  study  by Daisne e t  al. validated  
th e ir  resu lts  against h istopatho logy  11. It is obvious, th a t add itional validation  stud ies 
are  needed  as w ell as carefully  designed clinical tria ls  to ad d ress th e  issue of safety 
(side-effects) and  th e  clinical im pact (locoregional control, survival) of inco rpo ra ting  
PET for GTV delineation. H owever, it w ill be a t least challenging to  design and  conduct 
such tria ls  w hile PET-CT is increasingly  inco rp o ra ted  in to  clinical practice on th e  basis 
of nonrandom ized  clinical stud ies in often relatively  sm all p a tie n t populations.
Thus far, m ost delineation  stud ies in head  and  neck cancer inco rpo ra ting  18FDG-PET 
have concen tra ted  on th e  p rim ary  tum or. This is p robab ly  due to  the  fact th a t CT-based 
delineation  of m etasta tic  lym ph nodes is usually  less p ro n e  to  e r ro r  due to  b e tte r  
d iscrim ination  from  the  su rro u n d in g  fatty  tissue. H owever, th is  can be m ore  difficult in 
cases w ith  large, m a tted  nodes. As discussed  in th e  p rev ious section, 18FDG-PET m ight 
be helpful in these  situations, a lthough  one should  be aw are  of th e  possib ility  of 
negative 18FDG-PET read ings in necro tic  p a rts  of th e  lym ph node.
A part from  m ore accurate  ta rg e t volum e delineation  for rad io th e rap y  p lanning  
purposes, PET m ay identify  p a rts  of the  GTV poten tially  requ iring  additional rad ia tion  
doses. A ssum ing th a t 18FDG uptake rep resen ts  tu m o r cell density, 18FDG-PET can be 
used  to  d irec t dose escalation to  18FDG-avid subvolum es of th e  tum or. The feasibility of
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th is  approach  w as d em o n stra ted  in various theore tica l p lanning  stud ies applying e ither 
uniform  dose d is tribu tion  o r voxel-in tensity-based  IMRT 21,22. The fo rm er m ethod  
delivers a uniform  escalated  dose to  an 18FDG-avid subvolum e w ith in  the  CT-based 
ta rg e t volum e. This approach  w as p ioneered  by Schw artz e t  al. escalating to ta l dose up 
to  75 Gy in a theore tica l p lann ing  study  involving 20 head  and  neck cancer p a tien ts  21. 
W ith voxel-in tensity  based  IMRT, th e  18FDG signal-in tensity  in th e  PET-voxel is 
p ropo rtionally  re la ted  to  the  dose p rescribed  to  th a t voxel, i.e., th e  h igher th e  PET- 
signal, th e  h igher th e  p rescribed  dose 22. Both m ethods are  a lte rna tives for boosting  
18FDG-PET subvolum es inside a CT-based p lann ing  ta rg e t volum e. The clinical feasibility 
of dose escalation using a uniform  dose d istribu tion  w as recen tly  proven  in a phase I 
clinical tria l 23. Forty-one head  and  neck cancer p a tien ts  w ere  tre a te d  w ith  IMRT to  tw o 
dose levels of 72.5 Gy and 77.5 Gy using a sim ultaneous in teg ra ted  b o o st (SIB). W ith th is 
technique, th e  escalated  dose is delivered  sim ultaneously  w ith  th e  low er dose to  th e  low  
risk  areas as opposed  to  sequen tially  w here  th e  boost is delivered  at th e  end of the  
trea tm en t. Acute toxicity  (dysphagia > grade 3) occurred  in 50%  of p a tien ts  a t bo th  
dose levels and  dose-lim iting toxicity w as observed  in tw o p a tien ts  at th e  low er dose 
level and  one p a tien t at the  higher. The au th o rs  concluded th a t PET-guided dose 
escalation appea red  to  be w ell-to le ra ted  w ith  high local contro l ra te s  in b o th  the  low er 
and  h igher dose groups of 85%  and  87% , respectively, a t 1 y ear of follow-up (Fig. 2 .3 )23. 
D uring th e  course of rad io therapy , th e  tu m o r volum e gradually  decreases and  one 
m igh t consider ad justing  th e  GTV and u ltim ately  th e  rad io th e rap y  dose d istribu tion  
accordingly. This could facilitate sparing  of no rm al tissues. For exam ple, du ring  the  
trea tm e n t course for o ropharyngeal tum ors, th e  paro tid  gland is shifted  centrally  
to w ard s  th e  high-dose reg ion  by tu m o r shrinkage and  w eigh t loss of th e  p a tien t 24. As a 
resu lt, a la rger p a rt of th e  paro tid  gland is poten tially  irrad ia ted  to  a h igher dose, w hich 
m ay re su lt in a h igher incidence and  g rea te r severity  of xerostom ia. “A daptive image- 
guided rad io th e rap y ” using repetitive  PET-CT scanning  du ring  the  course of tre a tm e n t 
is a p rom ising  approach  to  ad just tre a tm e n t volum e and  dose d istribu tion . This has 
been  recen tly  d em o n stra ted  in a p ro o f of princip le s tudy  18. T hroughou t the  course of 
rad io therapy , th e  GTVs based  on 18FDG-PET significantly decreased  and  w ere  at all 
tim es sm aller th an  those  defined using p re -trea tm en t CT and  MRI. R adiation trea tm e n t 
p lann ing  based  on 18FDG-PET and  volum e adap ta tion  progressively  reduced  the  
irrad ia ted  volum es by 27% -42%  (V9 0-V 1 0 0 ) com pared  to  trad itio n a l CT-based tre a tm e n t 
p lans ob ta ined  p rio r  to  trea tm en t. D isappointingly, th is  volum e reduction  only 
m arginally  im pacted  on the  doses to  th e  organs at risk, such as th e  paro tid  gland. 
A daptive 18FDG-PET-guided rad io th erap y  n everthe less  m ay be an a ttrac tive  approach, 
especially for dose escalation  strategies.
In conclusion, 18FDG-PET can provide im p o rtan t com plem entary  in form ation  for 
rad io th e rap y  p lann ing  in head  and  neck  cancer. Potentially, th e  GTV can be reduced  
based  on th e  PET inform ation, w hich facilitates sp aring  of nearby  norm al tissues and
34
Role o f PET in radiotherapy
allow s dose escalation to relatively  sm all subvolum es. F urtherm ore , biological im aging 
using 18FDG-PET m ay identify  areas of tu m o r sp read  no t recognized by CT o r MRI, 
w hich can po ten tia lly  im prove th e  accuracy of GTV definition. H owever, to  ad d ress the  
clinical value and  possible shortcom ings of these  concepts, add itional histological 
validation  stud ies and  p ro p erly  designed clinical stud ies are  needed.
Table 2.1 Common terminology used in radiation therapy
Terminology Explanation
Gross Tumor Volume (GTV) Macroscopic tumor volume as detected by clinical examination and 
anatomical imaging (ultrasound, CT, MRI, PET)
Clinical Target Volume (CTV) Gross Tumor Volume with margin added for sub-clinical microscopic 
spread
Planning Target Volume (PTV) Clinical Target Volume with margin added for organ motion and 
setup inaccuracy
Treatment Volume Tissue volume treated to substantial radiation dose (typically larger 
than PTV)
Metabolic Tumor Volume Metabolically active tumor volume as detected by biological 
imaging, e.g., 18FDG-PET
Hypoxic Tumor Volume Hypoxic tumor volume as detected by biological imaging, i.e., 
hypoxia or hypoxia-related PET tracers (18FMISO, 18FAZA or 
18FETNIM) or BOLD-MRI
Recently, th e  firs t resu lts  on clinical tre a tm e n t outcom e afte r in teg ra tion  of 18FDG-PET- 
CT data  into IMRT planning  have been  published. In a case-control-study, Rothschild e t  
al. com pared  45 p a tien ts  w ith  stage IV-A pharyngeal carcinom as tre a te d  w ith  18FDG- 
PET-CT-based IMRT w ith  a m atched  h istorical coh o rt receiving s tan d ard  th re e ­
dim ensional conform al rad io th e rap y  25. The 2-year overall survival and  event-free 
survival ra te s  of p a tien ts  tre a te d  w ith  18FDG-PET-CT-based IMRT w ere  91%  and 80% , 
and  significantly b e tte r  th an  for th e  contro l group. In a sim ilar study, V ernon e t  a l. 
rep o rte d  2 -year overall survival and  d isease-free survival ra te s  of 83%  and 71%  for 42 
p a tien ts  w ith  head  and  neck cancer of various stage and  subsites 26. Toxicity profiles in 
th is second study  w ere  rep o rte d  as favorable.
Even though  these  initial resu lts  a re  encouraging, they  m ust be in te rp re te d  cautiously  
because they  are  based  on sm all and  he terogeneous pa tien t populations, they  only have 
sh o rt follow-up periods, and  they  use h isto rical controls. F urtherm ore , it rem ains 
unclear from  b o th  stud ies w h e th e r  th e  suggested  im provem ents in tu m o r control m ust 
be a ttr ib u ted  to  im proved  rad io th e rap y  techniques, o r th e  in troduction  of 18FDG-PET- 
CT o r to o th e r factors.
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2.3 Imaging biological tumor characteristics relevant for radiation 
treatment response
T hree m ajor tu m o r characteristics adversely  affect trea tm e n t ou tcom e and prognosis 
afte r rad ia tion  therapy : tu m o r cell hypoxia, repopu la tion  during  the  course of tre a tm e n t 
and  in trin sic  rad io resistance . These factors largely d e term in e  th e  outcom e of 
rad io th e rap y  in te rm s of local and  regional tu m o r control, b u t u ltim ately  also th e  risk  of 
d is tan t m etastases and  survival. PET enables non-invasive biological profiling of the  
tu m o r p rio r to and  during  rad ia tion  trea tm e n t w ith  th e  po ten tia l to  ta ilo r th e rap y  
accord ing  to individual characteristics.
2.3.1 Hypoxia
Hypoxia is a featu re  of m any solid tu m o rs  and  in p articu la r squam ous cell carcinom as of 
th e  cervix and  th e  head  and  neck  27,28. T um or cell hypoxia can re su lt from  tw o 
m echanism s: lim ited  diffusion capacity of oxygen due to  a large d istance from  the  
supply ing  blood-vessel (chronic hypoxia) o r im paired  perfusion  of the  supplying vessel 
due to  tem p o ra ry  vasoconstric tion  or endovascular o b struc tion  (acute hypoxia) 29. 
T rea tm en t m odifications are  available, bu t at th e  cost of increased  m orb id ity  30,31. In 
o rd e r  to  individualize trea tm e n t and  to select p a tien ts  for these  trea tm e n t 
m odifications, assessm en t of th e  tu m o r oxygenation sta tu s  is com pulsory. In accessible 
tu m o rs  of th e  head  and  neck o r u te rine  cervix, th is  can be done by invasive 
po larograph ic  electrode m easu rem en ts  o r by im m unohistochem ical stain ing  of m arkers  
in tu m o r biopsies 32-34. The advantage of th e  po larograph ic  electrodes is th a t th e  en tire  
tu m o r can be m apped  using m ultip le tracks. H ow ever, its clinical use is lim ited  due to 
th e  invasive n a tu re  of the  p rocedure , th e  res tric tio n  to accessible tu m o rs  and  the  
inability  to  d istinguish  be tw een  norm al, necro tic  o r tu m o r tissue. Im m unohistochem ical 
sta in ing  of tu m o r b iopsies resu lts  in h igh-reso lu tion  im ages th a t can be analyzed for 
several endogenous and  exogenous m arkers  of in terest. U nfortunately, th e  tu m o r 
biopsies are  often sm all and  only rep re sen t a fraction of the  en tire  tum or. F urtherm ore , 
exogenous m arkers req u ire  in travenous adm in is tra tion  before b iopsy  taking. Finally, 
th e  acquisition  of tu m o r b iopsies often req u ires  th e  use of general anesthesia , and  th is 
p ro ced u re  is n o t a ttrac tive  for repetitive  m easurem en t. Non-invasive im aging using PET 
can p rov ide a spatial m ap of th e  in tra-tum ora l d is tribu tion  of hypoxia before and  during  
trea tm en t. This in form ation  can po ten tia lly  be used  no t only as a selection in s tru m en t 
for trea tm e n t m odification, b u t also for optim ization  of rad io th erap y  p lann ing  and 
delivery.
18F-fluorom isonidazole (18FMISO) is a n itro im idazole PET-tracer th a t is reduced  and  
bound  to  cell constituen ts  u n d e r hypoxic conditions. In th e  early  1 9 9 0 ‘s, 18FMISO-PET 
w as applied  in several sm all clinical tria ls  on d ifferent p rim ary  tu m o rs  35-37. Since then, 
18FMISO-PET has been  extensively  used  for th e  detection  of hypoxia in head  and  neck
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tu m o rs  38-44. Im portan tly , in head  and  neck cancer it w as show n th a t th e  level of hypoxia 
depicted  by 18FMISO-PET p rio r  to tre a tm e n t w as co rre la ted  w ith  locoregional 
failure 38,42,43. A part from  its p rognostic  value, Rischin e t  a l. pub lished  data  su p p o rtin g  
th e  pred ic tive value of 18FMISO-PET 42. They perfo rm ed  18FMISO-PET scans in p a tien ts  
w ith  advanced stage head  and  neck  carcinom as th a t w ere  tre a te d  w ith  rad io th erap y  
and  co n cu rren t chem otherapy  alone or com bined w ith  a hypoxic cytotoxin. Patien ts 
w ith  hypoxic p rim ary  tu m o rs  tre a te d  w ith  th e  add itional cytotoxin experienced 
significantly less local failures com pared  to pa tien ts  tre a te d  w ith  chem otherapy  alone 
(zero of eigh t p a tien ts  versus  six of nine). F u rtherm ore , the  absence of hypoxia on 
18FMISO-PET w as associated  w ith  a low  risk  of locoregional failure w hen  tre a te d  w ith  
chem otherapy  alone 42. 18FMISO-PET can thus serve as a pred ic tive too l allow ing 
trea tm e n t selection based  on biological tu m o r characteristics. U ltimately, reduction  of 
side effects in p a tien ts  n o t benefiting  from  tre a tm e n t m odification will be feasible.
A part from  tu m o r characterization , first a ttem p ts  w ere  m ade to  delineate  a biological 
ta rg e t volum e and  to escalate th e  dose to th e  p rim ary  tu m o r based  on 18FMISO-PET 45­
47. Two theo re tica l p lann ing  stud ies p roved  th e  feasibility of dose escalation to  the  
18FMISO-PET detected  hypoxic subvolum e using IMRT 45,46. R ajendran e t  al. 
d em o n stra ted  th a t using an IMRT technique, th e  dose to  th e  18FMISO-PET detected  
hypoxic subvolum e could be escalated  by an add itional 10 Gy 46. Lee e t  al. achieved a 
dose of 84 Gy in hypoxic a reas w ith o u t exceeding th e  norm al tissue to lerance 45. Their 
a tte m p t to  fu rth e r escalate th e  dose to 105 Gy in hypoxic regions w as only successful in 
one of the  tw o plans stud ied . In a th ird  study, T horw arth  e t  al. com pared  IMRT p lanning  
w ith  dose pain ting  by n um bers based  on dynam ic 18FMISO-PET data  47. Thereby, 
spatially  varian t doses a re  delivered  to  th e  tu m o r according to  dose-escalation factors 
d e term ined  on the  bases of th e  dynam ic 18FMISO-PET scan. A pplying th is approach , the  
tu m o r control p robab ility  w as increased  from  56%  to  70%, w hile m ain tain ing  the  sam e 
level of toxicity  47. However, one has to  be cautious in te rp re tin g  th e  data  as th e  n um ber 
of p a tien ts  included  in th is s tudy  w as small.
Until now , clinical experience w ith  hypoxic PET trace rs  o th e r th an  18FMISO is lim ited. 
60Cu(II)-diacetyl-bis(W 4-m ethy lth iosem icarbazone) (60Cu-ATSM) w as in troduced  into 
th e  clinic afte r successful pre-clinical stud ies dem o n stra tin g  a s tro n g  co rrelation  
b e tw een  tra c e r  up take and  low  pO 2 levels 48. It w as th e  first hypoxia-re lated  PET trac e r 
for w hich th e  po ten tia l use of a selective boost to  th e  hypoxic subvolum e w as 
illu s tra ted  49. However, p a rtly  due to  its lim ited  specificity, especially if im aging is 
perfo rm ed  at early  tim e po in ts afte r adm in istra tion , th is  com pound did not find its w ay 
in la rger scale clinical studies.
18F -fluoroery th ron itro im idazo le (18FETNIM), 18F-fluoroazom ycin arab inoside  (18FAZA) 
and 18F-2-(2-n itro im idazol-1-y l)-N -(3 ,3 ,3-trifluoropropyl)-acetam ide (18F-EF3) are
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m em bers of a new  genera tion  nitro im idazoles. 18FETNIM show ed  a h igher and  m ore 
he terogeneously  d is trib u ted  tra c e r  up take in tu m o rs  th an  in ad jacen t neck m uscle 50. 
F urtherm ore , a high up take of 18FETNIM p rio r to rad ia tion  th e ra p y  w as associated  w ith  
a tre n d  to w ard s  poo r overall survival 51. 18FAZA has sim ilar trac e r  characteristics 
com pared  to  18FETNIM, and  w as p roven  feasible and  of sufficient quality  for clinical use 
in head  and  neck cancer p a tien ts  52,53. Grosu e t  al. in co rp o ra ted  18FAZA-PET in rad ia tion  
trea tm e n t p lann ing  and  detected  hypoxic subvolum es of d ifferen t size and  d istribu tion  
(rep resen tin g  on average 11%  of th e  p rim ary  tu m o r volum e and  8%  of th e  m etasta tic  
lym ph node volum e) 54. Dose escalation to  80.5 Gy in 18FAZA-PET detected  hypoxic 
areas w as show n feasible. 18F-EF3 w as used  in a phase I s tu d y  in head  and  neck cancer 
p a tien ts  55. In th is study, th e  use of th is tra c e r  w as show n to be safe, b u t th e  n u m b er of 
advanced stage tu m o rs  show ing increased  tra c e r  up take w as d isappoin tingly  low.
In sum m ary, although num erous hypoxic or hypoxia-related  PET-tracers are  available 
for clinical use, th e ir  p rognostic  and  predic tive value needs to  be assessed  in la rger 
clinical stud ies before im plem en tation  for pa tien t selection. Preferably, the PET-tracer 
used  m ust also v isualize changes in th e  oxygenation sta tu s  caused by trea tm e n t 
m odifications coun teracting  hypoxia, such as carbogen  b rea th in g  56. M ore im portan tly , 
th e  concep t of dose pain ting  to hypoxic subvolum es e ith er by uniform  doses o r by dose- 
pain ting  by n um bers is still sub jec t of in tense  debate. T here are  m ajor concerns ab o u t 
th e  spatial reso lu tion  of hypoxic PET im aging w hen  com pared  to  the  d istribu tion  and 
fluctuation  of tu m o r cell hypoxia at th e  m icroregional level. In th is context, w e 
investigated  ten  d ifferent head  and  neck carcinom a xenograft tu m o r lines using 18FMISO 
au to rad iog raphy  and pim onidazole im m unoh istochem istry  57 (Fig. 2.4). We found th a t 
th e  p a tte rn  of th e  18FMISO signal depended  on th e  d istribu tion  of hypoxia at the  
m icroregional level. In five xenograft tu m o r lines, a significant co rre la tion  be tw een  the  
m ean 18FMISO and pim onidazole signal in tensity  w as found and th is depended  on the  
underly ing  m icroarch itectu re . This indicates th a t one shou ld  be cautious w hen  studying  
sm all tu m o r subvolum es for dose escalation 57.
A part from  d ifferen t d is tribu tion  p a tte rn s  of hypoxia a t th e  m icroregional level, one has 
to  consider th a t th e  oxygenation s ta tu s  changes du ring  the  course of rad io therapy , 
w hich m akes repetitive  PET-imaging before and  du ring  tre a tm e n t com pulsory  58. 
Finally, th e  question  regard ing  th e  rad ia tion  dose levels req u ired  for effective 
elim ination  of th e  ra d io re sis tan t subpopu lations rem ains unsolved.
2.3.2 Tumor cell proliferation
The m ajor lim itations of 18FDG-PET in oncology are  false-positive read ings due to  tra c e r  
up take in in flam m atory  tissue  o r reactive lym ph nodes. T herefore, PET trac e rs  th a t 
m ore  specifically im age DNA-synthesis are  cu rren tly  being  developed and  tested .
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T um or cell p ro lifera tion  during  th e  course of th e ra p y  adversely  affects rad ia tion  
trea tm e n t outcom e and  p rognosis in squam ous cell carcinom as of th e  head  and  neck 59. 
3’-deoxy-3’-18F-fluorothym idine (18FLT) is a trac e r th a t reflects th e  activity  of thym idine 
kinase 1, a principal enzym e in the  salvage pathw ay  of DNA syn thesis 60. The 18FLT-PET 
signal is m ore  specific for actively dividing tu m o r cells com pared  to  18FDG. 
Inflam m atory  cells in the  proxim ity  of th e  tu m o r consum e glucose and  th u s  cause false- 
positive 18FDG-PET readings. However, as th e se  im m une response  cells are  term inally  
d ifferentiated, th e  DNA syn thesis ra te  and  th e re fo re  th e  18FLT up take are  n o t increased. 
18FLT-PET w as validated  against h istopatho logy  in a varie ty  of solid tum ors  including 
b reast, lung and  sarcom a 61-63. In soft-tissue sarcom a, Cobben e t  al. found a significant 
co rre la tion  be tw een  th e  SUV values and  labeling index of th e  p ro lifera tion  m arke r 
Ki-67. In addition, 18FLT-PET w as able to  d istinguish  low -grade from  high-grade soft- 
tissue sarcom as 61. In b re a s t tum ors, Kenny e t  al. rep o rte d  a s tro n g  co rre la tion  be tw een  
SUV values and  Ki p a ram e te r  of dynam ic 18FLT-PET and  stain ing  of Ki-6 7 62. Finally, Yap 
e t  a l. also observed  a significant co rre la tion  be tw een  18FLT up take in non-sm all cell lung 
cancer lesions and  th e  Ki-67 labeling index 63.
In p rim ary  head  and  neck tum ors, th is  p rom ising  com pound has th u s  far only been 
applied  to  p rim ary  laryngeal tu m o rs  64. C urrently, validation  of 18FLT-PET in a large 
series of squam ous cell carcinom as of the  head  and  neck is ongoing at ou r center. For 
th e  detection  of cervical lym ph node m etastases, first resu lts  d em o n stra ted  th a t 18FLT- 
PET is n o t su itab le  in th is tu m o r en tity  65. A high ra te  of false positive findings caused by 
18FLT up take in th e  germ inal cen ters of reac tive lym ph nodes resu lted  in a low  
specificity and  a low  positive-predic tive value (17%  and  38%, respectively) 65.
Until p resen t, adaptive im age-guided rad io th erap y  has been  based  on repetitive  PET- 
scanning  using 18FDG 18. As th e  trea tm e n t course progresses, th e  ob ta ined  18FDG-PET- 
signal is heavily influenced by th e  inflam m atory  response  of tu m o r-su rro u n d in g  tissues 
leading to  an increased  background  activity. As a resu lt, segm en tation  of th e  PET signal 
for tu m o r delineation  pu rposes becom es increasingly  difficult. The use of a 
proliferation-specific PET tracer, such as 18FLT, m ay be a so lu tion  to  th is problem . 
D uring th e  course of therapy , the  reduction  in th e  pro liferative activity  of th e  p rim ary  
tu m o r can be accurately  im aged by 18FLT, n o t d is tu rbed  by increased  tra c e r  up take in 
su rro u n d in g  inflam m atory  tissue. At p resen t, ou r group is assessing  th e  changes in the  
18FLT-PET-signal during  th e ra p y  in p a tien ts  w ith  squam ous cell carcinom as of the  head 
and  neck tre a te d  w ith  rad io th e rap y  alone o r w ith  concom itant chem otherapy  (Fig. 2.5). 
The pred ic tive po ten tia l of th is  approach  and  applicability  for ta ilo red  trea tm e n t are 
sub ject of investigation.
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2.3.3 Perfusion, protein synthesis and others
A nother significant tu m o r characteristic  strong ly  re la ted  to  tu m o r cell hypoxia is tu m o r 
blood  perfusion. Hypoxia is a s tro n g  stim ulus for neovascularization , b u t m any new ly 
form ed vessels are  of p o o r quality  w ith  severe s tru c tu ra l and  functional abnorm alities. 
D espite increased  vascu lar density, th e  im paired  functionality  of blood vessels m ay 
re su lt in depriva tion  of oxygen and  nu trien ts.
T herefore, an im aging tool for assessm en t of tu m o r blood flow m ay provide im po rtan t 
in fo rm ation  re lev an t for rad io th e rap y  responsiveness. Lehtio e t  al. u sed  15O-labeled 
w a te r (15O-H2O) and  18FETNIM for im aging of perfusion  and  hypoxia in 21 p a tien ts  w ith  
head  and  neck cancer 50. P relim inary  resu lts  from  th is sm all s tudy  indicated  an 
association be tw een  tu m o r perfusion  and  rad ia tion  tre a tm e n t outcom e 51.
0 -2 -18F-fluoroethyl-L-tyrosine (18FET) and  L-m ethyl-11C -m ethionine (11C-MET) are 
am ino acid analogues used  to  v isualize cellular am ino acid up take o r p ro te in  synthesis. 
18FET m ay be useful in d ifferen tiating  tu m o r from  p o st-trea tm en t in flam m atory  tissue  
as it is no t taken  up by in flam m atory  cells. Several stud ies com pared  18FET- w ith  18FDG- 
PET in squam ous cell carcinom as of th e  h ead  and  neck and  confirm ed th e  specific 
up take of 18FET by m alignant cells w ith  h istopatho logy  66-68. The specificity of 18FET- 
PET w as found to  be su p erio r to  18FDG-PET (95-100%  versus 63-79% ), b u t the  
sensitiv ity  of th e  am ino acid tra c e r  w as significantly low er (64-75%  versus  93-95% , 
respectively). As th e  SUV values for 18FET-PET w ere  significantly low er com pared  to 
18FDG-PET, th e  new  trac e r  will p robab ly  n o t replace 18FDG-PET as d iagnostic tool b u t it 
can p rov ide com plem en tary  in form ation  for d iscrim ination  betw een  tu m o r and 
in flam m atory  tissue 66-68. 11C-MET has a sim ilar sensitiv ity  and  specificity com pared  to 
18FDG-PET 69. In a delineation  study, 11C-MET w as com pared  to 18FDG-PET and CT. 
W hile 18FDG-PET y ielded significantly sm aller GTVs com pared  to  CT, GTVs based  on 11C- 
MET-PET w ere  no t different from  CT, p robab ly  because of up take  by su rro u n d in g  
norm al m ucosa and  salivary  gland tissue. The au th o rs  concluded th a t 11C-MET has no 
add itional value for ta rg e t volum e delineation  in head  and  neck tu m o rs  70.
1-11C-acetate (11C-ACE) is suggested  to  p referen tia lly  m etabolize to  th e  m em brane 
lipids in tu m o r cells. In a head  and  neck cancer staging and  rad io th e rap y  p lann ing  study, 
11C-ACE-PET detected  all p rim ary  tu m o rs  and  95%  of th e  m etasta tic  lym ph nodes, m ore 
th an  18FDG-PET and  CT/MRI 71. H owever, th e  GTVs derived  by 11C-ACE-PET w ere  51%  
la rger th an  those  based  on 18FDG-PET. Before 11C-ACE-PET can be in troduced  in the  
rad io th e rap y  p lanning  process, fu rth e r stud ies are  needed  to  explain th is d iscrepancy 
and  to  clarify th e  m echanism  of tu m o r uptake. Finally, non-invasive m ethods to  assess 
th e  up take and  b iod istribu tion  of biological m odifiers will be of g rea t value to  d irec t 
new  ta rg e ted  therap ies. R adiolabelled an tibodies and  sm all m olecules for PET im aging 
are  cu rren tly  being developed  and  te sted  in pre-clinical and  early  clinical stud ies 72,73.
40
Role o f PET in radiotherapy
In conclusion, PET trace rs  im aging specific biological tu m o r characteristics offer 
po ten tia l for ta ilo r-m ade rad ia tion  therapy . However, they  rem ain  in th e  research  arena  
until p ro p e r clinical validation.
2.4 Technical innovations
Several challenges regard ing  PET-scanning rem ain, of w hich som e m ay be reso lved  or 
im proved  w hile o thers  cannot. For exam ple, reso lu tion  is lim ited by th e  d istance a 
po sitro n  travels before it annih ilates, w hich is a given fact for a certain  rad ionuclide 
po sitro n  em itte r and  th e re fo re  unchangeable. F urtherm ore , various developm ents 
regard ing  an increase in th e  spatia l and  tem pora l reso lu tion  are  ongoing. Currently, the  
spatial reso lu tion  for hum an  PET-scanners is in th e  o rd e r of 5-7 m m  com pared  to
1-3 m m  for sm all anim al scanners. New developm ents regard ing  the  size of th e  de tec to r 
crystal, th e  coincidence tim ing w indow  and th e  signal p rocessing  have achieved a 
reso lu tion  of 2 m m  for th e  hum an  application  (p roduct in form ation  Siem ens). Through 
th is developm ent, th e  d is to rtion  of th e  im age and  its b lu rrin g  is reduced  w hich m ay 
re su lt in an increased  p recision  of tu m o r delineation.
In teg ra ted  PET-MRI scanners com bine anatom ical w ith  functional im aging and  m ay 
have a specific im pact on head  and  neck cancer staging and  trea tm e n t 74. The po ten tia l 
benefits of in teg ra ted  PET-CT scanning  for th e  p lann ing  p rocedu re  of rad io th e rap y  have 
been  discussed  in th is review . H owever, for particu la r subsites of th e  head  and  neck 
region, e.g., o ropharyngeal and  oral cavity tum ors, MRI is th e  diagnostic im aging 
m odality  of choice. In th ese  tu m o r sites, in teg ra ted  PET-MRI scanners m ay fu rth e r 
im prove th e  accuracy of gross tu m o r volum e delineation. In addition, dynam ic MR 
stud ies such as dynam ic co n trast enhancem en t MRI and  BOLD MRI as w ell as MR 
spectroscopy  m ay add  com plem en tary  functional inform ation.
2.5 General conclusions
18FDG-PET is th e  golden s tan d ard  for non-invasive functional im aging in oncology. In 
head  and  neck tum ors, 18FDG-PET is no t recom m ended  for the  detection  of the  p rim ary  
tu m o r and  its value for m etasta tic  lym ph nodes is still a m a tte r  of debate. W ith reg ard  to 
staging of th e  p rim ary  tum or, 18FDG-PET m ay influence th e  tre a tm e n t decision if d is tan t 
m etastases o r second p rim ary  tum ors are  detected .
For rad io th erap y  p lanning  in head  and  neck cancer, 18FDG-PET can p rov ide im p o rtan t 
com plem en tary  inform ation  to CT. Based on the PET inform ation, th e  volum e irrad ia ted  
to  high dose levels m ay be reduced  w hich facilitates no rm al s tru c tu re s  sparing  and  dose 
escalation. H owever, add itional histological validation  stud ies and  p ro p erly  designed 
clinical stud ies are  needed  to  ad d ress th e  clinical value and  possib le shortcom ings of 
th is concept. Several PET trace rs  to  im age biological tu m o r characteristics reflecting
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rad ia tion  resistance m echanism s are  available and  offer po ten tia l for ta ilo red  rad ia tion  
therapy . H owever, they  should  be re s tric ted  to  research  pu rp o ses  until p ro p e r clinical 
validation. In th is context, th e  use of m ore  th a n  one trac e r  m ay open new  horizons in 
th e  fu ture. Finally, technical developm ents in PET-scanning in general and  in th e  field of 
head  and  neck cancer in p articu la r m ay increase th e  precision  of rad io th erap y  p lann ing  
and  th u s  im prove tu m o r control and  reduce trea tm en t-re la ted  m orbidity .
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Abstract
Purpose. In head and neck cancer, it has been shown that hypoxic tumors respond poorly to 
therapy. Methods to identify hypoxic tumors are therefore of importance to select patients for 
oxygenation modifying or other intensified treatments. The aim of this study was to compare 
tumor cell hypoxia assessed by the hypoxic cell marker pimonidazole (PIMO] with expression of 
the endogenous hypoxia-related marker carbonic anhydrase IX (CA-IX] in three human head 
and neck tumor lines.
Material and Methods. Forty-five tumors of three human head and neck tumor lines, SCCNij3, 
SCCNij59 and MEC82, xenografted in athymic mice, were used. CA-IX was quantified by 
biodistribution (% injected dose /  g tumor] after injecting 3-5 n.l m In-labeled G250 mouse 
antibody 3 days prior to euthanizing. In a tissue section from the same tumor, fractions of tumor 
area positive for PIMO, CA-IX and Hoechst 33342 (perfusion marker] were assessed after 
immunohistochemical staining, using a digital image analysis system.
Results. SCCNij3 and MEC82 were relatively hypoxic tumor lines with fractions of tumor area 
positive for pimonidazole of 0.16 and 0.15, respectively. SCCNij59 was a better oxygenated 
tumor line with a PIMO-fraction of 0.03. The three tumor lines showed different levels and 
patterns of CA-IX immunohistochemical staining, but only in MEC82 there was a good 
correlation between PIMO-fraction and CA-IX-fraction (r2 = 0.92, p<0.0001). Correlations 
between 111In-G250 uptake and CA-IX-fraction or PIMO-fraction within tumor lines were weak 
or absent.
Conclusion. Assessment of CA-IX expression depends largely on the techniques and tumor lines 
used. Furthermore, the immunohistochemical staining pattern of CA-IX relative to PIMO differs 
between human tumor lines of similar anatomical origin. Therefore, the use of CA-IX as 
endogenous marker of tumor hypoxia remains questionable.
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3.1 Introduction
Hypoxia is one of the m ajor factors contributing to radiotherapy resistance of solid 
tum ors and it leads to adverse trea tm en t outcome x-2. It was shown th a t assessm ent of 
tum or cell hypoxia by m eans of pimonidazole binding can predict for trea tm ent 
outcome in head and neck cancer 3. It is therefore im portan t to develop reliable, 
preferably non-invasive m ethods to identify hypoxic tum ors enabling selection of 
patients for oxygenation modifying or other intensified treatm ents 4.
Hypoxia can be assessed a t the m icroregional level after adm inistration of bioreductive 
m arkers such as 2-nitroim idazole pimonidazole hydrochloride (PIMO) and EF5 5-8. 
However, these m arkers require intravenous adm inistration. Endogenous hypoxia 
m arkers are therefore currently  proposed as a prom ising and convenient way of 
detecting hypoxia 9. CA-IX, a m em ber of the carbonic anhydrase family is the m ost 
prom ising endogenous hypoxia-related cell m arker of the 15 carbonic anhydrase 
subtypes. This transm em branic enzyme catalyses the reversible hydration of carbon 
dioxide to carbonic acid and is involved in acid-base balance and cell-to-cell adhesion. 
CA-IX is up-regulated under increased cell density and under hypoxic conditions with 
pO2 levels below  20 mmHg. Therefore, regions w ith high CA-IX expression are typically 
peri-necrotic. Interestingly, several studies on solid tum ors, including the uterine cervix 
and head and neck cancer, rep o rt overexpression of CA-IX in tum or tissue w ith absence 
of CA-IX in corresponding norm al tissue 3,10-12. Studies on co-localization betw een PIMO 
and CA-IX, however, have revealed conflicting results to date 3,12-14.
Over the past few years, various tools to assess CA-IX expression have been developed, 
e.g., immunohistochem ical visualization in tissue sections and m easurem ent of uptake 
of radioactive labeled anti-CA-IX antibody in tum or tissue following intravenous 
adm inistration 1,3,10,11,15. G250 is one of the two currently  available monoclonal 
antibodies against CA-IX used in nuclear medicine, and it only binds to the native form 
of the CA-IX antigen. G250 is gaining in terest as antibody for non-invasive molecular 
imaging m ethods such as im m unohistochem istry, uptake m easurem ent and possibly 
SPECT and PET analysis of CA-IX.
In the p resen t study, the exogenous hypoxic cell m arker PIMO was com pared w ith the 
endogenous hypoxia-related m arker CA-IX. CA-IX was determ ined 
immunohistochemically and by assessing the concentration of 111In-labeled G250 
antibody following intravenous adm inistration.
3.2 Material and Methods
Mouse Tumor Model. Twenty-six SCCNij3 tum ors, seven SCCNij59 and twelve MEC82 
tum ors, xenografted in athymic BALB/c n u /n u  mice, w ere used in these experim ents. 
Viable 1 m m 3 tum or pieces w ere im planted subcutaneously. Tum ors w ith a mean
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diam eter of 6 -8  mm w ere used in the experiments. Animals w ere kept in a specific- 
pathogen-free unit in accordance w ith institutional guidelines. After euthanizing the 
animals, tum ors w ere snap frozen in liquid nitrogen. All experim ents w ere approved by 
the Animal Experim ents Committee of the Radboud University Nijmegen Medical 
Centre.
Monoclonal Antibody cG250. The isolation and im m unohistochem ical reactivity of 
mAb G250 have been described elsew here 16,17. In order to reduce the im munogenicity 
of the G250 antibody, the chimeric version, mAb cG250, has been developed, which is 
reactive w ith the antigen G250, the tum or-associated carbonic anhydrase isoenzyme IX 
(MN/CA-IX) 18,19.
Conjugation, Radiolabeling, and Quality Control. The conjugation of SCN-Bz-DTPA to 
mAb cG250 was perform ed as described by Ruegg e t  al. w ith m inor modifications 20. The 
num ber of DTPA moieties per cG250 molecule was determ ined as described by 
Hnatowich e t  a l . 21. The DTPA-cG250 conjugate was labeled w ith 111InCl3 in a 0.1 mol/L 
am m onium  acetate buffer of pH 5.4 for 30 min a t room  tem perature. All radio-labeled 
cG250 preparations w ere purified by gel filtration on a PD-10 column eluted with 
phosphate buffered saline (PBS) supplem ented w ith 0.5% bovine serum  albumin (BSA). 
For all preparations, the am ount of non-mAb-bound radiolabel was determ ined by 
instan t thin-layer chrom atography (ITLC) using ITLC silica gel strips, using 0.1 m ol/L 
citrate buffer (pH 6.0) as the mobile phase.
Biodistribution. Tum or-bearing mice w ere injected intravenously w ith 3.7 MBq 
(0.1 mCi) 1nIn-DTPA-cG250 diluted in PBS + 0.5% BSA. All mice received a protein dose 
of 3-5 pg cG250 (volume, 200 pL/m ouse). Mice w ere euthanized a t 3 d after injection, 
and the tum or and norm al tissues (blood, muscle, lung, spleen, kidney, liver, and small 
intestines w ithout contents) w ere dissected, weighed, and counted in a y-counter. To 
correct for radioactive decay, injection standards w ere counted simultaneously. The 
activity in samples was expressed as percentage of injected dose per gram tissue 
(%ID/g).
Immunohistochemical staining. PIMO (80 m g/kg) and the perfusion m arker Hoechst 
33342 (15 m g/kg) w ere injected 1 h and im m ediately p rio r to euthanizing the animals, 
respectively. From the frozen tum ors, 5 pm sections w ere cut, m ounted on poly-L-lysine 
coated slides and stored a t -80 °C. After thaw ing and fixation, slides w ere scanned for 
the fluorescent signal of Hoechst 33342 before they w ere stained for CA-IX, PIMO and 
vessels. Between all consecutive steps of the staining, sections w ere rinsed th ree times 
for 5 min in PBS and all antibodies w ere diluted in prim ary antibody diluent (PAD). 
Sections w ere incubated overnight a t room tem perature  w ith biotinylated mouse anti- 
CA9 (G250) antibody (E. Oosterwijk, D epartm ent of Urology, Radboud University 
Nijmegen Medical Centre) diluted 1:150. Then sections w ere incubated w ith mouse
52
CA-IX in head and neck xenograft tumor lines
anti-biotinCy3 diluted 1:400 for 30 min a t 37 °C. This was followed by incubation w ith 
Fab fragm ent donkey anti-m ouse IgG diluted 1:50 and rabb it anti-pimonidazole (J.A. 
Raleigh) diluted 1:1000 for 60 min a t room  tem perature. Then sections w ere incubated 
w ith 9F1 (ra t monoclonal to mouse endothelium , D epartm ent of Pathology, Radboud 
University Nijmegen Medical Centre) undiluted for 45 min a t room  tem perature. Finally, 
sections w ere incubated w ith chicken anti-rat-Alexa647 diluted 1:200 and donkey anti- 
rabbit-Alexa488 diluted 1:400 for 60 min a t 37 °C. Sections w ere m ounted in 
Fluorostab.
Image acquisition and analysis. All tum or sections w ere analyzed using a digital image 
analysis system  as described previously 22. After scanning whole tissue sections, grey 
scale images for vessels, perfusion (Hoechst), CA-IX and PIMO w ere obtained and 
subsequently converted into binary images. Thresholds for the fluorescent signals w ere 
interactively set above the background staining for each individual m arker. Binary 
images w ere used to calculate the fractions of the tum or area positive for CA-IX (fCA-IX) 
and PIMO (fPIMO) relative to the total tum or area, the num ber of vessels and the 
proportion of perfused vessels. Areas of necrosis w ere excluded.
Statistics. Statistical analyses w ere perform ed on a Macintosh com puter using the 
GraphPad Prism 4.0a software package (La Jolla, CA). Linear regression analysis was 
used to assess correlations betw een the different param eters and a p-value < 0.05 was 
considered significant.
3.3 Results
In this study, three hum an head and neck tum or lines xenografted in nude mice w ere 
used, two squam ous cell carcinomas (SCCNij3 and SCCNij59) and one m ucoepiderm oid 
carcinoma (MEC82). As illustrated in Figure 3.1, SCCNij59 showed peri-necrotic staining 
for PIMO (green) bu t no CA-IX expression. The SCCNij3 line showed areas of necrosis 
w ith PIMO and CA-IX (red) mainly expressed in areas around necrosis and areas of 
overlap betw een both m arkers (yellow), although generally, CA-IX was found a t greater 
distance from vessels than  PIMO. MEC82 expressed CA-IX abundantly and the staining 
pattern  differed strongly from SCCNij3. PIMO was localized in the peri-necrotic regions 
and there  was also overlap w ith CA-IX, but, in contrast to SCCNij3, CA-IX was already 
up-regulated closer to blood vessels than the PIMO staining.
3.3.1 Immunohistochemistry CA-IX, PIMO and vessels
Table 3.1 shows the results of the quantitative analysis of G250 concentration, fCA-IX, 
fPIMO and fraction of perfused vessels in the th ree  tum or lines. SCCNij3 and MEC82 are 
relatively hypoxic tum ors w ith high PIMO positive fractions. However, of these two
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Figure 3.1 ¡mmunofluorescent images o f SCCNij59 (A, B shows detail), SCCNij3 (C, D shows detail) and
MEC82 (E, F shows detail) showing vessels (lightblue), pimonidazole binding (green) and CA-IX expression 
(red). Yellow represents areas o f overlap between pimonidazole and CA-IX. Necrotic areas (N) were excluded 
from  the analysis. All images were scanned a t 100 x magnification, panels on left show complete tumor 
sections reduced in size.
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tum ors, MEC82 dem onstrated significantly m ore CA-IX expression and good correlation 
w ith PIMO staining (p<0.0001, r2=0.92, Fig 3.2B). Expression of CA-IX was low in 
SCCNij3 with, partly due to these low fCA-IX values, only a weak, non-significant 
correlation w ith fPIMO (Fig 3.2A). SCCNij59 is a be tter oxygenated tum or and does not 
express CA-IX. The fraction of perfused vessels was highest in MEC82 and low est in 
SCCNij3, bu t there  was a large variability betw een tum ors of the same tum or line.
CA-IX in head and neck xenograft tumor lines
Table 3.1 Biodistribution, fCA-IX, fPIMO and fraction o f perfused vessels in three xenograft tumor 
lines. Values are mean ±1  SD (range)
Biodistribution
(%ID/g)
fCA-IX fPIMO
Fraction vessels 
perfused
SCCNij3
25.2 ± 6.2 
(16.4 -  40.1)
0.02 ± 0.02 
(0-0.07)
0.16 ± 0.1 
(0.01 -  0.37)
0.56 ± 0.3 
(0.21 -  0.98)
SCCNij59
9.11 ± 3.3 
(6.1 -  14.6)
0
0.03 ± 0.03 
(0 -  0.06)
0.79 ± 0.24 
(0.31 -  0.95)
MEC82
17.1 ± 6.1 
(7.6 -  26.3)
0.10 ± 0.06 
(0 -  0.19)
0.15 ± 0.08 
(0 -  0.26)
0.88 ± 0.13 
(0.59 -  0.95)
3.3.2 G250 concentration versus CA-IX and PIMO immunohistochemistry
The two hypoxic tum ors (SCCNij3 and MEC82) showed higher uptake of 111In-labeled 
G250 relative to the well-oxygenated tum or (SCCNij59). The la tter was CA-IX negative 
as determ ined immunohistochemically. SCCNij3 and MEC82 showed reverse 
associations betw een fCA-IX and G250 biodistribution. SCCNij3 dem onstrated the 
highest G250 uptake levels bu t low fCA-IX values, w hereas MEC82 had the highest 
fCA-IX values bu t low er G250 biodistribution levels. Correlations betw een fCA-IX or 
fPIMO and G250 biodistribution w ithin tum or lines w ere w eak or absent (Fig 3.3).
SCCNijS
fPIMO
r = 0.11. p =  0.09, n.s.
B MEC82
fPIMO 
r2 -  0.92. p <  0.0001
Figure 3.2 Scatterplots comparing fCA-IX versus fPIMO in 26 tumors o f  the SCCNij3 line and 12 tumors 
of the MEC82 line. Linear best f i t  is shown.
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Figure 3.3 Scatterplots comparing fCA-lX versus 111ln-labeled G250 biodistribution in 26 tumors of the 
SCCNij3 line (A) and 12 tumors o f the MEC82 line (B), and fPlMO versus 111ln-G250 biodistribution in 
SCCNij3 (C) and MEC82 (D). Linear best f i t  is shown.
3.4 Discussion
Carbonic anhydrase IX (CA-IX) is one of the m ost prom ising endogenous hypoxia- 
related cell m arkers known a t present. Detectable by im m unohistochem istry in 
biopsies, quantification of CA-IX expression by injection of the radio-labeled antibody 
could potentially allow non-invasive determ ination of CA-IX expression by PET or 
SPECT imaging.
However, com parisons of the expression and microregional distribution of CA-IX and 
the exogenous hypoxic cell m arkers such as PIMO did not show straightforw ard 
correlations. In the p resen t study three hum an head and neck tum or lines w ere 
examined, two of which express CA-IX. Staining patterns for CA-IX and PIMO strongly 
differed betw een the two tum or lines. This is in agreem ent w ith previous findings by 
other groups. Lal e t  al. found sim ilar expression patterns for CA-IX and PIMO in biopsy 
sections of a hum an oropharyngeal squam ous cell carcinoma 13. In accordance w ith the 
findings in one of the tum or lines in the p resen t study (MEC82), Olive e t  al. and 
Kaanders e t  al. dem onstrated in carcinomas of the uterine cervix and head and neck 
th a t CA-IX staining was mainly observed a t shorte r distances from the blood vessels 
than PIMO staining 3,12. This indicates th a t CA-IX expression identifies areas w ith low as
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well as interm ediate tissue oxygenation status. In contrast, in skin and bladder 
carcinoma Wykoff e t  al. found th a t CA-IX staining was m ore dom inant in peri-necrotic 
regions a t greater distance to the vessels than  PIMO staining 12-14. The peri-necrotic 
pattern  of CA-IX is also found in SCCNij3 in the p resen t study. Thus, the difference in 
relationship betw een PIMO staining and CA-IX expression is no t simply related to tum or 
origin and histology, b u t also to the function of CA-IX in pH-maintenance in different 
tissues. The p resen t study clearly shows large differences in CA-IX staining patterns 
even w ithin one tum or entity. This indicates th a t the endogenous hypoxia-related 
m arker CA-IX is not a straightforw ard surrogate for the exogenous hypoxic cell m arker 
PIMO, bu t provides additional inform ation possibly related to its function in pH- 
homeostasis.
In the two tum or lines of the p resen t study th a t express CA-IX, only w eak correlations 
w ere established betw een the two m ethods used to m easure CA-IX. A possible reason 
for this could be the large interval of 3 days betw een injection of 111In-G250 and PIMO, 
the la tter 1 h later followed by rem oval and rapid freezing of the tum ors. In a recent 
publication, the half-life of hypoxic cells in the MEC82 line was reported  to be 23 h, 
much shorter than for the SCCNij3 line (49 h) 23. This implies th a t after a gap of 3 days, 
m ost of the hypoxic cells labeled by 1nIn-G250 have died, while in the SCCNij3 tum ors 
close to half the num ber of labeled hypoxic cells is still present. This is further 
complicated by different CA-IX expression patterns betw een the tum or lines as 
discussed previously. MEC82 up-regulates CA-IX already a t interm ediate oxygenation 
levels, w hereas in SCCNij3 up-regulation occurs only under severe hypoxia. Finally, the 
presence of tum or necrosis may contribute to the d iscordant results. With the 
immunohistochem ical assessm ent, necrotic areas are excluded from analysis, bu t this is 
no t possible w ith the 1nIn-G250 uptake assay, w here activity in the total tum or volume 
is m easured. It is unclear how  fast biodegradation and w ashout of labeled antibodies 
occurs after tum or cell necrosis. Tumor blood perfusion and blood volume, vascular 
perm eability and interstitial pressure, which differ betw een tum or lines, may play a role 
in this process as well. It is likely th a t labeled antibodies will rem ain detectable for 
some tim e in necrosis. Some suggestion for this is found in Figure 3.1, which 
dem onstrates red fluorescent signal in necrotic areas. Yet it rem ains unclear w hether 
this tru ly  represents fluorescence-labeled antibody or m erely aspecific staining.
It can be concluded from this prelim inary set of data, w ith varying results on CA-IX and 
PIMO correlation, tha t CA-IX cannot be regarded as surrogate for the nitroimidazole 
based hypoxic cell m arkers such as pimonidazole. Furtherm ore, different m ethods of 
CA-IX m easurem ent are no t directly comparable and need fu rther evaluation.
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Abstract
Purpose. Tumor cell hypoxia is a common feature in solid tumors adversely affecting 
radiosensitivity and chemosensitivity in head and neck squamous cell carcinomas. Positron­
emission tomography (PET] using the tracer 18Fluoromisonidazole (18FMISO) is most frequently 
used for non-invasive evaluation of hypoxia in human tumors. A series of ten human head and 
neck xenograft tumor lines was used to validate 18FMISO as hypoxia marker at the 
microregional level.
Material and Methods. Autoradiography after injection of 18FMISO was compared with 
immunohistochemical staining for the hypoxic cell marker pimonidazole in the same tumor 
sections of ten different human head and neck xenograft tumor lines. The methods were 
compared, first qualitatively considering the microarchitecture, second by obtaining a pixel-by- 
pixel correlation of both markers at the microregional level, third by measuring the signal 
intensity of both images, and forth by calculating the hypoxic fractions by pimonidazole 
labeling.
Results. The pattern of 18FMISO signal was dependent on the distribution of hypoxia at the 
microregional level. The comparison of 18FMISO autoradiography and pimonidazole 
immunohistochemistry by pixel-by-pixel analysis revealed moderate correlations. In five tumor 
lines, a significant correlation between the mean 18FMISO and pimonidazole signal intensity was 
found (range r2=0.91 to r2=0.99). Comparison of the tumor lines with respect to the 
microregional distribution pattern of hypoxia revealed that the correlation between the mean 
signal intensities strongly depended on the microarchitecture. Overall, a weak but significant 
correlation between hypoxic fractions based on pimonidazole labeling and the mean 18FMISO 
signal intensity was observed (r2=0.18, p=0.02). For the three tumor models with a ribbon-like 
microregional distribution pattern of hypoxia, the correlation between the hypoxic fraction and 
the mean 18FMISO signal intensity was much stronger and more significant (r2=0.73, p<0.001) 
than for the tumors with a more homogeneous, patchy, microregional distribution pattern of 
hypoxia.
Conclusion. Different patterns of 18FMISO accumulation dependent on the underlying 
microregional distribution of hypoxia were found in ten head and neck xenograft tumors. A 
weak albeit significant correlation was found between the mean 18FMISO signal intensity and 
the hypoxic fraction of the tumors. In larger clinical tumors, 18FMISO-PET provides information 
on the tumor oxygenation status on a global level facilitating dose painting in radiation 
treatment planning. However, caution must be taken when studying small tumor subvolumes as 
accumulation of the tracer depends on the presence of hypoxia and on the tumor 
microarchitecture.
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Figure 4.1 Left column: 18FMISO autoradiography images (A: SCCNij59, D: SCCNij153, G: SCCNij180); 
middle column: pseudo-colored grey-value images o f SCCNij59 (B; ribbon-like hypoxia), SCCNij153 (E; mixed 
pattern o f hypoxia) and SCCNij180 (H; patchy hypoxia) showing pimonidazole staining (green) and blood 
vessels (red); right column: detail o f the pseudo-colored grey-value image a t higher magnification, the area 
of origin is highlighted in the middle column (C: SCCNij59, F: SCCNij153, I: SCCNij180).
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4.1 Introduction
Tumor cell hypoxia is a common feature in various solid hum an tum ors, especially in 
hum an squam ous cell carcinomas of the uterine cervix and the head and neck region. In 
these tum ors, hypoxia is associated w ith a poor response to radiotherapy and cytotoxic 
agents, leading to w orse trea tm en t outcome and prognosis 1-5.
T reatm ent modifications counteracting the adverse effects of tum or cell hypoxia have 
been developed and applied in preclinical and clinical trials leading to be tte r loco- 
regional tum or control and im proved survival 6,7. To counteract hypoxia-associated 
radioresistance, hyperoxic gas breathing under norm al or hyperbaric conditions, 
vasoactive drugs and hypoxic cell radiosensitizers have been used clinically. However, 
these trea tm en t modifications are often accompanied by increased toxicity and 
morbidity. Furtherm ore, it is clear th a t no t all patients benefit from these trea tm en t 
intensifications. Patients w ith non-hypoxic tum ors will not gain by hypoxia modulation, 
while still experiencing increased toxicity. Therefore, patien t selection for these 
intensified trea tm en t modalities is compulsory.
In accessible hum an tum ors, e.g., tum ors of the uterine cervix or m etastatically involved 
lymph nodes of head and neck tum ors, the invasive oxygen-sensitive Eppendorf 
histograph needle electrode can be used for m easurem ent of the oxygen partial 
pressure (pO2) 3,5,8-10. Alternatively, hypoxia can be studied after the intravenous (i.v.) 
injection of exogenous bio-reductive hypoxic cell m arkers such as EF5 and 
pimonidazole 11,12. These m arkers can be visualized w ith immunohistochemical 
techniques in biopsies or in tum or resection specimen. At pO2 levels below 10 mmHg, 
the bio-reduction of these 2-nitroim idazoles is strongly increased 12,13. The predictive 
value of hypoxia detected by pimonidazole for trea tm en t outcome was shown in 
advanced head and neck cancer 14.
A prom ising non-invasive imaging modality for detecting hypoxia is positron-em ission 
tom ography (PET) w ith radio-labeled tracers. PET enables functional imaging of the 
entire tum or m ass and affected lymph nodes prior to trea tm en t and m ight be used for 
im proved target volume definition and delineation in radiotherapy, patien t selection for 
trea tm en t modification or for m onitoring trea tm en t efficacy during a course of 
radiotherapy or chemotherapy.
Currently, the m ost frequently used PET-tracer for detecting hypoxia in the clinical 
setting is 18F-fluoromisonidazole (18FMISO) 15-21. The clinical relevance of 18FMISO-PET 
has recently been dem onstrated in several patien t studies 22-24; 18FMISO uptake was 
correlated w ith locoregional failure and outcome after therapy.
Until present, however, the use of 18FMISO to image hypoxia has only been validated to 
a very limited extent. Therefore, knowledge about the perform ance of 18FMISO for
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detection of intratum oral and intertum oral differences in the quantity and distribution 
of hypoxia is limited 21,25-28.
In the p resen t study, ten hum an head and neck xenograft tum ors w ere investigated with 
different microregional distribution patterns of hypoxia: patchy, elongated ribbon-like 
and mixed 29. Intratum oral 18FMISO distribution as determ ined by autoradiography was 
correlated w ith immunohistochem ical detection of pimonidazole w ith specific emphasis 
on m arker distribution and signal intensity relative to the underlying patterns of 
hypoxia.
4.2 Material and Methods
Animals and tumor models. Nine hum an head and neck squam ous cell carcinoma 
xenograft tum or lines (SCCNij59, SCCNij68, SCCNij86, SCCNij153, SCCNij154, SCCNij167, 
SCCNij180, SCCNij185 and SCCNij202) and one m ucoepiderm oid carcinoma xenograft 
line (MEC82) w ere used for com parison of the distribution of 18FMISO and 
pimonidazole. All tum or lines w ere established in-house from tum or biopsies of head 
and neck cancer patients. Viable 1 m m 3 tum or samples w ere im planted subcutaneously 
in the abdom inal flank of n u /n u  BALB/c athymic mice and tum ors w ere used for the 
experim ents a t a d iam eter of 8 - 9 mm. All mice w ere kept in accordance with 
institutional guidelines and the Animal Welfare Committee of the Radboud University 
Nijmegen approved all experiments.
18FMISO synthesis. 18FMISO was synthesized according to the m ethod described by 
Lim and Berridge 30. The 1-(2'-nitro-1'-imidazolyl)-2-O-tetrahydropyranyl-3-O- 
toluenesulfonyl-propanediol (NITTP) precursor was obtained from ABX GmbH 
(Radeberg, Germany) and 18Fluoride was obtained from BV Cyclotron VU (Amsterdam, 
The Netherlands). Radiosynthesis was perform ed in an autom ated synthesizer 
(Synchrom R&D, Raytest GmbH, Straubenhardt, Germany). Radiochemical yield (decay 
corrected) was always higher than 40%  and radiochemical purity  was always higher 
than 98%. Specific activity a t the end of synthesis was always higher than 50,000 
GBq/mmol.
Experimental setup. Tum or bearing mice w ere injected i.v. w ith 30 MBq 18FMISO in
0.2 mL. After 5 min, pimonidazole (1-[(2-hydroxy-3-piperidinyl) propyl]-2- 
nitroim idazole hydrochloride; Natural Pharmacia International, Research Triangle Park, 
NC) was injected intraperitoneally a t a dose of 80 mg/kg. Mice from all ten xenograft 
lines w ere sacrificed by CO2-asphyxiation one hour after the adm inistration of 18FMISO. 
In order to analyze tracer distribution over time, additional mice bearing the SCCNij59 
and MEC82 xenograft tum ors (two tum ors per line) w ere killed four hours after the 
injection. Imm ediately after killing the mice, tum ors w ere dissected and snap frozen in
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liquid nitrogen. W ithin 30 min, frozen tum or sections of 5 pm thickness w ere cut a t the 
largest d iam eter and used for autoradiography of the 18F signal.
Autoradiography. Tumor sections w ere exposed to a phosphor imaging screen 
overnight. The screen was scanned in a phosphor im ager system  (Molecular Imager 
GS363, Bio-Rad Laboratories, Hercules, CA) a t a pixel size of 100 pm x 100 pm (dynamic 
range: 4095 grey-values). Images w ere processed w ith Quantity One software (version 
4.5.2, Bio-Rad Laboratories, Hercules, CA). The same tum or sections w ere then used for 
immunohistochem ical staining and analysis of pimonidazole labeling.
Immunohistochemical staining for hypoxia. Between all consecutive steps of the 
staining procedure, the sections w ere rinsed th ree  tim es for 5 min in 0.1 M phosphate­
buffer saline (PBS, Klinipath, Duiven, The Netherlands), pH 7.4. The sections w ere first 
fixed in cold acetone (4 °C) for 10 min. After re-hydration of the tissue sections in PBS 
during 20 min, they w ere incubated w ith rabb it anti-pim onidazole (gift J.A. Raleigh, 
D epartm ent of Radiation Oncology, University of North Carolina School of Medicine, 
Chapel Hill, NC) diluted 1:1000 in prim ary antibody diluent (PAD, Abcam, Cambridge, 
UK) for 30 min. Sections w ere then incubated w ith donkey anti-rabbit-Alexa488 
(Molecular Probes, Leiden, The Netherlands) diluted 1:400 in PBS for 30 min. Finally, 
sections w ere m ounted w ith Fluorostab (Organon, Boxtel, The Netherlands).
Immunohistochemical image acquisition. All tum or sections w ere analyzed using a 
digital image analysis system  as described previously 31. Grey-value images of 
pimonidazole w ere obtained after scanning whole tum or sections a t a pixel size of 
2.5 pm x 2.5 pm (dynamic range: 4095 grey-values). Thresholds for segm entation of the 
fluorescent signals w ere interactively set above the background level including all 
pimonidazole-positive tum or areas. Binary images w ere used to calculate the hypoxic 
fraction (HF; tum or area positive for pimonidazole relative to the total viable tum or 
area). Areas of necrosis w ere excluded from the analysis.
Analysis on co-localization, m ean signal intensity and hypoxic fraction: The 
autoradiography and im m unohistochem istry images w ere manually co-registered in 
IPLab (Scanalytics Inc., Fairfax, VA) and the pixel size of the la tter was rescaled to match 
the pixel size of the phosphor imager. The images w ere then analyzed with in-house 
developed software th a t was im plem ented in IDL 6.0 (Research Systems, Boulder, CO), 
restricting the analysis to the tum or area and excluding areas of necrosis by drawing 
masks.
Pixel-by-pixel analysis on the grey-value images was perform ed for co-localization 
analysis. Scatter plots w ere created and subsequently a linear regression was 
perform ed. Furtherm ore, the mean signal intensities of both imaging modalities w ere 
com pared using a linear regression. Finally, the hypoxic fraction obtained after
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segm entation of the pimonidazole signal was correlated w ith the m ean signal 
intensities of 18FMISO autoradiography using linear regression.
Statistical analysis. Linear regression analyses w ere perform ed using GraphPad Prism 
for Macintosh, version 4.0a (La Jolla, CA). The p-value, r  and r2 w ere calculated. A p- 
value < 0.05 was considered statistically significant.
4.3 Results
4.3.1 18FMISO autoradiography and pimonidazole staining
Images after 18FMISO autoradiography, the corresponding pseudo-colored grey-value 
images of pimonidazole staining and details of the tum or sections a t larger 
magnification w ere obtained (Fig. 4.1). Three of the ten hum an head and neck tum or 
lines studied showed a ribbon-like pattern  of hypoxia detectable after 
immunohistochem ical staining for pimonidazole (e.g., SCCNij59, Fig. 4.1B-C) 29. The 
corresponding autoradiography images showed a sim ilar distribution of 18FMISO, w ith a 
high accum ulation in pimonidazole positive and a low signal in pimonidazole negative 
areas. Six tum or lines showed a mixed pattern  of hypoxia w ith ribbon-like and patchy 
com ponents by im m unohistochem istry (e.g., SCCNij153, Fig. 4.1E-F) 29. Co-localization 
of 18FMISO and pimonidazole was dependent on the underlying m icroregional 
distribution pattern  of hypoxia. A clear correlation was only found in tum ors w ith a 
ribbon-like pimonidazole distribution pattern. In tum ors w ith a patchy distribution 
pattern, such as SCCNij180, accumulation of 18FMISO as detected by autoradiography 
occurred throughout the tum or section (Fig. 4.1H-I).
4.3.2 Pixel-by-pixel analysis of 18FMISO autoradiography and PIMO 
immunohistochemistry grey-value images
Amongst the ten head and neck xenograft lines harvested one hour after tracer 
adm inistration, a range of correlation coefficients after pixel-by-pixel grey-value 
analysis was found (Table 4.1). The underlying hypoxic pattern  a t the microregional 
level (e.g., ribbon-like versus  patchy) did not influence the degree of correlation of the 
two imaging modalities. In accordance w ith the tim e interval frequently used in hum an 
studies, additional tum ors originating from two lines (SCCNij59 and MEC82, two tum ors 
per xenograft line) w ere studied 4 hours after 18FMISO injection. No im provem ent in 
correlation of the imaging modalities was observed (data not shown).
4.3.3 Mean signal intensity of 18FMISO and pimonidazole
When analyzing all tum ors together - irrespective of the xenograft line and thus 
underlying m icroarchitecture - no correlation betw een the m ean 18FMISO and mean 
pimonidazole signal intensity was found (Fig. 4.2A). However, as the m icroarchitecture
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m ight influence the degree of correlation, fu rther analysis was perform ed taking the 
underlying hypoxic patterns into account. For the tum ors w ith a ribbon-like distribution 
of hypoxia, the correlation of the m ean signal intensities of both tracers was strong and 
statistically significant [SCCNijS9: r2=0.99, p=0.05; MEC82: r2=0.93, p=0.04 and 
SCCNij167: r2=0.98, p=0.01; Fig. 4.2B). Of the rem aining seven xenograft tum or lines 
with a mixed or patchy pattern  of hypoxia, only two w ith a mixed pattern  of hypoxia 
showed a statistically significant correlation betw een the mean 18FMISO and 
pimonidazole signal intensities [SCCNij86: r2=0.93, p=0.03 and SCCNij153: r2=0.91, 
p=0.05; Fig. 4.2C).
4.3.4 Hypoxic fraction versus mean 18FMISO and pimonidazole signal intensity
A w eak bu t statistically significant correlation betw een the hypoxic fraction based on 
segm entation of the pimonidazole signal and the mean 18FMISO signal intensity was 
found w hen all xenograft tum ors w ere analyzed together [r2=0.18, p=0.02; Fig. 4.3). For 
the th ree  tum or lines w ith a ribbon-like hypoxia pattern  [SCCNijS9, MEC82 and 
SCCNij167), the correlation betw een the hypoxic fraction and the mean 18FMISO signal 
intensity was much stronger and m ore significant [r2=0.73, p<0.001).
Table 4.1 Numbers o f tumors per xenograft line studied, mean linear regression coefficient r and
corresponding standard error o f the mean (SEM) obtained after pixel-by-pixel analysis o f the pimonidazole 
and 18FMISO image.
Xenograft line
Number of 
tumors studied
Regression coefficient r
mean SEM
SCCNij59 3 0.09 0.01
SCCNij68 4 0.11 0.07
MEC82 4 0.12 0.03
SCCNij86 4 0.06 0.03
SCCNij153 4 0.19 0.15
SCCNij154 5 0.09 0.03
SCCNij167 4 0.05 0.03
SCCNij180 5 0.04 0.01
SCCNij185 4 0.06 0.03
SCCNij202 3 0.19 0.06
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Figure 4.2 Mean 18FMISO versus mean pimonidazole signal intensity o f all xenografts tumor lines 
studied (A) and o f the tumors with a ribbon-like (B) or patchy and mixed (C) pattern o f hypoxia.
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Figure 4.3 Linear regression of the hypoxic fraction based on segmentation o f the pimonidazole signal 
versus mean 18FMISO signal intensity in all xenograft tumor lines studied.
4.4 Discussion
Tum or cell hypoxia is a tum or characteristic responsible for poor trea tm en t outcome 
and prognosis, especially in squam ous cell carcinoma of the head and neck. Various 
trea tm en t modifications aiming at reducing tum or hypoxia have been developed. Most 
of these trea tm en t intensifications are at the cost of increased toxicity, necessitating 
patient selection. The assessm ent of hypoxia by endogenous (e.g., Glut-1 and -3, CA-IX) 
or exogenous hypoxic cell m arkers (e.g., EF5 and pimonidazole) enables pre-treatm ent 
assessm ent of tum or hypoxia 1. Non-invasive imaging using PET provides biological and 
geometrical inform ation on the prim ary tum or and on potentially m etastatic lymph 
nodes or distant m etastases. This inform ation is required  for patient selection prior to 
trea tm en t initiation and for radiation trea tm en t planning. Furtherm ore, these 
techniques make it possible to m onitor tum or response during treatm ent, eventually 
allowing to adjust the trea tm en t based on tum or response characteristics 23.
Clinical and preclinical studies published on 18FMISO have only been perform ed on 
small cohorts of patients and on a limited num ber of experim ental tum ors and tum or 
cell lines. Therefore, little is known about the influence of the m icroarchitecture on the 
18FMISO distribution and the correlation w ith immunohistochemical visualization of 2- 
nitroim idazole derivates. The aim of this study was to validate 18FMISO 
autoradiography versu s  pimonidazole im m unohistochem istry in ten hum an head and 
neck xenograft models, both qualitatively and quantitatively, and furtherm ore to 
analyze w hether tum or m icroenvironm ental characteristics affect 18FMISO distribution. 
In a series of hum an xenografts originating from squam ous cell carcinomas of the head 
and neck, Ljungkvist e t  al. described three different patterns of distribution of hypoxia: 
patchy, elongated ribbon-like and mixed 29. The patchy hypoxic pattern  is characterized 
by larger areas of chronic hypoxia w ith gradients of pimonidazole binding. The ribbon-
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like pattern  displays narrow er zones of hypoxia w ith m ore intense pimonidazole 
binding and a t further distance from the vasculature necrosis. In tum ors w ith ribbon­
like patterns of hypoxia, a strong 18FMISO accumulation was detected in the viable 
pimonidazole positive areas w ith no signal in necrotic or normoxic regions. The tum ors 
w ith a patchy or mixed pattern  of pimonidazole binding w ith little or no necrotic 
regions dem onstrated a m ore diffuse 18FMISO signal throughout the tumor.
These heterogeneous patterns of accumulation w ere also seen in studies by others 
using 18FMISO or 64CuATSM 21,25,27. Wyss e t  al. analyzed ten hum an xenografts 
originating from various tum or types using NanoPET imaging 21. They described a 
category of tum ors w ith a high-count density in the rim  of the tum or surrounding a 
central p a rt of low radioactivity and another category w ith a spotty distribution of 
18FMISO, indicating a heterogeneous pattern  of hypoxia. This finding was supported  by 
Allemann e t  al., who imaged seven cats w ith vaccine-associated sarcom a and found 
tum ors w ith high focal 18FMISO uptake and others w ith a m ore patchy distribution of 
the hypoxia PET-tracer 25. Using 64CuATSM as PET tracer, Tanaka e t  al. perform ed 
autoradiography and im m unohistochem istry in various xenografts and found 64CuATSM 
accumulation to be p resen t a t the edge of the tum ors w ith no accumulation in the 
necrotic areas 27. Two tum or characteristics a t the microregional level may explain 
these heterogeneous patterns of accumulation. As m entioned above, tum ors w ith a 
ribbon-like pattern  of hypoxia receive their blood-supply from vascular sheets as 
com pared to patchy tum ors w ith a central vessel being responsible for the blood- 
supply. These vascular structures are responsible for the PET tracer influx, bu t also for 
the w ash-out of the tracer. One could therefore hypothesize th a t the vascular sheets 
found in ribbon-like tum ors are m ore effective in facilitating tracer influx and wash-out. 
Furtherm ore, in the tum or lines w ith a ribbon-like hypoxia pattern, hypoxia may be 
m ore severe com pared to the patchy tum ors, resulting in an intense pimonidazole and 
18FMISO binding. As a resu lt of this, the hypoxic pattern  of ribbon-like tum ors imaged by 
18FMISO autoradiography is likely to be m ore distinct com pared to the patchy tum ors 
with m ore extensive areas w ith a distribution of hypoxia.
In the curren t study, the microregional distribution and spatial correlation betw een 
18FMISO and pimonidazole accumulation was assessed quantitatively by pixel-by-pixel 
analysis. Results obtained by these analyses varied betw een different xenograft lines, 
b u t w ere not influenced by the underlying hypoxic pattern  20. Yuan e t  al. studied three 
histologically different hum an xenografts using microPET and autoradiography, and 
found the correlation betw een 64CuATSM autoradiography and EF5 
im m unohistochem istry to differ substantially betw een tum or lines from r2=0.05 to 
r2=0.78 28. In two out of the th ree  lines studied, the regression coefficients w ere high 
com pared to our study. However, the scatter plots show th a t pixels outside the tum or 
area and presum ably also in necrotic areas w ere included in the pixel-by-pixel analysis. 
In our study, signal intensities outside the tum or and in necrotic areas w ere excluded
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from the analysis resulting in lower regression coefficients. Another explanation for the 
w eak correlation found in several of our tum or lines could be the difference in binding 
characteristics of pimonidazole and 18FMISO. For the pimonidazole staining, an 
antibody th a t is raised against the reduced pimonidazole adducts is used and therefore, 
extracellular (non-reduced) pimonidazole is not detected. In contrast to this, the signal 
of the autoradiography images com prises both, bound and reduced, and unbound non­
reduced 18FMISO. Finally, m anual co-registration of the images may introduce 
m ism atches th a t influence the results of the pixel-by-pixel analysis.
A strong and significant positive correlation betw een mean signal intensity of 18FMISO 
and pimonidazole was found in five of the ten xenograft lines studied. Remarkably, 
w ithin these five tum ors, all tum ors w ith a ribbon-like pattern  of hypoxia are presented. 
In these specific tum ors, the influx, wash-out, accumulation and reduction of both 
tracers m ust be very sim ilar resulting in a strong correlation of the mean signal 
intensities of both modalities.
The correlation of the hypoxic fraction, obtained after segm entation of the 
pimonidazole signal, w ith the mean 18FMISO signal intensity showed a significant albeit 
w eak correlation w hen including all ten xenografts lines in the analysis. Not 
surprisingly, w hen only including the tum ors w ith a ribbon-like pattern  of hypoxia, the 
correlation of m ean 18FMISO signal intensity and the hypoxic fraction improved. These 
findings are in agreem ent w ith results by Hoebers e t  al. on ten head and neck cancer 
patients 32. They found a correlation betw een SPET scans using the novel radioactively 
labeled 2-nitro-imidazole hypoxic m arker 99mTc-BRU 59-21 and pimonidazole-positive 
areas (prim ary tum or: r=0.73, p=0.016; prim ary tum or + lymph nodes: r=0.86, 
p<0.001). Additionally, the correlation was found to vary betw een individual patients 
supporting our hypothesis on the influence of the m icroarchitecture. Also, these 
findings support the observation th a t correlation of different imaging modalities (and 
different tracers) may vary depending on the imaging m ethods used and are not 
necessarily interchangeable 33. However, m ore im portantly, our results and those by 
Hoebers e t  al. show  th a t the tum or oxygenation status macroscopically assessed by 
nuclear imaging techniques corresponds w ith the overall hypoxic fraction. This 
indicates th a t 18FMISO-PET can provide prognostic and predictive inform ation on the 
overall oxygenation status of a tum or. The prognostic potential was shown by 
Thorw arth e t  al., who found a correlation betw een 18FMISO uptake and radiotherapy 
outcome in a series of 12 head and neck cancer patients 24. Rischin e t  al. showed the 
predictive potential of 18FMISO in 45 patients w ith advanced head and neck cancer 23. 
They perform ed pre-treatm ent and m idtreatm ent 18FMISO-PET scans and found 
18FMISO-PET to be predictive for the response to the hypoxic cytotoxin tirapazam ine.
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In contrast to these encouraging results on entire tum or volumes, the use of 18FMISO- 
PET for the identification of sm aller hypoxic areas, for instance w hen considering 
boosting hypoxic tum or subvolumes w ith radiation therapy, probably depends on the 
m icroarchitectural organisation of the tum ors.
4.5 Conclusions
Comparison of 18FMISO with pimonidazole in a variety of hum an head and neck 
xenograft tum ors revealed different patterns of tracer accumulation depending on the 
tum or m icroarchitecture. A significant correlation was found betw een the mean 
18FMISO signal intensity and the hypoxic fraction of the tum or assessed by 
pimonidazole staining. 18FMISO-PET may provide inform ation on the global tum or 
oxygenation status, bu t is less reliable for studying tum or subvolumes.
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Abstract
Purpose. One of the major reasons of resistance to radiation therapy is tumor cell hypoxia. 
Visualization and quantification of the hypoxic cell marker pimonidazole has been shown to be 
a potential predictor for treatment outcome in advanced stage head and neck cancer. Positron 
emission tomography [PET] using 18P-labeled misonidazole [18PMISO] is a non-invasive way of 
imaging tumor hypoxia. However, in contrast to pimonidazole, little is known about its value 
under varying levels of hypoxia induced by oxygenation modifying treatment. Aim of this study 
was to validate the PET-tracer 18PMISO against pimonidazole immunohistochemistry under 
different oxygenation conditions.
Material and Methods. A human head and neck squamous cell carcinoma (SCCNij3) and two 
human glioblastoma [E102 and E106] xenograft tumor lines were studied after injection of 
18PMISO and pimonidazole. Control mice were compared with a second group breathing 
carbogen [95% O2 and 5% CO2) to reduce tumor hypoxia and a third group, where tumors were 
clamped to increase hypoxia. Tumor sections were analyzed overnight using a phosphor 
imaging system for autoradiography and consecutively, the same sections were stained 
immunohistochemically [IHC] for visualization of pimonidazole. A pixel-by-pixel analysis was 
used to compare 18PMISO with pimonidazole. Also, the hypoxic fraction obtained after 
segmentation of the pimonidazole signal, was related to the mean optical density of 18PMISO 
and pimonidazole.
Results. A moderate pixel-by-pixel correlation between 18PMISO autoradiography and 
pimonidazole IHC was found for the control tumors, after carbogen breathing and after 
clamping for SCCNij3. Only very weak correlations were found for the glioblastoma lines. Mean 
signal intensities for pimonidazole significantly decreased after carbogen breathing and 
increased after clamping in E102 and E106. Mean 18PMISO signal intensities increased 
significantly after clamping for both glioma xenograft tumor lines. A significant correlation 
between the hypoxic fractions obtained after segmentation of the pimonidazole signal and the 
mean 18PMISO signal intensities was found only for the glioblastoma xenograft tumor lines [r2 
ranging from 0.28 to 0.86].
Conclusions. 18PMISO autoradiography and pimonidazole immunohistochemistry can both be 
used to visualize treatment induced changes in tumor hypoxia. However, the response to these 
modifications differs widely between xenograft tumor lines. Therefore, clinical studies 
validating 18PMISO against pimonidazole immunohistochemical staining in different tumor 
entities are necessary.
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5.1 Introduction
Hypoxia is p resen t in m ost solid tum ors due to im paired oxygen and nu trien t supply to 
the tum or 1. Hypoxia is associated w ith an increased likelihood of locoregional 
recurrence and distant m etastases. Furtherm ore, hypoxia decreases the response to 
radiation therapy and to several cytotoxic agents, leading to poor trea tm en t outcome 
and prognosis 2-5. To overcome hypoxia-induced radioresistance, several trea tm en t 
modifications have been developed, such as the use of hyperoxic gas breathing under 
norm al or hyperbaric conditions, vasoactive drugs and hypoxic cell sensitizers. These 
modifications often lead to increased toxicity and m orbidity for the patient. 
Furtherm ore, no t all patients benefit from this trea tm en t intensification. For instance, 
patients w ith non-hypoxic tum ors will no t gain by hyperoxic gas breathing while still 
experiencing the increase in side effects. Therefore, careful selection of patients for 
these intensified trea tm en t modalities is necessary.
Traditionally, the oxygen partial pressure (pO2) in accessible hum an tum ors, e.g., the 
uterine cervix and lymph nodes, is m easured using the invasive oxygen-sensitive 
Eppendorf histograph needle electrode 3,5-8. Hypoxia can also be detected by 
visualization of bio-reductive hypoxic cell m arkers in tum or sections. The two 
exogenous hypoxia m arkers approved for patien t studies are EF5 and pim onidazole 9, 10. 
Bio-reduction of these 2-nitroim idazoles strongly increases a t pO2 levels below 
10 mmHg. Recently, the predictive value of hypoxia detected by pim onidazole for 
trea tm en t outcome was shown in advanced stage head and neck cancer 11. The use of 
endogenous hypoxia-related m arkers, such as carbonic anhydrase IX (CA-IX) or glucose 
transporters (Glut-1 and -3), has been extensively investigated for this purpose. 
However, results thus far are conflicting 12-15.
Although these hypoxic cell m arkers are excellent tools for quantification of hypoxia at 
the microregional level, these assays cannot be used to m onitor changes of tum or 
hypoxia over time. Prom ising non-invasive imaging modalities perm itting repeated 
m easurem ents include magnetic resonance imaging techniques and positron-em ission 
tom ography (PET) of radio-labeled bio-reductive m arkers 16,17. Currently, the clinically 
m ost widely used hypoxia PET-tracer is 18F-fluoromisonidazole (18FMISO) 16,18-20. 
However, 18FMISO cannot be validated as a hypoxia m arker a t m icroregional level as no 
antibody is available until present.
This study was designed to evaluate the potential usefulness of 18FMISO for the 
detection of changes in tum or hypoxia in three hum an xenograft tum or lines after 
carbogen (95%  O2, 5% CO2) breathing and clamping and com pare the results w ith the 
well established hypoxic cell m arker pimonidazole.
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5.2 Material and Methods
Animals and tumor models. The hum an head and neck squam ous cell carcinoma 
xenograft tum or line SCCNij3, and the hum an glioblastoma tum or lines E102 and E106 
w ere used for these experim ents. Viable 1 m m 3 tum or pieces w ere im planted 
subcutaneously in the abdom inal flank of athymic BALB/C n u /n u  mice and tum ors w ere 
used for the experim ents a t a diam eter of 8 - 9 mm. All mice w ere kept in accordance 
w ith institutional guidelines. All experim ents w ere approved by the Animal 
Experim ents Committee of the Radboud University Nijmegen.
18FMISO synthesis. 18FMISO was synthesized according to the m ethod described by Lim 
and Berridge 21. The 1-(2'-nitro-1'-im idazolyl)-2-O-tetrahydropyranyl-3-O- 
toluenesulfonyl-propanediol (NITTP) precursor was obtained from ABX GmbH 
(Radeberg, Germany) and 18Fluoride was obtained from BV Cyclotron VU (Amsterdam, 
The Netherlands). Radiochemical yield (decay corrected) was always higher than 40%  
and radiochemical purity  was always higher than 98%. Specific activity a t end of 
synthesis was higher than 50,000 GBq/mmol.
Experimental setup. Mice w ere stratified into three  groups of 5-6 animals, based on 
tum or size; one group served as control, the o ther groups w ere studied either under 
carbogen breathing or clamping. At the s ta rt of the experiment, the control animals 
w ere injected i.v. w ith 37 MBq of the hypoxia PET-tracer 18FMISO in 0.2 mL. After five 
minutes, the exogenous hypoxia m arker pimonidazole hydrochloride (1-[(2-hydroxy-3- 
piperidinyl) propyl]-2-nitroim idazole hydrochloride; Natural Pharmacia International, 
Research Triangle Park, NC) was injected i.p. a t a dose of 80 m g/kg. One hour after 
injection of 18FMISO the animals w ere killed by cervical dislocation. The mice in the 
carbogen group started  breathing carbogen (95%  O2, 5% CO2; Hoek Loos, Schiedam, 
The Netherlands) 5 min before injection of 18FMISO and continued until the animals 
w ere killed. In the clamping group, 30 min after adm inistration of 18FMISO, tum ors 
w ere clamped for 30 or 60 min until killing of the animals. Imm ediately after killing the 
mice, tum ors w ere rem oved and snap frozen in liquid nitrogen. Within 30 min, frozen 
tum or sections of 5 pm thickness w ere cut from the central p a rt of the tum or and 
sections w ere used to detect the 18FMISO signal on the phosphor imaging system  (PPI).
Autoradiography. From each tum or, a central 5 pm section was cut and m ounted on 
poly-L-lysine coated slides. Tum or sections w ere exposed to the phosphor imager 
overnight. The screen was scanned in a phosphor im ager system (Molecular Imager 
GS363, BioRad Laboratories, Hercules, CA) a t a pixel size of 100 pm x 100 pm. Images 
w ere processed w ith Quantity One software (version 4.5.2, BioRad Laboratories, 
Hercules, CA). The same tum or section was then used for immunohistochem ical 
staining and analysis of pim onidazole labeling.
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Immunohistochemical staining for hypoxia and blood vessel perfusion. Between all 
consecutive steps of the staining procedure, the sections w ere rinsed th ree tim es for 5 
min in 0.1 M phosphate-buffer saline (PBS, Klinipath, Duiven, The Netherlands), pH 7.4. 
The sections w ere first fixed in cold acetone (4 °C) for 10 min. After re-hydration of the 
tissue sections in PBS during 20 min, they w ere incubated w ith rabbit anti- 
pimonidazole (gift J.A. Raleigh) diluted 1:1000 in prim ary antibody diluent (PAD, 
Abcam, Cambridge, UK) for 30 min. Sections w ere then incubated w ith donkey anti- 
rabbit-Alexa488 (Molecular Probes, Leiden, The Netherlands) diluted 1:400 in PBS for 
30 min. For vessel staining, sections w ere first incubated w ith undiluted 9F1 (rat 
monoclonal to endothelium; D epartm ent of Pathology, Radboud University Nijmegen 
Medical Centre, The Netherlands) for 30 min and then w ith goat anti-rat-TRITC 
(Jackson Immuno Research Laboratories Inc., W est Grove, PA), diluted 1:200 in PBS for 
30 min. Finally, sections w ere m ounted on Fluorostab (Organon, Boxtel, The 
Netherlands).
Co-localization analysis. The autoradiography and im m unohistochem istry images 
w ere manually co-registered in IPLab (Scanalytics Inc., Fairfax, VA) and the pixel size of 
the la tter was rescaled to m eet th a t of the autoradiography (pixel size: 100 pm x 
100 pm). The images w ere then analyzed w ith in-house developed softw are th a t was 
im plem ented in IDL 6.0 (Research Systems, Boulder, CO). The rescaled and co­
registered images w ere used to create scatter plots, which w ere fitted w ith a linear 
regression line. In addition, mean, median and standard  deviation of the signal 
intensities w ere calculated.
Statistical analysis. Pixel-by-pixel correlations w ere calculated in IDL. For inter- and 
intratum oral correlation, mean, median and standard  deviation w ere calculated by 
linear regression and by applying the Kruskal-Wallis te st (GraphPad Prism for 
Macintosh, version 4.0a; La Jolla, CA). A p-value < 0.05 was regarded statistically 
significant.
5.3 Results
5.3.1 18FMISO autoradiography and pimonidazole staining
Figure 5.1 depicts examples of hypoxia visualized after pimonidazole 
im m unohistochem istry, segm entation of the pimonidazole signal and 18FMISO 
autoradiography of the SCCNij3 and E106 tum ors. In the SCCNij3 tum ors, visualization 
of pimonidazole revealed a significant increase of the hypoxic fraction (obtained after 
segm entation of the grey-value image) after clamping and a decrease of the hypoxic 
fraction after carbogen breathing (Table 5.1). However, in this tum or no significant 
changes in the 18FMISO autoradiography images w ere observed w ith only a minimal 
response after carbogen breathing. In the E102 and E106 tum ors, a reduction of the
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hypoxic fraction in the carbogen group was found as well as an increase after clamping 
(Fig. 5.1 and Table 5.1). 18FMISO autoradiography after clamping showed an increase in 
signal intensity. After carbogen breathing only a minimal reduction of 18FMISO signal 
was observed.
5.3.2 Pixel-by-pixel analysis of autoradiography and immunohistochemistry
Figure 5.2 shows examples obtained after pixel-by-pixel analysis based on pixel 
intensity illustrating a m oderate correlation betw een pimonidazole 
im m unohistochem istry and 18FMISO autoradiography for SCCNij3. The mean regression 
coefficient (r2) was 0.10 for the controls, 0.12 after carbogen breathing and 0.29 after 
clamping. For E102 the mean r2 was 0.05 for the control, 0.06 for the carbogen 
breathing and -0.02 for the clamping group. Corresponding mean r2-values for E106 
w ere 0.14 for the controls, 0.07 after carbogen breathing and 0.03 after clamping.
Table 5.1 Mean hypoxic fraction o f  xenograft tumor lines
Hypoxic fraction (SEM)
(tumor area positive for pimonidazole compared to total tumor area)
control carbogen p-value* clamping p-value*
SCCNij3 0.06 (0.03) 0.04 (0.02) n.s. 0.21 (0.04) 0.02
E102 0.03 (0.00) 0.01 (0.00) n.s. 0.85 (0.06) 0.02
E106 0.03 (0.00) 0.00 (0.00) 0.03 0.40 (0.80) 0.003
SEM = standard error o f the mean, * = relative to control, n.s. = not significant
5.3.3 Mean signal intensity of 18FMISO and pimonidazole
Figure 5.3 illustrates the analysis of mean signal intensities of pimonidazole and 
18FMISO. In contrast to the hypoxic fraction, which is obtained after segm entation of the 
pimonidazole image, the m ean  s ig n a l  in te n s i ty  of both pimonidazole and 18FMISO 
showed only a m inor change after carbogen breathing. Only for E102, and to a lesser 
extent for E106, a significant reduction of the m ean pimonidazole signal intensity was 
observed (Fig. 5.3). Clamping of the tum ors resulted in a significant increase of the 
mean signal intensity of both pim onidazole and 18FMISO in all tum ors, except in SCCNij3 
in which the increase of 18FMISO signal by autoradiography after clamping was not 
statistically significant.
5.3.4 Hypoxic fraction (HF) versus signal intensity
Figure 5.4 shows hypoxic fraction versus  mean signal intensity of pimonidazole and 
18FMISO. For SCCNij3 (Fig. 5.4A), a significant bu t w eak correlation betw een hypoxic 
fraction and mean pimonidazole signal intensity was found. For both, the E102 (Fig. 
5.4B) and E106 (Fig. 5.4C) xenograft tum or lines, we found a statistically significant 
correlation betw een the HF and both the mean PIMO and 18FMISO signal intensity.
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Figure 5.1 Pseudo-colored grey-value pimonidazole images (top row), images after segmentation of  
the pimonidazole signal (middle row) and 18FMIS0 autoradiography images (bottom  row) of SCCNij3 and 
E106 for control tumors (a), after carbogen breathing (b) and clamping (c).
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r2 = 0.27 r2 = 0.39 r2 = 0.28
(a) (b) (c)
r2 = 0.06 r2 = 0.03 r2 = -0.01
(d) (e) (f)
r2 = 0.22 r2 = 0.12 r2 = -0.10
(g) (h) (i)
control carbogen clamping
Figure 5.2 Examples o f scatter plots obtained after pixel-by-pixel analysis o f pimonidazole intensity 
and 18FMlSO intensity fo r the control (left panel), carbogen (middle panel) and clamping (right panel) group 
of SCCNij3 (top row), E102 (middle row) and E106 (bottom row) with the best linear fit. Regression 
coefficient r2 is shown.
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Figure 5.3 Mean signal intensities o f  pimonidazole and 18FMISO in the control, carbogen breathing 
and clamping groups. A p<0.05 is indicated by*, a p<0.01 by ** and a p<0.001 by ***, Kruskal-Wallis test was 
applied. Error bars represent standard deviation.
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Figure 5.4 Linear regression analysis comparing hypoxic fraction obtained after segmentation o f the 
pimonidazole immunohistochemical staining with mean pimonidazole and 18FMISO signal intensities. P- 
values and r2 are shown.
5.4 Discussion
A w ell-established m ethod for quantification of hypoxia is the use of hypoxic cell 
m arkers such as pimonidazole. Immunohistochemical detection of pimonidazole in 
tissue sections has been shown to predict for prognosis in advanced stage head and 
neck cancer 11. A possible alternative to this m ethod is PET imaging of the hypoxic 
tracer 18FMISO. In various solid tum ors hypoxia was detected using 18FMISO-PET 16,18-2°.
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The advantage of imaging hypoxia w ith a 18FMISO-PET scan is th a t it can be used 
repeatedly on an alm ost daily basis due to the sho rt half-life of the tracer (1.83 h). 
Another advantage is the possibility to visualize hypoxia in the whole tum or, albeit a t a 
low resolution (5 mm). Aim of this study was to validate the hypoxia PET-tracer 
18FMISO against pimonidazole im m unohistochem istry under different oxygenation 
conditions. For this purpose, three  hum an xenograft tum or lines w ere studied under 
am bient conditions and after carbogen breathing and clamping of the tum ors. 
Assessm ent of the m icroregional distribution of hypoxia was based on 
immunohistochem ical staining of the bio-reductive hypoxia m arker pimonidazole. 
Hypoxic fractions obtained after image analysis showed a decrease after carbogen 
breathing and an increase after clamping, the extent of the changes varied widely 
betw een the tum or lines.
In the p resen t study, hypoxia detected by pimonidazole staining was quantified in two 
different ways: first after segm entation of the pimonidazole-based grey-value images 
and second based on intensity profiles of both 18FMISO and pimonidazole (Fig. 5.1). 
Previously, it was shown th a t the range of staining profiles of the nitroim idazole EF5 - 
detected by im m unohistochem ical staining techniques directly correlates w ith hypoxia 
levels in tum or sections 22. For visualization of pimonidazole we used a two-step 
staining technique th a t has the advantage of creating an optimal signal-to-noise ratio. 
The disadvantage of an indirect labeling technique is th a t the range of intensity values 
could be affected. This may explain the observation th a t correlations related to intensity 
profiles of pimonidazole and 18FMISO are only m oderate. However, by optimizing the 
signal-to-noise ratio, segm entation of the grey-value images becomes m ore reliable. The 
resu lt is th a t the hypoxic fraction is a m ore robust param eter for tum or hypoxia than 
th a t based on intensity profile analysis.
Dubois e t  al. com pared 18FMISO microPET and autoradiography w ith 
im m unohistochem istry (pim onidazole and CA-IX) under am bient conditions in a ra t 
rhabdom yosarcom a model 23. A significant correlation betw een 18FMISO-PET and 
pim onidazole-positive volume was found. In tha t study, both volumes w ere based on 
segm entation of the microPET and staining images and no t on intensity profiles. In our 
study, for two of the three  xenograft tum or lines, a significant correlation was also 
found betw een hypoxic fractions and the m ean 18FMISO signal intensity, which clearly 
shows the heterogeneity of tum ors in response to carbogen breathing.
The pixel-by-pixel correlation betw een the mean signal intensity of pimonidazole and 
18FMISO varied from very w eak to m oderate in the th ree  xenograft tum or lines. This 
may be due to the reform atting of the pixel size of the im m unohistochem ical image to 
the pixel size of the phosphor imager. In this procedure, microregional differences in 
signal intensity are lost due to integration over a relatively large volume. Small 
inaccuracies after m anual co-registration of both images may introduce m ismatch 
betw een both imaging modalities resulting in a fu rther decrease of the pixel-by-pixel
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correlation. Finally, differences may also be tum or line dependent. The pixel-by-pixel 
correlation is stronger for tum ors w ith larger patches of hypoxia and w eaker if hypoxia 
is p resen t in sm aller areas throughout the tumor.
Clamping resulted in a significant increase of the mean signal intensity for both 
pimonidazole and 18FMISO relative to control tum ors in the two glioblastoma xenograft 
lines. However, a significant reduction in mean signal intensity after carbogen breathing 
was only found for the mean pimonidazole signal intensity in these tum ors and no t for 
the mean 18FMISO signal intensity. This higher than expected activity of 18FMISO could 
be caused by in tra-tum or trapping of unbound m arker. Van der Sanden e t  al. described 
a decrease in tum or blood perfusion after carbogen breathing - m easured by MR- 
imaging of gadolineum DTPA-uptake - in a glioblastoma xenograft tum or line 24. This 
decrease in perfusion may lead to an incomplete w ash-out of 18FMISO resulting in 
relatively high values after carbogen breathing. Bentzen e t  al. found a significant 
reduction in 18FMISO PET defined hypoxic tum or volume in C3H m am m ary carcinoma 
after carbogen breathing 25. With this same tum or model, Grönroos e t  al. showed a 
decrease in 18FMISO signal intensity by autoradiography after carbogen breathing 
relative to the control tum ors 26. These results indicate th a t the response to carbogen 
breathing likely depends on the tum or model studied and may potentially also be 
influenced by the site of tum or transplantation, such as orthotopic versus  subcutaneous 
transplantation.
5.5 Conclusions
Pimonidazole labeling can be used to detect viable hypoxic cells a t pO2 levels below 
10 mmHg. By visualizing pimonidazole, hypoxia can be studied w ith a high spatial 
resolution providing detailed inform ation a t the microscopic level. 18FMISO can be used 
as PET-tracer to study hypoxia a t the global level in tum ors in situ. In the p resen t study, 
pimonidazole labeling was used for validation of 18FMISO autoradiography. This 
pimonidazole signal reflects only reduced and bound m arker. The autoradiography 
signal may rep resen t bio-reduced intracellularly bound as well as unbound 
extracellular radioactivity tha t is trapped  in the tum or. Therefore, the results obtained 
by using PET-markers such as 18FMISO are susceptible to inaccuracies if insufficient 
tim e is allowed for biodistribution, bio-reduction and w ash-out of unbound marker. 
Both imaging m ethods provide inform ation on the level and spatial distribution of 
hypoxia; a t the microscopic level by pimonidazole and a t a m ore global level by 
18FMISO.
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Abstract
Introduction. Accelerated tumor cell repopulation is an important mechanism adversely 
affecting therapeutic outcome in head and neck cancer. Non-invasive assessment of a tumor’s 
proliferative state by positron emission tomography (PET] may provide a selection tool for 
customized treatment. 3’-deoxy-3’-18F-fluorothymidine (18FLT) is a PET tracer that is 
phosphorylated by thymidine kinase 1 (TK-1) and as such reflects cellular proliferation. Before 
the use of 18FLT-PET for tumor characterization is accepted and introduced into clinical studies, 
validation against tumor histology is mandatory. The aim of this study was to validate 18FLT- 
PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the 
proliferation marker iododeoxyuridine (IdUrd) and for TK-1.
Materials and Methods. Seventeen patients with primary squamous cell carcinomas of the 
oral cavity underwent an 18FLT-PET-CT scan prior to surgery, and IdUrd was administered 
20 min prior to tumor resection. 18FLT-PET-CT scans were segmented, and CT/PET volumes 
and PET signal intensities calculated (SUVmean and SUVmax). Multiple paraffin-embedded tumor 
sections were immunohistochemically stained for IdUrd and TK-1. For IdUrd, labeling indices 
and optical densities were calculated and correlated with SUVmean and SUVmax. TK-1 staining was 
visually and semi-quantitatively assessed.
Results. All primary tumors were identified with 18FLT-PET, but with a large range in tracer 
uptake (mean SUVmax 5.9; range 2.2-5.2). Also, there was a large variability in IdUrd labeling 
indices (mean 0.09; range 0.01-0.29] and optical densities (mean 28.2; range 12.6-37.8). The 
IdUrd optical densities correlated significantly with SUVmean and SUVmax, but the labeling index 
did not. In most tumors, TK-1 staining of varying intensity was present, but did neither correlate 
with IdUrd binding nor with 18FLT-uptake.
Conclusions. The current study demonstrated only a weak correlation between 18FLT-uptake 
and IdUrd staining intensity in oral cavity tumors. This may be explained by differences in 
biomarker characteristics, resolution, and quantification methods. The potential role of 18FLT- 
PET in clinical oncology remains to be further explored.
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6.1 Introduction
Positron emission tom ography (PET) w ith the glucose analogue 2-18F-fluoro-2-deoxy-D- 
glucose (18FDG) is accepted as a powerful, non-invasive m etabolic imaging m ethod 
suitable for diagnosis and staging of various types of cancer 1. A part from high-energy 
expenditure, tum or cell repopulation is an im portan t indicator of tum or aggressiveness 
and of its resistance to various types of trea tm en t including radiotherapy. As a response 
to radiotherapy, squam ous cell carcinomas of the head and neck show  accelerated 
repopulation of clonogenic tum or cells during the course of trea tm en t adversely 
affecting trea tm en t outcome 2-5. T reatm ent regimes counteracting this effect have 
dem onstrated to improve the outcome of head and neck cancer. Randomized trials have 
convincingly shown th a t a reduction of the overall trea tm en t tim e by accelerated 
radiotherapy schedules increases the locoregional tum or control rate by about 10% 6-8. 
Targeting the signal transduction pathw ays th a t control tum or cell proliferation by 
inhibition of the epiderm al grow th factor receptor (EGFR) in combination w ith 
radiotherapy improves no t only local tum or control, b u t also ultim ate survival 9,10.
Non-invasive assays m onitoring the proliferative activity of the tum or before and 
during therapy may assist in be tte r patien t selection for these intensified trea tm en t 
strategies. Shields e t  al. introduced the thym idine analogue 3’-deoxy-3’-18F- 
fluorothym idine (18FLT) as PET tracer for visualization of proliferating (tum or) cells n . 
18FLT is transported  via the m em branous hum an nucleoside transpo rte r 1, 
phosphorylated by the cytosolic thym idine kinase 1 (TK-1) enzyme and trapped 
intracellularly 12. During the late G1 and S phase of the cellular cycle, TK-1 activity 
increases by alm ost tenfold. As 18FLT trapping is related to TK-1 activity, it is in tu rn  
also linked to cellular proliferation 13-15.
Before trea tm en t decisions can be based on these functional imaging modalities, it is of 
u tm ost im portance th a t histological validation studies are perform ed. Quantitative 
18FLT-PET data m ust be correlated w ith quantitative data of proliferation a t the tissue 
and cellular level obtained by histological examination.
The aim of this study was to validate 18FLT-PET imaging by immunohistochem ical 
staining of the exogenous proliferation m arker iododeoxyuridine (IdUrd) and of 
thym idine kinase 1 (TK-1), the enzyme phosphorylating 18FLT, in prim ary resection 
specimen of oral cavity tum ors.
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Figure 6.1 18FLT-PET-CT scans o f patients with primary squamous cell carcinomas o f the oral cavity 
with different SUVmax. Left panel: contrast-enhanced CT, middle panel: 18FLT-PET scan, right panel: fusion of 
both images; window-level-setting were kept identical. A: pT2N1 floor o f mouth, SUVmax 2.2 (patient 12); B: 
pT4N0 hard palate, SUVmax 6.8 (patient 9); C: pT2N2b floor o f mouth, SUVmax 14.7 (patient 7). Note 18FLT- 
uptake in bone marrow o f the cervical spine.
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Figure 6.2 Immunohistochemical staining for TK-1 (left panels; brown), IdUrd (right panels; brown) and 
nuclei (blue) in adjacent sections o f squamous cell carcinomas o f the oral cavity. A: absent staining for TK-1 
and intense staining for IdUrd in tumor and adjacent inflammatory cells; B: weak staining fo r TK-1 and 
intense staining for IdUrd in tumor cells; C: Intense staining for TK-1 and IdUrd in tumor cells; D: positive 
staining for both markers (TK-1 weak, IdUrd strong) in the invasive fron t o f a squamous cell carcinoma.
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6.2 Material and Methods
Patients. From July 2005 until March 2008, 17 patients w ith newly diagnosed clinical 
stage II-IV prim ary squam ous cell carcinoma of the oral cavity eligible for surgical 
tum or resection w ere included in this study after giving w ritten  inform ed consent. The 
Institutional Review Board of the Radboud University Nijmegen Medical Centre 
approved this study.
18FLT synthesis. 18FLT was obtained from the D epartm ent of Nuclear Medicine and PET 
Research, VU University Medical Centre, Amsterdam, the Netherlands. Synthesis was 
perform ed according to the m ethod of Machulla e t  al. 16. 18FLT was produced by 18F- 
fluorination of the 4,4'-dim ethoxytrityl protected anhydrothym idine, followed by a 
deprotection step. After purification by reversed phase high perform ance liquid 
chrom atography, the p roduct was m ade isotonic and passed through a 0.22 pm filter. 
18FLT was routinely produced w ith a non-decay corrected radiochem ical yield of 5­
10%, a radiochemical purity  of >97% and a specific activity higher than 10,000 
GBq/mmol.
PET/CT acquisition. Prior to the surgical tum or resection, integrated PET and CT 
images w ere acquired on either a hybrid PET-CT scanner, or by m eans of software 
fusion of dedicated stand-alone PET and CT images. All scans w ere perform ed w ith the 
patien t in supine position and fixated in a rigid custom ized m ask covering the 
head /neck  area in order to increase position accuracy and to reduce m ovem ent artifacts 
during PET-CT scanning.
Hybrid PET/CT images w ere acquired using a Siemens Biograph Duo scanner 
(Siemens/CTI, Knoxville, TN). Emission images of the head and neck area w ere 
recorded 60 m inutes after intravenous injection of approxim ately 250 MBq 18FLT, w ith 
7 m inutes per bed position in 3D mode. PET images w ere reconstructed using the OSEM 
iterative algorithm  w ith param eters optimized for the head and neck area (i.e., 4 
iterations, 16 subsets and 5 mm 3D Gaussian filter 17), w ith correction for photon 
attenuation. In addition, CT images w ere acquired for anatom ical correlation and 
attenuation correction purposes using 80 mAs, 130 kV, slice w idth 3 mm, and 
intravenous contrast agent in the venous phase (Optiray, Mallinckrodt Inc., Hazelwood, 
MO).
Dedicated PET images w ere acquired using a Siemens ECAT Exact scanner 
(Siemens/CTI, Knoxville, TN). Emission and transm ission images of the head and neck 
area w ere recorded 60 m inutes after intravenous injection of approxim ately 250 MBq 
18FLT, w ith 5 m inutes per bed position in 3D m ode for emission and 3 m inutes per bed 
position in 2D mode for transm ission.
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PET image reconstruction param eters w ere identical to the hybrid PET/CT. Dedicated 
CT images w ere acquired using a Philips AcQsim CT scanner (Philips, Cleveland, OH), 
applying the same acquisition param eters as for the hybrid PET/CT. PET and CT image 
sets w ere anatom ically co-registered using Iterative Closest Point-based optim ization of 
surface maps derived from PET transm ission and CT images, w ith an average 
registration accuracy of 3 mm 18.
PET tracer uptake analysis and image segmentation. After reconstruction and co­
registration, SUV-PET images w ere created w ith in-house developed software 
correcting for injected dose, tracer decay, and patien t body weight. Subsequently, these 
SUV-PET images w ere resliced using the CT image as reference. SUV-PET and CT images 
w ere im ported into Pinnacle3 (version 8.0d; Philips Radiation Oncology System, 
Madison, WI), the radiotherapy planning system routinely used a t our departm ent.
The gross tum or volume (GTV) was first delineated on CT (G T V c t) . Self-written scripts 
in Pinnacle3 aided w ith the segm entation of the prim ary tum or and w ith the calculation 
of the mean and maximum standardized uptake value (SUVmean and SUVmax) from the 
PET data. Two previously described m ethods for segm entation of PET images w ere 
used 19,20. First, the 50% isocontour (GTVs0%) was based on a fixed percentage of the 
maximum signal intensity in the gross tum or volume. Second, an adaptive threshold  
delineation based on the signal-to-background ratio was perform ed (G T V sbr) 19. For this 
means, the SUVmax was defined as m ean activity of the ho ttest voxel in the tum or and its 
eight surrounding voxels in a transversal slice. Mean background activity was acquired 
in a manually defined region of in terest in the left neck m usculature (approxim ately 
10 cm3) a t sufficient distance from the prim ary tum or, m etastatic cervical lymph nodes 
and vertebrae. W ithin the segm ented volumes, the mean and maximum standardized 
uptake values w ere calculated.
Administration of IdUrd and immunohistochemical staining of IdUrd and TK-1.
Twenty m inutes before the s ta r t of surgery, IdUrd (Centre Hospitalier Universitaire 
Vaudois, Lausanne, Switzerland), 200 mg diluted in 100 mL NaCl 0.9%, was 
adm inistered intravenously as bolus injection.
The paraffin blocks containing the resection m aterial from the 17 prim ary oral cavity 
tum ors w ere collected from the Pathology Department. In order to obtain a 
representative sam ple of the tum or, we aimed at collecting th ree blocks per patient, one 
from the tum or center and two localized m ore peripherally.
From these blocks, 5 pm consecutive sections w ere stained for IdUrd and TK-1. 
Between all steps of this procedure, prim ary tum or sections w ere rinsed w ith 0.1 M 
phosphate-buffered saline (PBS; Klinipath Duiven, The Netherlands), pH 7.4. The 
staining procedure was perform ed a t room tem peratu re  unless stated differently. The 
sections w ere deparaffinized and re-hydrated in histosafe and graded alcohols (100%  -
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96%  - 70%). For antigen retrieval, slides w ere heated (90°C) in 10 mM citrate buffer pH 
6.0 for 30 min (DAKO, Glostrup, Denmark).
For IdUrd staining, sections w ere incubated w ith 2 N HCl for 30 min, w ith 0.1 M Borax 
for 15 min, and w ith norm al donkey serum  5% diluted in prim ary antibody diluent 
(PAD; GeneTex Inc., San Antonio, TX) a t 37 °C for 30 min. Then, sections w ere incubated 
w ith m ouse-anti-IdUrd (Caltag Laboratories, Burlingame, CA), diluted 1:3000, for 60 
min and peroxidase was blocked w ith 3% H2O2 in m ethanol for 10 min.
For TK-1 staining, endogenous peroxidase was blocked w ith 3% H2O2 in m ethanol for 
10 min, followed by pre-incubation w ith PAD and incubation w ith 5% norm al donkey 
serum  diluted in PAD for 30 min. Finally, sections w ere incubated overnight w ith mouse 
anti-TK-1 (AbD Serotec, Raleigh, NC), diluted 1:800 in PAD at 4°C.
Next, all sections w ere incubated w ith donkey-anti-m ouse-biotin (Jackson Immuno 
Research Laboratories, W est Grove, PA), diluted 1:400 (IdUrd) or 1:200 (TK-1) in PBS, 
for 60 min and subsequently w ith ABC-reagent (Vector Laboratories, Burlingame, CA) 
for 30 min. Then, sections w ere rinsed w ith deionized w ater before incubation w ith 
diam inobenzidine (DAB; Zymed Laboratories) for 15 min. Finally, after rinsing w ith tab 
w ater and staining w ith hematoxylin (Klinipath) for 30 sec, sections w ere dehydrated 
and captured in m ounting m edium (Klinipath).
Immunohistochemical image acquisition and image processing
IdUrd labeling index and optical density. After im m unohistochem ical staining, the 
entire tum or sections w ere scanned a t 200 x magnification using a digital image 
processing system consisting of a color CCD cam era (Retiga SRVm 1392 x 1040 pixels) 
and a RGB filter (Slider Module; QImaging, Burnaby, BC, Canada) attached to a 
m otorized bright field microscope (DM6000 Leica, Wetzlar, Germany). Whole tum or 
sections w ere scanned using a Macintosh com puter running IPLab (Scanalytics Inc., 
Fairfax, VA), which controlled this m otorized system and generated 24-bit color 
composite images. For every scan session, separate background images w ere recorded.
To extract and separate the color inform ation from the DAB and hematoxylin signals, 
the RGB linear unmixing module in the TRI2-software was applied using the 
“Absorption” mode (Randall Division and Gray Cancer Institute, London, UK). For this 
procedure reference files from single-stained control sections w ere used containing 
color inform ation for the blue (hematoxylin; all nuclei) and brow n (IdUrd in 
proliferating nuclei) signal. Additionally, each RGB color image was corrected for the 
microscope illumination using the background image and was subsequently 
normalized. Next, threshold  values for the DAB and hematoxylin signal w ere manually 
set. For the image analysis, a tum or m ask was delineated including tum or, in tratum oral 
strom a as well as areas of necrosis bu t excluding surrounding norm al tissues. W ithin
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this mask, the labeling index for IdUrd was calculated by dividing the DAB-positive area 
(nuclei positive for IdUrd) by the hematoxylin area (all nuclei).
In o rder to adjust for different sizes of immunohistochemically stained nuclei and for 
variation in the staining intensity for IdUrd, mean optical densities w ere calculated for 
the entire tum or area using a Macintosh com puter running IPLab.
Analysis of immunohistochemical staining for TK-1. Due to a relatively w eak 
immunohistochem ical staining of TK-1 in m ost of the tum ors, autom ated quantitative 
analyses w ere no t possible. Therefore, two investigators, who w ere blinded for the 
results obtained by PET and IdUrd im m unohistochem istry, perform ed a visual and 
sem i-quantitative analysis. The entire tum or sections w ere assessed using 200 x 
magnification, and the intensity of the staining (no, weak, strong), the percentage of 
positive cells and their localization w ere estimated. The combination of staining 
intensity w ith percentage of positive cells resulted in four categories: absent TK-1 
staining, w eak and sparse (<5%), w eak and abundant (>5-20%), and strong and 
abundant (>5-20%) staining. There w ere no tum ors w ith strong and sparse TK-1 
staining. A greem ent on all tum or sections was achieved before further analysis. TK-1 
staining categories w ere subsequently correlated to the SUVmax of 18FLT-PET, the IdUrd 
labeling indices and the IdUrd optical densities.
Statistical analysis. Statistical analyses w ere perform ed using GraphPad Prism Version 
4.0c for Macintosh (La Jolla, CA). Gaussian distribution of the values was analyzed using 
the Kolmogorov-Smirnov test. Comparison of the G T V c t and G T V sb r was perform ed 
using a tw o-tailed Mann W hitney test. Correlation of SUV for PET w ith IdUrd labeling 
indices was perform ed with Pearson correlation. Linear regression was perform ed for 
the SUV and IdUrd optical densities under the assum ption th a t an optical density of zero 
resulted in a standardized uptake value of zero for 18FLT-PET. The results of the sem i­
quantitative analysis for TK-1 versus  the SUVmax, IdUrd labeling indices and optical 
densities w ere analyzed using one-way ANOVA. A p-value < 0.05 was regarded 
statistically significant.
6.3 Results
6.3.1 Patients and tumor characteristics
Thirteen male and four female patients w ith an average age of 57 years (range 43 to 75 
years) participated in this study. Patient and tum or characteristics are given in Table 
6.1. Most tum ors w ere clinically and pathologically classified as T2. Patients 1-3 w ere 
scanned on the dedicated CT- and PET-machines on the same day, the other patients 
underw ent the 18FLT-PET-CT scan on the hybrid scanner. The m edian interval betw een 
PET-CT scan and surgery was five days (mean interval: eight days, range 2-36 days).
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The longest interval of 36 days was caused by an in tercu rren t infection, which delayed 
the surgery.
Table 6.1 Patient characteristics, clinical and pathological stages, and therapeutic procedures
Patient Site Gender Age Surgical Procedure Clinical
stage
Pathological
stage
Tumor
grade
1 Lower alveolar ridge m 46 TE + MRND right T4N2bM0 T4N0M0 2
2 Floor of mouth f 53 TE + bilateral SND T2N0M0 T2N0M0 2
3 Tongue m 43 TE + SND right T3N0M0 T3N1M0 3
4 Tongue m 70 TE + MRND left T4N0M0 T2N0M0 2
5 Floor of mouth m 61 TE + SND left T2N0M0 T2N0M0 2
6 Floor of mouth f 49 TE + SND right T2N0M0 T2N0M0 2
7 Floor of mouth m 72 TE + MRND right T4N2bM0 T2N2bM0 3
8 Retromolar trigone m 75 TE + SND left T4N0M0 T4N1M0 3
9 Hard palate m 54 TE T4N0M0 T4N0M0 2
10 Tongue / floor of 
mouth
m 62 TE + SND left + 
MRND right
T2N1M0 T2N2bM0 3
11 Tongue f 45 TE + bilateral MRND T4N2cM0 T4N2cM0 3
12 Floor of mouth m 53 TE + MRND right T2N1M0 T2N1M0 2
13 Floor of mouth m 56 TE + MRND left T3N0M0 T1N2bM0 2
14 Tongue m 67 TE + SND right T2N0M0 T1N0M0 2
15 Tongue / floor of 
mouth
m 45 TE + MRND left T2N1M0 T2N2bM0 2
16 Tongue f 59 TE + bilateral SND T2N0M0 T2N2bM0 2
17 Tongue m 43 TE + SND left T2N0M0 T1N1M0 2
f =female, m = male; TE = tumor excision; MRND = modified radical neck dissection; SND = supraomohyoid neck 
dissection (level I-III).
6.3.2 18FLT uptake in primary tumor
18FLT-PET data w ere available for all 17 patients, and all prim ary tum ors w ere detected 
by 18FLT-PET, as opposed to only 12 by contrast enhanced CT (Fig. 6.1). Results 
obtained for the signal-to-background segm entation m ethod (SBR) w ere alm ost 
identical to the 50% m ethod (data on file). Therefore, only the SBR data are further 
discussed and shown. The tum or volume delineated on CT [mean G T V c t (± standard  
deviation; SD): 13.6 cm3 (± 8.2 cm3)] was significantly larger than  the mean G T V sbr 
[7.2 cm3 (± 5.6 cm3); p  = 0.03]. The mean 18FLT-SUVmax (± SD) in the prim ary tum ors 
was 5.9 (± 3.2) and the mean SUVmean w ithin the G T V sb r was 4.0 (± 2.2).
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6.3.3 IdUrd labeling index and optical density and correlations with 18FLT-PET
No adverse events occurred during the intravenous adm inistration of IdUrd or 18FLT. 
From all 17 patients, paraffin blocks containing prim ary tum or tissue w ere available. 
We aimed a t collecting three  blocks per patient, one from the tum or center and two 
m ore peripherally. However, only one block was available for six patients, two blocks 
w ere retrieved for seven patients, and three tum or blocks w ere available for the 
rem aining four patients, since the tum or tissue was only p resen t in one or two blocks in 
m ost cases. In all tum or sections, tum or cells stained positively for IdUrd, and in two 
cases, IdUrd staining was also p resen t in peritum oral inflam m atory tissue (Fig. 6.2A). 
There was a large variability in IdUrd labeling indices w ith a mean value of 0.09 and a 
standard  deviation of ± 0.14 (range 0.01-0.29). Furtherm ore, there  was a large range in 
optical densities for IdUrd, w ith a mean of 28.2 (± 12.7; range 12.6-37.8).
There was no significant correlation betw een the mean IdUrd labeling index and the 
SUVmax or SUVmean of 18FLT-PET (Fig. 6.3A; data for SUVmean no t shown). In contrast to 
this, the signal intensities, i .e ., optical densities for im m unohistochem ical IdUrd staining 
versus  18FLT-PET SUVmax and SUVmean dem onstrated a significant albeit w eak correlation 
(p < 0.0001; Fig. 6.3B; data for SUVmean no t shown).
6.3.4 TK-1 staining and correlations with IdUrd and 18FLT-PET
In th irteen  of the seventeen squam ous cell carcinomas of the oral cavity, TK-1 staining 
was found in the cytoplasm of tum or cells, w ith an intensity ranging from w eak to 
intense (Fig. 6.2A-C). In one tum or, TK-1 staining was predom inantly localized in the 
invasive tum or front (Fig. 6.2D). Overall, staining for TK-1 was substantially w eaker 
com pared to IdUrd and less tum or cells stained positive. Mostly, TK-1 and IdUrd co­
localized in the same tum or areas, b u t correlation a t the cellular level could no t be 
assessed, because the stainings w ere perform ed on consecutive sections.
After sem i-quantitative analysis of TK-1 staining, four categories w ere identified based 
on staining intensity and percentage of positive cells. These categories w ere correlated 
to the SUVmax of 18FLT-PET (Fig. 6.4A), the IdUrd labeling indices (Fig. 6.4B) and the 
IdUrd optical densities (Fig. 6.4C). However, no statistically significant correlations 
betw een these param eters w ere found.
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Figure 6.3 A: Two-tailed Spearman correlation o f the mean IdUrd labeling indices (IdUrd LI) with the 
maximum standardized uptake values (SUVmax) fo r all squamous cell carcinomas o f the oral cavity; p=0.18, 
r2=0.12; B: Linear regression analysis o f mean IdUrd optical densities versus the SUVmax; p<0.0001.
Figure 6.4 Kruskal-Wallis test o f semi-quantitative analysis o f TK-1 staining (horizontal axis) 
correlating with A: the maximum standardized uptake values (SUVmax; p=0.44), B: the IdUrd labeling indices 
(IdUrd LI; p=0.19), and C: the IdUrd optical densities (p=0.75). TK-1 staining was categorized in absent (-), 
weak and sparse (+), weak and abundant (++) and strong and abundant (+++).
6.4 Discussion
18FLT is a potential PET-tracer for non-invasive tum or characterization and trea tm en t 
response m onitoring related to tum or cell proliferation. In prim ary squam ous cell 
carcinomas of the oral cavity, we validated 18FLT PET against im m unohistochem ical 
staining of the exogenous proliferation m arker IdUrd and expression of the TK-1 
enzyme th a t is involved in DNA synthesis.
In oral cavity tum ors, we found a relatively high mean SUVmax of 5.9 (range 2.2-15.2). 
The sensitivity for tum or detection was high (100%) as com pared to contrast-enhanced 
CT (76%) th a t was ham pered by the relatively small tum or size and dental artifacts. 
Lower SUVmax (mean maximum SUV 1.6; range 1.0-5.7) w ere observed in laryngeal 
tum ors w ith a low er sensitivity (88%), possibly due to the generally sm aller volumes of 
larynx carcinomas 21. Two other publications involving head and neck cancers of 
various sites and non-small cell lung cancer both reported  a mean SUVmax of 4.8 22,23.
The gross tum or volumes delineated after segm entation of the PET signal (G T V sb r) w ere 
significantly sm aller than the GTVs manually delineated on contrast enhanced CT scans.
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A sim ilar finding has previously been reported  for laryngeal tum ors using 18FDG-PET 24. 
Daisne e t  al. correlated true  tum or volumes m easured in laryngeal resection specimen 
with GTVs delineated on anatom ical (CT, MRI) and functional imaging modalities (PET). 
The GTVs using PET w ere the sm allest com pared to CT and MRI, and the m ost accurate 
com pared to histology.
However, the potential application of 18FLT-PET in oncology may no t be so much in 
improving the sensitivity of tum or detection or its anatom ical extensions, bu t m ore in 
its ability to characterize the biological behavior of a tum or. Therefore, we com pared 
quantitative analysis of 18FLT-uptake w ith standard  m ethods for quantification of 
proliferation by im m unohistochem ical m arkers. IdUrd is an S-phase specific and robust 
m arker of proliferation. It was hypothesized th a t IdUrd binding should correlate w ith 
18FLT-uptake, as the activity of TK-1, the key enzyme in 18FLT phosphorylation, is also 
mainly upregulated during the S-phase 13. Som ewhat unexpectedly, we did no t find a 
correlation betw een the IdUrd labeling indices and the 18FLT SUVmax or SUVmean. In 
contrast to our findings, several studies on different tum or types found significant 
positive correlations betw een standardized uptake values for 18FLT-PET and 
proliferation assessed by Ki-67 im m unohistochem istry (Table 6.2) 25-33. Three other 
studies in thoracic, b reast and gastric tum ors did no t dem onstrate such a correlation 34-
There are a num ber of factors th a t potentially play a role in the lack of correlation 
betw een IdUrd labeling indices and 18FLT-PET standardized uptake values in the 
cu rren t study. (1) All o ther validation studies w ere based on the endogenous 
proliferation m arker Ki-67 th a t is upregulated during various phases of the cell cycle 
(G1, S, G2, M), and for which labeling indices of up to 30% have been reported  21,25-29,31­
33,37. The exogenous proliferation m arker IdUrd is only incorporated during the S-phase 
of the cell cycle, and therefore theoretically should correlate be tte r w ith 18FLT- 
uptake 13. This was no t confirmed in the curren t study. Subsequently, we also stained 
the prim ary tum or sections for Ki-67 and calculated the labeling index by the same 
autom ated analysis m ethodology as described for IdUrd. However, analysis of Ki-67 
revealed sim ilar or slightly w orse correlations w ith 18FLT-uptake com pared to IdUrd 
(data on file).
(2) For m ost patients, only one or two paraffin-em bedded blocks containing tum or 
tissue w ere available and from each block one single section was analyzed. Thus, only a 
relatively small tum or volume was assessed com pared to the entire tum or volume 
characterized by 18FLT-PET, w ith the inherent risk of sampling error. However, in 
contrast to studies by others, we tried  to minimize this e rro r by analyzing a t least two 
tum or-containing paraffin blocks in 11 of the 17 patients and by examining the entire 
tum or sections (Table 6.2).
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(3) There was an interval betw een PET scanning and surgery of several days. However, 
com pared to o ther studies reported  in the literature, the m edian interval of 5 days was 
relatively sho rt and we do not expect the tum or’s proliferative activity to change 
substantially during this period.
(4) The resolution of the imaging modalities profoundly differed, i.e., 2.5 pm for 
autom atic analysis of bright field microscopy of immunohistochemical sections as 
opposed to 5-8 mm using PET.
(5) Different quantification procedures may influence the results. Some investigators 
assessed the mean labeling index or mean standardized uptake value, while others 
calculated the respective maximum values. Furtherm ore, these values w ere mostly 
estim ated in the areas of highest proliferative activity or g reatest staining intensity as 
opposed to complete tum or sections in our study. To specifically address this question, 
we also correlated the IdUrd labeling indices in the areas of highest proliferative activity 
w ith 18FLT SUV, bu t again, this did not resu lt in significant correlations (data on file). 
The IdUrd labeling index is a m easure of the relative num ber of tum or cells in S-phase, 
as opposed to the 18FLT standardized uptake value, which reflects the signal intensity of 
the tracer a t a certain time point. 18FLT uptake is determ ined by the tum or cells’ DNA 
synthesis rate and m ight be better represented  by the IdUrd staining intensity and less 
by labeling index. In o rder to te st this, we assessed the IdUrd optical densities as a 
m easure of staining intensity w ithin the previously defined tum or areas. This approach 
yielded statistically significant albeit w eak correlations w ith SUVmax and SUVmean for 
18FLT (Fig. 6.3B). However, no significant results w ere found w hen com paring Ki-67 
optical densities w ith 18FLT standardized uptake values (data on file).
Finally, we assessed the expression of TK-1, the key enzyme involved in the exogenous 
(salvage) pathw ay of DNA synthesis 13. We studied the intensity of staining, its 
localization and the global co-localization w ith IdUrd. The m ajority of the tum ors 
stained positive for TK-1, although m ost of the staining was ra ther faint and only 
p resen t in a few tum or cells. In the consecutive tum or sections, the area of 
cytoplasmatic TK-1 staining co-localized w ith nuclear staining for IdUrd on a global 
level, bu t correlation on a cellular level could not be assessed. There was no correlation 
betw een TK-1 staining intensity and num ber of TK-1 positive cells on the one hand, and 
the 18FLT SUVmax, the IdUrd labeling indices or the IdUrd optical densities on the other.
TK-1 staining has been used for flow cytometric analyses, bu t experience w ith 
immunohistochem ical staining for TK-1 in tum or sections is very limited 38. A few 
groups have perform ed im m unohistochem istry on histological tum or sections of breast, 
non-small cell lung cancer and colorectal cancer patients 39-43. Statistically significant 
correlations w ith Ki-67 and the proliferating cell nuclear antigen (PCNA) w ere found 40­
43. The TK-1 labeling indices reported  in these four studies w ere high (50-80%) 
com pared to our experience in squam ous cell carcinomas of the oral cavity 40-43. To date,
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only one study on head and neck squam ous cell carcinoma xenografts has been 
published 44. Molthoff e t  al. assessed the value of 18FLT-PET for trea tm en t response 
m onitoring in xenografted squam ous cell carcinomas after fractionated irradiation and 
immunohistochemically stained tum or sections for TK-1. The authors reported  a 
significant decrease in 18FLT tum or-to-norm al-tissue ratios, while TK-1 expression in 
control and irradiated tum ors rem ained similar.
Table 6.2 Published validation studies on 18FLT-PET
Author Primary tumor site No of 
patients
Method
Positive correlation
Buck 25 NSCLC 30 Number of positive cells in high proliferative areas, 
manual assessment
Chen 26 Cerebral glioma 25 Positive tumor cells per quartile of tumor tissue in 
high proliferative areas
Cobben 27 Soft tissue sarcoma 19 Percentage of positive nuclei per 1000 cells in area 
of highest staining intensity
Eckel 28 Hepatocellular
carcinoma
12 Percentage of positive cells per 2000 tumor cells
Kenny 29 Breast cancer 15 Number of positive cells in 8 random microscopic 
fields, manual assessment
Muzi 30 NSCLC 17 Percentage of positive nuclei in four microscopic 
fields
Vesselle 31 NSCLC 10 Fraction of labeled tumor cells in one microscopic 
field with highest average fraction of positive cells, 
manual assessment
Yamamoto 32 NSCLC 18 Percentage of positive nuclei per 500-1000 tumor 
cells in region of greatest staining intensity
roroŒÍÜ> NSCLCand 
pulmonary lesions
22 Percentage of stained nuclei, computerized 
morphometry
No correlation
Dittmann 34 Thoracic tumors 
(incl. nine NSCLC)
16 Not specified
Kameyama 35 Gastric cancer 21 Percentage of positive nuclei per 500-1000 tumor 
cells in region of greatest staining intensity
Smyczek-Gargya 36 Breast cancer 12 Semi-automatic morphometry system
N°= number; NSCLC = non-small cell lung cancer.
However, details regarding TK-1 staining intensity, localization and labeling index w ere 
no t provided. Based on the curren t results, the value of TK-1 staining as a m easure of 
proliferative activity in oral cavity tum ors seem s limited. However, fu rther research is
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needed (e.g., studies on co-localization w ith standard proliferation m arkers a t the 
cellular level) until definite conclusions can be draw n about its significance as a 
biom arker for tum or cell proliferation.
6.5 Conclusions
Non-invasive 18FLT-PET imaging assessing the proliferative status of tum ors may be a 
valuable aid for patien t selection and trea tm en t response m onitoring in head and neck 
cancer, bu t it needs to be validated before introduction in the clinic. This validation 
study dem onstrated only a w eak correlation betw een 18FLT-uptake and IdUrd staining 
intensity in squam ous cell carcinomas of the oral cavity. Immunohistochemical staining 
of TK-1, the key enzyme in 18FLT phosphorylation, did neither correlate w ith 18FLT- 
uptake nor w ith the standard  immunohistochemical proliferation markers. This may be 
due to differences in biom arker characteristics, discrepancies in resolution of the 
imaging modalities, and differences in quantification methods. The potential role of 
18FLT-PET in clinical oncology rem ains to be fu rther explored.
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Abstract
Introduction. Repopulation of clonogenic tum or cells is inversely correlated with radiation 
treatm ent outcome in head and neck squamous cell carcinomas. A functional imaging tool to 
assess the proliferative activity of tumors could improve patient selection for treatm ent 
modifications and could be used for early treatm ent response evaluation. The PET tracer 3’- 
deoxy-3’-18Fluorothymidine (18FLT] can image tum or cell proliferation prior to and during 
radiotherapy, and it may provide biological tum or information useful in radiotherapy planning. 
In the present study, the value of 18FLT-PET in determining the lymph node status in squamous 
cell carcinoma of the head and neck was assessed, with pathology as the gold standard.
Materials and Methods. Ten patients with newly diagnosed stage II-IV squamous cell 
carcinoma of the head and neck underwent 18FLT-PET prior to surgical tum or resection with 
lymph node dissection. Emission 18FLT-PET and CT images of the head and neck were recorded 
and fused, and standardized uptake values (SUV] were calculated. From all 18 18FLT-PET 
positive lymph node levels and from eight 18FLT-PET negative controls, paraffin embedded 
lymph node sections were stained and analyzed for the endogenous proliferation marker Ki-67 
and for the pre-operatively administered proliferation marker iododeoxyuridine. Sensitivity, 
specificity, positive predictive value and negative predictive value were calculated for 18FLT- 
PET.
Results. Primary tum or sites were oral cavity (7], larynx (2] and maxillary sinus (1). Nine of the 
ten patients examined had 18FLT-PET positive lymph nodes (SUVmean: median 1.2, range 0.8-2.9], 
but only three of these patients had histologically proven metastases. All metastatic lymph 
nodes showed Ki-67 and iododeoxyuridine staining in tumor cells. In the remaining seven 
patients, there was abundant Ki-67 and iododeoxyuridine staining of B-lymphocytes in germinal 
centers in PET positive lymph nodes explaining the high rate of false positive findings. 
Sensitivity, specificity, positive and negative predictive values of 18FLT-PET were 100%, 16.7%, 
37.5% and 100%, respectively.
Conclusions. In head and neck cancer patients, 18FLT-PET scan showed uptake in metastatic as 
well as in non-metastatic reactive lymph nodes, the latter due to reactive B-lymphocyte 
proliferation. Because of the low specificity, 18FLT-PET is not suitable for assessment of 
pretreatm ent lymph node status. This observation may also negatively influence the utility of 
18FLT-PET for early treatm ent response evaluation of small metastatic nodes.
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7.1 Introduction
Lymph node invo lvem ent in squam ous cell carc inom a of th e  head  and  neck is a poo r 
p rognostic  indicator, reducing  cure ra te  by a lm ost 50%  1. S tandard  diagnostic w ork-up  
for assessing  cervical lym ph node sta tu s  is perfo rm ed  by com puted  tom ography  (CT) or 
m agnetic resonance im aging (MRI). The sensitiv ity  (50%>-80%) and  specificity (70% - 
90% ) of CT and MRI are  com parable  2,3. For m arginally  en larged  lym ph nodes, 
exam ination by u ltraso u n d  im aging (US) w ith  fine needle asp ira tion  cytology, is 
su p e rio r to CT and MRI if perfo rm ed  by an experienced  rad io log ist (sensitiv ity  and 
specificity up to  76%  and 100% , respectively) 4,5. M ore recently , a nu m b er of stud ies 
have been  perfo rm ed  to  assess th e  value of po sitro n  em ission tom ography  w ith  18F- 
fluorodeoxyglucose (18FDG-PET) for cervical lym ph node staging 6-11. The resu lts  of 
these  stud ies ind icate th a t  th e  perfo rm ance of 18FDG-PET is n o t clearly su p erio r to  US, 
CT o r MRI. Therefore, 18FDG-PET is generally  n o t considered  as p a r t  of th e  s tan d ard  
w ork-up  for head  and  neck cancer p a tien ts  for th is indication.
An add itional biologic factor of prognostic  relevance is tu m o r cell p ro liferation . Head 
and  neck squam ous cell carcinom as show  accelera ted  rep opu la tion  of clonogenic tu m o r 
cells du ring  th e  course of rad ia tio n  th e ra p y  and  th is is re la ted  to  p o o r tre a tm e n t 
outcom e 12-15. Several tre a tm e n t m odifications have been  developed to  co u n te rac t th is 
phenom enon , such as accelera ted  rad io th e rap y  and  inh ib ition  of th e  ep iderm al grow th  
factor recep to r (EGFR), b u t a t th e  cost of increased  toxicity  for the  p a tie n t 16-18. Hence, 
careful p a tien t selection  for these  tre a tm e n t s tra teg ies  is req u ired  ensu ring  m axim al 
p a tien t benefit, w hile p reven ting  undue  toxicity and  costs. A diagnostic tool to  identify  
lym ph node m etastases w ith  high accuracy th a t can also p rov ide inform ation  on the 
pro liferative activity  of th e  tu m o r could be of g rea t value for tre a tm e n t selection  and 
rad io th e rap y  planning.
Shields e t  al. in troduced  th e  novel PET-tracer 3’-deoxy-3’-18F-fluorothym idine (18FLT) 
th a t is m onophosphory la ted  by th e  cytosolic enzym e thym id ine kinase 1 (TK-1) and 
trap p e d  in tracellu larly  19. TK-1 activity  is inc reased  du ring  DNA synthesis and  18FLT 
trap p in g  is re la ted  to  TK-1 activity  and  thus to  pro liferation . It is of im portance to  note  
th a t 18FLT is n o t in co rpo ra ted  in to  th e  DNA and th a t th is  TK-1 m ed iated  pathw ay  could 
theore tically  be u p regu la ted  although DNA synthesis is inhibited . A nu m b er of stud ies 
evaluated  th e  usefu lness of 18FLT in assessing  tu m o r cell p ro lifera tion  in th e  p rim ary  
tum or, m o st of them  including a com parison  w ith  18FDG-PET 20-31. Several stud ies 
validated  18FLT tra c e r  up take w ith  th e  p ro lifera tion  m ark e r Ki-67 in p rim ary  tum or 
resection  m ateria l o r b iopsies 23,30-35. A single s tu d y  on laryngeal carcinom a by Cobben 
e t  al. com pared  18FLT- w ith  18FDG-PET for im aging of th e  p rim ary  tu m o r w ith o u t 
histological verification 27. Only th ree  studies, tw o on b re a s t carc inom a and one on
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tho rac ic  tum ors, have validated  18FLT-PET versu s  h is topatho logy  for the  detection  of 
m etasta tic  lym ph nodes 2°,3°,31.
D ifferent m arkers  have been  used  for histological assessm en t of pro liferation . These 
include endogenous m ark e rs  such as Ki-67, p ro lifera ting  cell nuclear an tigen  (PCNA) 
and m em bers of th e  cyclin group, o r in travenous adm in is tra tion  of th e  thym idine 
analogues b rom odeoxyurid ine  (BrdU rd) and  iododeoxyurid ine (IdUrd) 36-38. The la tte r  
have a sh o rt half-life and  are  rap id ly  inco rp o ra ted  in th e  DNA of S-phase cells 39. For 
im m unohistochem ical validation  of 18FLT these  thym id ine analogues seem  m ost 
su itab le because TK-1 activity  is increased  m ainly du ring  DNA synthesis.
Thus far, validation  of th e  PET-tracer 18FLT has m ainly focused on p rim ary  tu m o r sites 
and  only recen tly  th is w as expanded to  determ in ing  lym ph node status. 
C haracterization  of b o th  th e  p rim ary  tu m o r and  th e  lym ph nodes is com pulsory  for 
selection of th e  tre a tm e n t s tra teg y  in p a tien ts  w ith  squam ous cell carcinom as of the  
head  and  neck. The aim  of th is study  w as to  de term ine  th e  value of 18FLT-PET for 
a ssessm en t of th e  cervical lym ph node sta tu s  and  pro liferative activity  w ith  histological 
evaluation as th e  gold standard .
Coronal Transverse Coronal T ransverse
Figure 7.1 18FLT-PET-CT images of patient number 9 (pT2N0M0 oral cavity carcinoma). The upper 
panels show the PET-images, the middle panels the CT-images and the lower panels the fusion of both image 
modalities. Cervical lymph nodes with increased 18FLT uptake are found bilaterally in level II (A: indicated by 
white arrows) and in levels III and IV (B: white arrows in the coronal images). All lymph nodes detected with 
18FLT in this example were false-positive for metastasis, due to uptake in proliferating B-lymphocytes in 
reactive germinal centers.
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Ki-67 IdUrd
Figure 7.2 Ki-67 and IdUrd staining in: A: germinal center harboring proliferating B-lymphocytes and 
remaining lymphoid tissue; B: remaining lymphoid tissue with proliferating lymphoid cells; C: metastasis of 
a squamous cell carcinoma of the maxillary sinus; D: micrometastasis with keratinization (indicated by 
purple arrow), fragment of a germinal center (white arrow) and surrounding lymphoid tissue.
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7.2 Material and Methods
Patients. Ten p a tien ts  w ith  new ly d iagnosed stage II-IV p rim ary  squam ous cell 
carcinom a of th e  head  and  neck  aw aiting  surgical tu m o r and  lym ph node resection  w ere  
included  in th is study  afte r giving w ritten  inform ed consent. The study  w as approved  by 
th e  Institu tiona l Review Board of th e  R adboud U niversity Nijm egen Medical Centre, the  
N etherlands.
18FLT synthesis. 18FLT w as ob ta ined  com m ercially  from  th e  Cyclotron B.V., VU Medical 
Centre, A m sterdam , The N etherlands. Synthesis w as perfo rm ed  according  to  the 
m ethod  of M achulla e t  al. 40. In brief, 18FLT w as p roduced  by 18F luorination  of th e  4,4'- 
d im ethoxytrity l p ro tec ted  anhydro thym id ine, follow ed by a d ep ro tec tion  step. After 
purification  by reversed  phase high perform ance liquid chrom atography, th e  p ro d u c t 
w as m ade isotonic and  passed  th ro u g h  a 0.22 pm filter. 18FLT w as p roduced  w ith  a n o n ­
decay co rrected  rad iochem ical yield of 5 - 10%, a rad iochem ical pu rity  of >95%  and a 
specific activity  of >10 TB q/m m ol.
PET/CT acquisition. P rio r to surgical tu m o r resection, in teg ra ted  PET and CT im ages 
w ere  acqu ired  w ith  e ith er a hybrid  PET/CT (p a tien t 7, 9, 10), o r w ith  so ftw are fusion of 
dedicated  PET and CT im ages (all rem ain ing  patien ts). All scans w ere  perfo rm ed  w ith  
th e  p a tien t positioned  in a rigid custom ized  m ask  covering th e  h e a d /n e c k  a rea  in o rd er 
to  increase position  accuracy and  to  reduce m ovem ent artifacts du ring  PET-scanning.
Hybrid PET/CT im ages w ere  acqu ired  using a Siem ens B iograph Duo scanner 
(Siem ens/CTI, Knoxville, TN). Em ission im ages of th e  head  and  neck a rea  w ere  
reco rd ed  60 m inu tes afte r in travenous in jection of 250 MBq 18FLT, w ith  4 m inu tes per 
bed  position  in 3D m ode. PET im ages w ere  reco n stru c ted  using th e  OSEM iterative 
a lgorithm  w ith  p aram ete rs  optim ized  for th e  head  and  neck  a rea  (i.e., 4 itera tions, 16 
subse ts  and  5 m m  3D G aussian filter), w ith  co rrection  for pho ton  attenuation . In 
addition, CT im ages w ere  acqu ired  w ith  80 mAs, 130 kV, and  slice w id th  3 mm, w ith  i.v. 
co n tra s t in th e  venous phase, for anatom ical corre la tion  and  a tten u a tio n  correction  
purposes.
D edicated PET im ages w ere  acqu ired  using a Siem ens ECAT Exact scanner 
(Siem ens/CTI, Knoxville, TN). Em ission and  transm ission  im ages of th e  head  and  neck  
a rea  w ere  reco rd ed  60 m inu tes a fte r in travenous injection of 250 MBq FLT, w ith  5 
m inu tes p e r bed  position  in 3D m ode for em ission and  3 m inu tes p e r bed  position  in 2D 
m ode for transm ission . PET im age reco n stru c tio n  w as identical to  im ages from  hybrid  
PET/CT. D edicated CT im ages w ere  acqu ired  using a Philips AcQsim CT scanner 
(Philips, Cleveland, OH), w ith  th e  sam e acquisition  p a ram ete rs  as CT im ages from  
hybrid  PET/CT. PET and  CT im age sets w ere  anatom ically  co-reg istered  using Iterative 
C losest Poin t-based  optim ization  of surface m aps derived  from  PET transm ission  and 
CT im ages, w ith  an average reg is tra tio n  accuracy of 3 m m  41.
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PET analysis. Before analyzing th e  histological sections, th e  com bined PET/CT im age 
sets w ere  rev iew ed in consensus by tw o experienced  observers b linded  for all p a tien t 
data. Im ages w ere  sco red  for p resence o r absence of 18FLT-PET uptake. Lymph node 
levels w ere  d e term ined  as described  by G regoire e t  al. 42. M axim um and m ean 
stan d ard ized  up take values (SUVmax and SUVmean) w ere  calculated  for visible lym ph 
nodes. SUVmean w as calculated afte r construc ting  a reg ion  of in te re s t a t the  50%  
isocon tour of the  SUVmax.
Surgery. T w enty m inu tes before th e  s ta r t  of surgery, IdUrd (C entre H ospitalier 
U niversitaire Vaudois, Lausanne, Sw itzerland), 200 m g dilu ted  in 100 mL NaCl 0.9%, 
w as adm in iste red  in travenously  as bo lus injection. After resection, th e  neck dissection  
specim ens w ere  p re sen te d  on a uniform  left- o r righ t-sided  plate resem bling  th e  neck 
levels I-VI.
Immunohistochemical staining of IdUrd and Ki-67. From  th e  ten  patien ts, a to ta l of 
236  lym ph nodes w ith o u t m e tastases  and  14 lym ph nodes w ith  m etasta tic  invo lvem ent 
localized in 44  lym ph node levels w ere  rem oved. From  these, paraffin  blocks contain ing  
lym ph nodes from  26 d ifferen t lym ph node levels w ere  collected for th is study. These 
included  18 18FLT-PET positive lym ph node levels and 8 random ly  chosen levels th a t 
w ere  18FLT-PET negative.
From  these  blocks, five pm sections w ere  cu t and  consecutive sections w ere  sta ined  for 
Ki-67 and  IdUrd. B etw een all consecutive steps of th e  stain ing  p rocedure , lym ph node 
sections w ere  rin sed  w ith  0.1 M phosphate-buffered  saline (K linipath, Duiven, The 
N etherlands), pH 7.4. The stain ing  p rocedu res  w ere  perfo rm ed  a t room  te m p era tu re  
unless s ta ted  differently. The sections w ere  deparaffin ized  and  re-h y d ra ted  in histosafe 
and  graded  alcohols. For an tigen  retrieval, slides w ere  h ea ted  (90 °C) in 10 mM citrate  
buffer pH 6.0 for 30 min. For the  Ki-67 staining, sections w ere  incubated  w ith  norm al 
donkey serum  5%  d ilu ted  in p rim ary  an tibody  d iluen t (PAD, Abcam, Cam bridge, UK) a t
37 °C for 30 min. O vernight, sections w ere  incubated  w ith  m ouse-anti-hum an-K i67 
(Zymed L aboratories, San Francisco, CA), und ilu ted , a t 4  °C.
For th e  IdUrd staining, sections w ere  incubated  w ith  2 N HCl for 30 m in followed by 
incubation, w ith  0.1 M Borax for 15 m in and  w ith  norm al donkey serum  5%  dilu ted  in 
PAD a t 37 °C for 30 min. Then, sections w ere  incubated  w ith  m ouse-anti-IdU rd (Caltag 
L aboratories, Burlingam e, CA), d ilu ted  1:3000, for 60 min. In b o th  stain ing  procedures, 
perox idase w as blocked w ith  3%  H2O2 in m ethanol for 10 min. Next, all sections w ere  
incubated  w ith  donkey-anti-m ouse-b io tin  (Jackson Im m uno Research Laboratories, 
W est Grove, PA), d ilu ted  1:400, for 60 m in and  w ith  ABC-reagent (Vector Laboratories, 
Burlingam e, CA) for 30 min. Then, sections w ere  rin sed  w ith  deionized w a te r before 
incubation  w ith  d iam inobenzid ine (Zym ed L aboratories) for 15 min. Finally, after 
rin sing  w ith  tab  w a te r and  stain ing  w ith  hem atoxylin  (K linipath) for 30 sec, sections 
w ere  d ehyd ra ted  and  cap tu red  in m ounting  m edium  (K linipath).
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Pathology evaluation and assessment of proliferation. The rem oved  lym ph nodes 
w ere  rou tinely  sta ined  for hem atoxylin  and  eosin (H&E) and  assessed  for m etasta tic  
invo lvem ent by a pathologist. Next, th e  clinical investigato rs and  an experienced  
patho log ist (PS) rev iew ed all lym ph node sections s ta ined  for Ki-67 and  IdUrd. Based on 
18FLT-PET im ages and  pathologic findings, lym ph nodes w ere  assigned to  one of th ree  
groups: tru e  positive (18FLT positive lym ph node w ith  histologically proven  m etastasis), 
tru e  negative (18FLT negative lym ph node w ith o u t m etastasis) and  false positive (18FLT 
positive lym ph node w ith o u t m etastasis) o r false negative (18FLT negative lym ph node 
w ith  histologically proven  m etastasis).
T hree histologically d istinc t a reas w ere  d istingu ished  in th e  lym ph node sections: 
germ inal centers, m etasta tic  tu m o r (if p resen t) and  rem ain ing  lym phoid tissue (Fig. 
7.2). In these  areas, Ki-67 and  IdUrd positive and  negative nuclei w ere  coun ted  using a 
grid  w ith  25 fields placed in th e  eyepiece a t 100 x m agnification (th ree  random ly  
selected  fields w ere  analyzed in germ inal centers, th ree  fields in m etasta tic  tissue  and 
one field in rem ain ing  lym phoid tissue). The Ki-67 and  IdUrd labeling index (LI) w as 
d e term ined  as th e  nu m b er of positively  s ta ined  nuclei re la tive to th e  to ta l n um ber of 
nuclei in a certain  area.
In all lym ph node sections, th e  to ta l lym ph node a rea  and  th e  (relative) a rea  occupied 
by germ inal cen ters and, if p resen t, m etasta tic  tu m o r w ere  calculated. This w as done by 
scanning  th e  en tire  section u n d e r b rig h t field m icroscopy and  reconstruc ting  a 
com posite im age of th e  com plete lym ph node using im age analysis so ftw are (IPLab, 
Scanalytics Inc., Fairfax, VA). Masks w ere  d raw n  on these  scans ind icating  th e  to ta l 
lym ph node area, th e  germ inal cen ters and  m etasta tic  tu m o r deposits. Next, using the  
im age analysis softw are, th e  abso lu te  and  rela tive areas occupied by germ inal cen ters 
and  m etasta tic  deposits w ere  calculated.
SUVmean v e r s u s  Ki-67 and IdUrd staining. As a m easu re  of to ta l p ro liferative activity  in 
th e  germ inal cen ters of a lym ph node section, th e  p ro d u c t of th e  Ki-67 o r IdUrd LI and 
th e  abso lu te  a rea  occupied by th e  germ inal cen ters w as calculated. These p aram ete rs  
w ere  called: Ki-67germinal center and  IdUrdgerminal center. Similarly, as a m easu re  of to ta l 
p ro liferative activity  in th e  en tire  lym ph node, th e  sum  of th e  p roducts  of LI and 
abso lu te  a rea  of germ inal cen ters, rem ain ing  lym phoid tissue  and, if p resen t, m etasta tic  
deposits  w as calculated: Ki-67lymph node and  IdUrdlymph node. These p a ram ete rs  w ere  
com pared  be tw een  tru e  positive, false positive and  tru e  negative lym ph nodes and  w ere  
co rre la ted  w ith  SUVmean.
Statistical analysis. The ANOVA-test w as used  to  assess differences in abso lu te  area  
and  Ki-67 and  IdUrd LI betw een  tru e  negative, false positive and  tru e  positive lym ph 
nodes. The t- te s t w as applied  for com parison  of nu m b er and  abso lu te  a rea  of germ inal 
cen ters and  for com parison  of Ki-67germinal center and  IdUrdgerminal center be tw een  tru e
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negative and  false positive lym ph nodes. C orrelations be tw een  Ki-67lymph node and 
IdUrdlymph node and  SUVmean w ere  calculated using linear regression . All statistical 
analyses w ere  calculated  using G raphPad Prism  for M acintosh (version 4.0a; La Jolla, 
CA). A p-value < 0.05 w as reg ard ed  statistically  significant.
7.3 Results
7.3.1 Patients and treatment
P atien t characteristics are  sum m arized  in Table 7.1. Four m en and six w om en w ith  a 
m ean age of 59 years (range 43-80  years) w ere  included. P rim ary  tu m o r sites w ere  oral 
cavity (7), larynx (2) and  m axillary sinus (1). P reoperative  staging of th e  neck w as 
perfo rm ed  w ith  u ltraso u n d  im aging (8 patien ts) - w ith  fine needle asp ira tion  cytology 
in 6 p a tien ts  and  w ith o u t in tw o - w ith  CT (3 patien ts) o r MRI (4 patien ts). All pa tien ts  
u n d e rw en t surgical tu m o r resection  com bined w ith  assessm en t of cervical lym ph node 
invo lvem ent according to Dutch N ational Guidelines: Six p a tien ts  w ith  clinically N0 oral 
cavity carcinom a u n d e rw e n t selective neck  dissection  of level I-III. A (m odified) radical 
neck dissection  w as done in th re e  p a tien ts  w ith  p re-operatively  p roven  cervical lym ph 
node involvem ent. In one p a tie n t w ith  a glottic laryngeal carcinom a w ith o u t suspected  
lym ph node involvem ent only sam pling  of level II and  III nodes w as perform ed . Neck 
su rgery  w as perfo rm ed  un ila tera lly  in seven p a tien ts  and  b ila tera lly  in th ree  patien ts.
Table 7.1 Patient characteristics, diagnostic and therapeutic procedures and histopathology of
lymph nodes
Patient Site
US and 
fine needle 
aspiration cytology 
(side)
CT MRI
Clinical
stage
Pathological
stage
1 Maxillary sinus + (left) n.p. pos. T4N1M0 pT4pN1M0
2 Larynx tn.p. neg. n.p. T3N0M0 pT3pN0M0
3 Larynx n.p. pos. n.p. T4N2cM0 pT4pN2cM0
4
Lower alveolar 
ridge
- (left) neg. n.p. T4N2bM0 pT4pN0M0
5 Floor of mouth tn.r. n.p. n.p. T2N0M0 pT2pN0M0
6 Tongue - (right) n.p. n.p. T3N0M0 pT2pN0M0
7 Soft palate n.p. n.p. n.p. T2N0M0 pT2pN0M0
8 Tongue n.p. n.p. neg. T3N0M0 pT3pN1M0
9
Tongue/ 
Floor of mouth
- (left) n.p. neg. T4N0M0 pT2pN0M0
10
Tongue / 
Floor of mouth
- (left) n.p. neg. T2N0M0 pT2pN0M0
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Table 7.1 (continued)
Procedure
*
Pathology LN 
(number of 
pathological LN)
LN positive on PET and 
available for pathologic 
assessment 
(number of LN indicated)
LN positive on PET 
but not available for 
pathologic assessment 
(number of LN indicated)
left right left right side indicated
TE§ + MRND11 left pos (1) n.a. 1 n.a. 1, right
TLE1 + bilateral NS# neg neg 1 1 2, right
TLE + bilateral 
RND**
pos (7) pos (5) 2 2 1, right
TE + MRND right n.a. neg n.a. 2 2, left
TE + bilateral SNDtt neg neg neg neg -
TE + SND right n.a. neg - 5 -
TE + SND left neg n.a. neg n.a. 1, right
TE + SND right n.a. pos (1) - 1 1, right
TE + SND left neg n.a. 3 n.a. 2, right
TE + SND left neg n.a. 2 - -
* t  t  § I ILN = lymph node, n.p. = not performed, n.r. = not representative, TE = tumor excision, MRND = modified
V # ** t tradical neck dissection, TLE = total laryngectomie, NS = node sampling, RND = radical neck dissection, SND 
= selective neck dissection (level I-III)
7.3.2 18FLT-PET
18FLT-PET scans w ere  acqu ired  sim ultaneously  on PET/CT (3) o r consecutively on CT 
and PET (7). The m edian  tim e in terval betw een  18FLT-PET and  su rgery  w as 5 days 
(average 9.9 days, range 4-37 days). In all b u t one case, su rgery  w as perfo rm ed  w ith in  
4 -14  days a fte r th e  PET-scan. In th e  case w ith  th e  longest in terval (37 days), th e  surgical 
resection  of an oral cavity carcinom a w as postponed , because th e  p a tie n t u n d e rw en t 
laser evapora tion  of a sm all laryngeal lesion first. In all b u t one p a tien t (num ber 5), 
increased  m ean SUV rang ing  from  0.8-2.9 (m edian 1.2, s tan d ard  deviation  (± SD) 0.41) 
w ere  detected, m ostly  in m ultip le lym ph nodes. A typical 18FLT-PET-CT im age is show n 
in Figure 7.1.
7.3.3 Pathological evaluation
R outine pathology based  on H&E stain ing  revea led  th ree  p a tien ts  to  have m etasta tic  
cervical lym ph node disease (num bers 1, 3, 8), w hereby  clinical exam ination  and 
anatom ical im aging had  p red ic ted  th is only in tw o p a tien ts  (num bers 1 and  3). The 
th ird  p a tien t had  a m icrom etastasis  of less th an  2 m m  in one lym ph node (num ber 8). 
A lthough p re-opera tive  staging of th e  neck  revea led  m ultip le ipsila te ra l en larged  lym ph 
nodes in p a tien t 4, final histology show ed  no signs of m etasta tic  disease.
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In to tal, paraffin -em bedded  sections contain ing  26 lym ph node levels w ere  selected  for 
Ki-67 and  IdUrd stain ing  and  analysis. E ighteen of these  levels w ere  positive on 18FLT- 
PET, eight levels w ere  negative. As show n in Table 7.2, com parison  of 18FLT-PET resu lts  
w ith  pathology revealed  six tru e  positive, tw elve false positive and  eigh t tru e  negative 
findings.
Table 7.2 Histological LN* assessment: SUVmean, histopathology and mean Ki-67 and
IdUrd staining
patient
LN level Pathology Ki-67 and IdUrd staining
FLT + SUVmean FLT - (metastasis + or - ) Metastasis GC Remaining LT
R* II11 1.5
t
n.a.
1 L III - (TN1) + +
L§ II 2.9 + (TP#) + +
R II 1.2 - (FP**) ++ +
2
R III 0.9 n.a.
R IV 1.2 n.a.
L III 1.1 - (FP) ++ +
R II 1.2 n.a.
R III 1.3 + (TP) + ++ +
3 R IV 1.1 + (TP) + ++ +
L II 1.7 + (TP) + -
L IV 1.3 + (TP) + + +
R II 1.4 - (FP) ++ +
R III - (TN) +
4
R IV 1.1 - (FP) +
R V - (TN) ++ +
L II 1.0 n.a.
L IV 0.8 n.a.
5
R I - (TN) + +
L II - (TN) + ++
R I 1.4 - (FP) ++ ++
6 R II 1.3 - (FP) ++ ++
R III 0.9 - (FP) + +
R IV 1.5 n.a.
7 L I - (TN) ++ +
L III - (TN) ++ +
8
R II 1.0 + (TP) + ++ +
RIII 0.8 n.a.
R II 2.1 n.a.
R IV 1.0 n.a.
9 L II 1.3 - (FP) ++ +
L III 2.0 - (FP) + +
L IV 1.0 - (FP) + +
L I - (TN) +
10 L II 1.6 - (FP) + ++
L III 1.3 - (FP) + ++
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* t  t  § I I  VLN = lymph node, n.a. = not available, R = right, L = left, II = level indicated by Roman number, TN = true 
negative (FLT negative lymph node without metastasis), #TP = true positive (FLT positive lymph node with
**metastasis), FP = false positive (FLT positive lymph node without metastasis)
T here w ere  no false negative 18FLT-PET studies. Based on these  findings, sensitiv ity  of 
18FLT for determ in ing  lym ph node sta tu s  in head  and  neck cancer p a tien ts  w as 100% , 
specificity 40% , positive p red ic tive value 33.3%  and negative pred ic tive value 100%  on 
lym ph node level. On p a tien t level, afte r excluding p a tien t 7 as no histological co rrelate  
for th e  18FLT-positive lym ph node w as available, n um bers w ere  100% , 16.7%, 37.5%  
and 100% , respectively.
N ot all lym ph nodes show ing enhanced  18FLT-PET-uptake w ere  rem oved  during  
surgery . These lym ph nodes w ere  e ith er n o t included in th e  neck d issection specim en 
(p a tien t 3 and  8), o r s itua ted  in th e  con tra la te ra l neck (p a tien t 1, 2, 4, 7, 9). Based on the  
resu lts  of th e  s tan d ard  diagnostic w ork-up  and  th e rap eu tic  guidelines, th e re  w as no 
ind ication  for rem oval of th ese  nodes.
Follow -up (m edian 13 m onths, range 11-15 m onths) has revealed  re c u rre n t p rim ary  
tu m o r in one p a tien t tre a te d  w ith  su rgery  and  post-operative  rad io th erap y  (pT2N0M 0 
carcinom a of th e  tongue). Until p resen t, no lym ph node recu rren ce  has been  observed  
in any of th e  patien ts.
7.3.4 Ki-67 and IdUrd staining
Ki-67 and  IdUrd stain ing  w as p re se n t in m etasta tic  tu m o r cells, germ inal cen ters and  in 
rem ain ing  lym phoid  tissue  as show n in Figure 7.2. In alm ost all lym ph nodes exam ined, 
b o th  18FLT-PET positive and  negative, germ inal cen ters sta in ing  positive for Ki-67 and 
IdUrd w ere  p resen t. M etastatic tu m o r cells in p a tien ts  1 and  3 had  a lm ost fully 
destroyed  th e  lym ph node arch itectu re . In p a tien t 8, th e  m icrom etastasis  occupied only 
a sm all reg ion  of the  affected lym ph node leaving reactive germ inal cen ters and 
rem ain ing  lym ph node tissue  u n p ertu rb ed .
In germ inal centers, m etastases, and  rem ain ing  lym phoid  tissue, nuclei sta in ing  positive 
for Ki-67 and  IdUrd w ere  counted  and  th e  LI w as calculated. Figure 7.3 show s the  
overall resu lts  for Ki-67 LI and  IdUrd LI in th ese  th ree  lym ph node areas. Table 7.3 
p resen ts  th e  quan tita tive  da ta  for Ki-67 LI and  IdUrd LI in th e  germ inal centers, 
rem ain ing  lym phoid tissue, m e tastases  and  overall for th e  tru e  negative, false positive 
and  tru e  positive lym ph nodes. The m edian  Ki-67 and  IdUrd LI in th e  germ inal cen ters 
w as 52.8%  and 25.7%  w ith  no difference be tw een  th e  th ree  groups. In th e  rem ain ing  
lym phoid tissue th is w as 3.3%  and 1.6% respectively, also w ith  no difference betw een  
th e  groups. In the  m etastases, th e  m edian  LI w as 26.7%  for Ki-67 and  9.3%  for IdUrd. In 
all th ree  areas and  p a tie n t g roups studied, Ki-67 LI w as significantly h igher com pared  to 
IdUrd LI (p<0.0001).
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Figure 7.3 A: Ki-67 labeling index (LI) and B: IdUrd LI in germinal centers (GC), remaining lymphoid 
tissue (LT) and metastases (MET).
Table 7.3 Ki-67 and IdUrd labeling index (LI) in germinal centers, remaining
lymphoid tissue and in metastases
Ki-67 LI
germinal centers remaining lymphoid tissue metastases
*
TN FPf TP* overall TN FP TP overall TP
mean 58.6 52.1 50.5 53.9 3.7 2.8 7.4 3.8 26.8
stdv§ 16.6 13.2 4.2 13.8 1.9 2.4 7.5 3.6 7.7
median 55.1 53.1 49.5 52.8 3.6 2.5 4.6 3.3 26.7
IdUrd
germinal centers remaining lymphoid tissue metastases
TN FP TP overall TN FP TP overall TP
mean 33.5 27.4 23.0 28.8 1.4 1.8 4.2 2.1 10.4
stdv 15.7 9.4 4.5 11.7 0.7 1.3 6.4 2.8 6.1
median 29.6 23.9 24.9 25.7 1.6 1.6 1.5 1.6 9.3
* tTN = true negative (FLT negative lymph node without metastasis), FP = false positive (FLT positive lymph node 
without metastasis), *TP = true positive (FLTpositive lymph node with metastasis), §stdv = standard deviation
7.3.5 Germinal centers
The m edian  n um ber of germ inal cen ters p e r lym ph node w as 9 (SD 6.7) in tru e  negative 
lym ph nodes, 20.5 (SD 27.0) in false positive nodes and  4 (SD 18.1) in tru e  positive 
nodes. The difference in n u m b er of germ inal cen ters be tw een  tru e  negative and  false 
positive lym ph nodes w as significant (p=0.03). Also th e  abso lu te  a rea  occupied by 
germ inal cen ters w as h igher in false positive nodes rela tive to  tru e  negative nodes b u t 
th e  difference w as only b o rd erlin e  significant (p=0.06), see Figure 7.4A. The to ta l 
p ro liferative activity  in th e  germ inal cen ters expressed  as Ki-67germinal center and 
IdUrdgerminal center w as h igher in th e  false positive lym ph nodes com pared  to  th e  tru e  
negative nodes, a lthough th e  difference did n o t reach  statistical significance (p=0.07, 
respectively), see Figures 7.4B and  7.4C.
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Figure 7.4 A: Absolute area (in mm2) occupied by germinal centers in true negative (TN; 18FLT 
negative lymph node without metastasis), false positive (FP; 18FLT positive lymph node without metastasis) 
and true positive (TP; 18FLT positive lymph node with metastasis) lymph nodes. B and C: Ki-67germinai center 
and IdUrdgerminal center in TN and FP lymph nodes as a measure of the total proliferative activity in germinal 
centers (calculated as area in mm2).
7.3.6 Total proliferative activity in lymph nodes and correlation with SUVmean
The to ta l pro liferative activity  in lym ph nodes expressed  as Ki-67iymph node and  IdUrdiymph 
node w as found to  be significantly h igher in th e  tru e  positive lym ph nodes as com pared  
to  false positive lym ph nodes (p=0.006 and  p=0.05, respectively). As show n in 
Figure 7.5, th e re  w as a m o d era te  b u t significant co rre la tion  be tw een  SUVmean and 
Ki-67lymph node (r2=0.47, p=0.0009) and  be tw een  SUVmean and  IdUrdlymph node (r2=0.55, 
p=0.0004).
Figure 7.5 A: Scatterplot of Ki-67ymph node and B: scatterplot of IdUrdiymph node as a measure of the total 
proliferative activity in the lymph node (calculated as area in mm2) versus SUVmean of 18FLT-PET. Solid lines 
indicate linear best fit.
124
18FLT-PET for detection of lymph node metastases
7.4 Discussion
The PET tra c e r  18FLT for im aging of cell p ro lifera tion  has been  s tud ied  by various 
groups, co rre la ting  18FLT w ith  18FDG 20-26,28-31. Buck e t  al. s tud ied  18FLT-PET and 18FDG- 
PET in 47 p a tien ts  w ith  benign and  m alignan t pu lm onary  nodules and  found a high 
sensitiv ity  of FLT for m alignan t p rim ary  tum ors (sensitiv ity  90% ), b u t n o t for 
m ediastinal lym ph node invo lvem ent (sensitiv ity  53% ) o r detection  of lung m etastasis  
(sensitiv ity  67% ) 22. T w enty-one p a tien ts  w ith  p rim ary  o r re c u rre n t laryngeal 
carcinom as w ere  s tud ied  by Cobben e t  a l 27. Data on sensitiv ity  and  specificity for 
detection  of the  p rim ary  tu m o r w ere  only rep o rte d  for 18FDG and n o t for 18FLT. 
H owever, th e  s tan d ard ized  up take value (SUV) for 18FLT w as found to be significantly 
low er com pared  to  th e  SUV for 18FDG and th e re fo re  th e  ro u tin e  use of 18FLT-PET for 
detection  of laryngeal carcinom a w as n o t recom m ended. A dditional stud ies corre la ted  
18FLT w ith  histological a ssessm en t of p ro lifera tion  by Ki-67 labeling in fibrosarcom a, 
b re a s t and  lung cancer 23,30-35. In lung carcinom a, Buck e t  al. found th a t the  Ki-67 LI 
co rre la ted  w ith  18FLT up take 23. This finding has recen tly  b een  confirm ed by Yap e t  al.
31. In a fib rosarcom a xenograft, Leyton e t  al. found th a t 18FLT up take and  PCNA labeling 
index w ere  linearly  co rre la ted  33. In co n tra s t to  these  studies, Smyczek-Gargya e t  al. 
found no corre la tion  betw een  Ki-67 labeling index and  18FLT up take in p rim ary  b re a s t 
carcinom a 30. A lthough th e  resu lts  are  n o t en tire ly  consistent, th ese  stud ies suggest th a t 
18FLT-PET m ay be of value for th e  quantification  of tu m o r cell p roliferation.
In th e  cu rren t study, th e  value of 18FLT-PET in assessing  th e  cervical lym ph node sta tus 
and  pro liferative activ ity  of m etasta tic  lym ph nodes in squam ous cell carcinom a of the  
head  and  neck w as investigated. The endogenous p ro lifera tion  m ark e r Ki-67, w hich is 
expressed  in th e  G1, S-, G2- and  M -phase of th e  cell cycle, w as chosen for com parison  
w ith  18FLT-PET, because endogenous m arkers do n o t req u ire  in travenous 
ad m in istra tion  and  because re c e n t stud ies validated  18FLT-PET w ith  Ki-67 23,30,31. In 
addition, th e  exogenous m ark e r IdUrd w as used. IdUrd is a ro b u s t and  specific S-phase 
m ark e r and  it w as hypothesized  th a t th is m ark e r m igh t correlate  b e tte r  w ith  18FLT 
uptake, because TK-1 activity  is increased  m ainly  during  DNA synthesis. In n ine of the  
ten  p a tien ts  studied, increased  18FLT up take w as observed  in th e  lym ph nodes. Only 
th ree  of these  n ine 18FLT-PET positive p a tien ts  had  m e tasta tic  nodal d isease confirm ed 
by h istopathology, and  tw o of th em  had  already  been  de tected  by ro u tin e  p reopera tive  
screening. In none of th e  18FLT-PET negative lym ph nodes m etasta tic  d isease w as 
p resen t.
As th e  nu m b er of false positive lym ph nodes w as high, fu rth e r analysis w as perfo rm ed  
tak ing  in to  accoun t th e  a rch itec tu re  and  pro liferative s ta te  of th e  lym ph nodes. In m ost 
lym ph nodes evaluated, in tense  stain ing  of b o th  Ki-67 and  IdUrd w as p re se n t in B-
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lym phocytes p ro lifera ting  in germ inal centers. Less in tense  stain ing  w as found in 
m etasta tic  tu m o r cell deposits  and  th e  pro liferative activity  in rem ain ing  lym ph node 
tissue w as very  low. In germ inal centers, the  labeling index of b o th  m arkers w as 
significantly h igher com pared  to m etastases o r lym phoid  tissue. T here w as no 
difference in th e  p ro liferative activity  in germ inal cen ters be tw een  tru e  negative and  
false positive lym ph nodes. However, false positive nodes on average contained  a 
significantly g rea te r nu m b er of germ inal cen ters and  th ese  occupied a la rger abso lu te  
a rea  rela tive to  th e  tru e  negative nodes, a lthough th is la tte r  finding w as only bo rderline  
statistically  significant. Also th e  p ro d u c t of Ki-67 LI and  IdUrd LI and  a rea  occupied by 
germ inal cen ters w as h igher in th e  false positive com pared  to  th e  tru e  negative lym ph 
nodes. It is th e re fo re  likely th a t th e  active p ro lifera tion  of B-lym phocytes in germ inal 
cen ters is responsib le  for th e  false-positive 18FLT-PET resu lts. This high pro liferative 
activity  of B-lym phocytes m igh t also be responsib le  for 18FLT-PET positiv ity  of the 
m icrom etastasis  in p a tien t 8.
T hree o th e r studies, tw o in b re a s t cancer and  one in tho rac ic  tu m o rs  com pared  18FLT- 
PET w ith  h istopatho logy  for the  a ssessm en t of lym ph node sta tu s  2°,3°,31. The study  by 
Smyczek-Gargya e t  al. included 14 b re a s t cancer patien ts, of w hom  eight had 
histologically p roven  axillary lym ph node m etastasis  and  seven w ere  detected  by 18FLT- 
PET (sensitiv ity  87.5%  and specificity 100% ) 30. In th e  study  by Been e t  al. th a t included 
ten  patien ts, only tw o of seven p a tien ts  w ith  histologically p roven  m etasta tic  axillary 
lym ph nodes w ere  de tected  by 18FLT-PET (sensitiv ity  28.5%  and specificity 100% ) 20. 
Yap e t  al. s tud ied  22 p a tien ts  w ith  thoracic  tu m o rs  and  rep o rte d  sensitiv ity  and 
specificity for detection  of m ediastinal lym ph nodes by 18FLT to  be 33.3%  and 98.2% , 
respectively  31. The low  sensitiv ity  in som e of these  stud ies m ay be explained by th e  fact 
th a t som e histological tu m o r types, such as m am m ary  carcinom a, can exhib it lim ited 
pro liferative activity. A second explanation  m igh t be th a t the  m e tasta tic  tu m o r load of 
som e of these  lym ph nodes w as low.
All th ree  stud ies rep o rte d  a high specificity in co n tra st to  th e  cu rren t study  w here  
specificity w as only 16.7%. The localization of the  lym ph nodes m ay be of im portance in 
explaining th is discrepancy. Reactive lym ph nodes in th e  head  and  neck a rea  are  found 
frequen tly  as response  to  bac teria l o r v iral infections, w hereas reactive axillary lym ph 
nodes are  less com m on. F urtherm ore , p a tien ts  w ith  squam ous cell carcinom as of the  
oral cavity -  in th is study  th e  la rg est p a tien t group  -  often p re se n t w ith  non-healing  
u lcers accom panied w ith  reactive lym ph nodes. This is consisten t w ith  th e  observation  
th a t false positive lym ph nodes on average contained  a h igher subvolum e of germ inal 
cen ters w ith  very  active p ro life ra tion  of B-lym phocytes as com pared  to  tru e  negative 
nodes.
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In th is study, 18FLT-PET reached  only low  m ean SUV in m etasta tic  as w ell as in n o n ­
m etasta tic  cervical lym ph nodes com pared  to  the  SUV for 18FDG-PET generally  rep o rted  
in head  and  neck cancer s,8,10,28. This is in ag reem en t w ith  the  p revious finding for 
p rim ary  laryngeal tu m o rs  by Cobben e t  al. 27. In accordance w ith  stud ies d iscussed  
above, a significant co rre la tion  betw een  SUVmean and  overall Ki-67 and  IdUrd stain ing  
(Ki-67lymph node and  IdUrdlymph node) w as found in th is s tudy  (Fig. 7.5) 31,33. The correlation  
w as s tro n g es t for IdUrd and  w e recom m end th is m ark e r for fu tu re  stud ies w ith  18FLT 
th a t include histological validation.
7.5 Conclusions
A lthough 18FLT-PET correctly  identified  all head  and  neck  cancer p a tien ts  w ith  
m etasta tic  lym ph nodes, th e  specificity and  positive predic tive value w ere  low  due to 
tracer-u p tak e  in germ inal cen ters of lym ph nodes. T herefore, th e  use of 18FLT-PET for 
assessing  p re tre a tm e n t lym ph node sta tu s  and  for determ in ing  the  pro liferative activity  
of affected lym ph nodes is n o t encouraged  in head  and  neck cancer patien ts. This also 
lim its th e  usefulness of 18FLT-PET for rad ia tion  th e ra p y  p lann ing  and  possib ly  for early  
tre a tm e n t response  evaluation  of sm all m etasta tic  lym ph nodes. The value of 18FLT-PET 
for assessm en t of th e  p ro liferative s ta te  of th e  p rim ary  head  and  neck tu m o r and  the  
relevance for rad io th e rap y  p lann ing  is a top ic of cu rre n t investigations.
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Abstract
Introduction. Accelerated tum or cell proliferation is an im portant mechanism adversely 
affecting therapeutic outcome in head and neck cancer. 3’-deoxy-3’-18F-fluorothymidine (18FLT) 
is a PET tracer to non-invasively image tum or cell proliferation. The aims of this study were to 
monitor early tumor response based on repetitive 18FLT-PET-CT scans and to identify 
subvolumes with high proliferative activity eligible for dose escalation.
Materials and Methods. Ten patients with oropharyngeal tumors underw ent an 18FLT-PET-CT 
scan prior to and twice during radiotherapy. The primary tum or and metastatic lymph nodes 
were delineated based on CT ( G T V c t ), and after segmentation of the PET signal using the 50% 
isocontour of the maximum signal intensity (GTVso%) or an adaptive threshold based on the 
signal-to-background ratio ( G T V sbr) .  Gross tum or volumes were calculated, and similarity 
between G T V ct and G T V sbr was assessed. Within G T V sbr, the maximum and mean standardized 
uptake values (SUVmax and SUVmean) were calculated. Within G T V ct, tumor subvolumes with high 
proliferative activity were identified based on the 80% isocontour (GTVso%) for radiotherapy 
planning with dose escalation.
Results. The G T V ct decreased significantly in the fourth week, but not in the initial phase of 
treatment. SUVmax and SUVmean decreased significantly as early as one week after therapy 
initiation and even further before the fourth week of treatment. For the primary tumor, the 
average (± 1 SD) SUVmean values of the G T V sbr were 4.7 (± 1.6), 2.0 (± 0.9) and 1.3 (± 0.2) for the 
consecutive scans (p<0.0001). The similarity between G T V ct and G T V sbr decreased during 
treatment, indicating an enlargement of G T V sbr outside G T V ct caused by increasing difficulty to 
segment tracer uptake in the tum or from the background, and by proliferative activity in the 
nearby tonsillar tissue. Subvolumes with high proliferative activity (GTV80%) were successfully 
identified in all primary tumors and metastatic lymph nodes, and dose escalation based on the 
GTV80% was dem onstrated to be technically feasible.
Conclusions. 18FLT is a promising PET tracer for imaging tumor cell proliferation in head and 
neck carcinomas. 18FLT-PET signal changes precede volumetric tum or response and are 
therefore suitable for early response assessment. Definition of tum or subvolumes with high 
proliferative activity and dose escalation to these regions is technically feasible.
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8.1 Introduction
Radiotherapy with or without concomitant chemotherapy is the therapy of choice for 
advanced stage primary squamous cell carcinomas of the oropharynx 1. For radiation 
therapy planning, a single computed tomography (CT) scan in treatment position is 
acquired prior to the initiation of treatment. Traditionally, a homogeneous dose 
distribution is prescribed to the gross tumor volume (GTV) defined on CT with a margin 
for subclinical growth and setup inaccuracy. In the last decade, intensity modulated 
radiation therapy (IMRT) revolutionized the field of radiotherapy. IMRT is based on the 
use of photon beams with optimized non-uniform fluence profiles. With this technique, 
the simultaneous delivery of different dose prescriptions to various target (sub)sites 
became feasible. Certain areas within the GTV can since be boosted to higher doses, 
whilst steep dose gradients allow to reduce the dose delivered to radiation sensitive 
tissues adjacent to the tumor 2,3. For this means, however, precise knowledge about the 
tumor location and extension is compulsory, and tumor areas requiring higher radiation 
doses must be identified.
Functional imaging can complement anatomical imaging modalities such as CT and 
magnetic resonance imaging (MRI) and provide biological tumor information relevant 
for radiotherapy dose planning. Initial studies with positron emission tomography 
(PET) using 18F-fluorodeoxyglucose (18FDG) demonstrated that the volume irradiated to 
high-dose levels can be reduced, thus promoting normal structure sparing and dose 
escalation 4-9. 18FDG uptake reflects metabolic activity, and false positive readings are 
caused by tracer uptake in inflammatory tissue. Other PET tracers can provide more 
specific biological information, in particular on radiotherapy resistance mechanisms.
Accelerated tumor cell repopulation during the course of radiotherapy is a frequently 
observed phenomenon in squamous cell carcinomas of the head and neck that 
adversely affects treatment outcome 10,11. 3’-deoxy-3’-18F-fluorothymidine (18FLT) 
uptake is enhanced during DNA synthesis, and 18FLT-PET therefore provides a non­
invasive imaging modality for tumor cell proliferation 12-15. Potential applications of 
18FLT-PET in radiation oncology are: patient selection for treatment modification based 
on the tumor’s proliferative state, identification of tumor subvolumes with a high 
density of actively proliferating cells amenable for boosting, and early treatment 
response monitoring.
In this study, patients with oropharyngeal tumors underwent three subsequent 18FLT- 
PET scans: prior to and twice during the course of radiotherapy. The aims of this study 
were: 1) to monitor early tumor response based on 18FLT-PET-CT volume and 18FLT- 
PET signal changes, 2) to assess the heterogeneity of intratumoral 18FLT distribution 
and identify subvolumes with a high density of proliferating cells, and 3) to determine 
the technical feasibility of adaptive radiation therapy based on 18FLT-PET-CT.
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8.2 Material and Methods
Patients. From March 2007 until September 2008, 10 patients with newly diagnosed 
primary oropharyngeal carcinomas eligible for radiotherapy with or without 
concomitant chemotherapy were included in this study after giving written informed 
consent. The Institutional Review Board of the Radboud University Nijmegen Medical 
Centre approved the study.
Treatment. Patients were treated with intensity modulated radiotherapy with a 
simultaneous integrated boost (SIB) technique, delivering a dose of 68 Gy in fractions of 
2 Gy to the primary tumor and metastatic cervical lymph nodes and 50.3 Gy in fractions 
of 1.48 Gy to the electively treated neck nodes. An accelerated fractionation schedule 
was used with an overall treatment time of 5.5 weeks delivering two fractions per day 
during the last 1.5 weeks of the treatment. Following the institution’s guidelines, two 
patients with bulky primary tumors were concomitantly treated with cisplatinum 
40 m g/m 2, administered intravenously once weekly.
18FLT synthesis. 18FLT was obtained from the Department of Nuclear Medicine and PET 
Research, VU University Medical Centre, Amsterdam, the Netherlands. The synthesis 
was performed according to the method of Machulla e t  al. 16. Briefly, 18FLT was 
produced by 18F-fluorination of the 4,4'-dimethoxytrityl protected anhydrothymidine, 
followed by a deprotection step. The product was purified by reversed phase high­
performance liquid chromatography, made isotonic and passed through a 0.22 pm filter. 
18FLT was routinely produced with a non-decay corrected radiochemical yield of 5­
10%, a radiochemical purity of >97% and a specific activity higher than 10,000 
GBq/mmol.
18FLT-PET-CT acquisition. Prior to and in the second and fourth weeks of radiotherapy, 
integrated 18FLT-PET and CT images were acquired on a hybrid PET-CT scanner 
(Siemens Biograph Duo scanner; Siemens/CTI, Knoxville, TN, USA). All scans were 
performed with the patient in supine position and immobilized with an individual head 
support and a rigid customized mask covering the head and neck area in order to 
increase position accuracy and to reduce movement artifacts during image acquisition. 
Emission images of the head and neck area were recorded 60 minutes after intravenous 
injection of approximately 250 MBq 18FLT, with 7 minutes per bed position in 3D mode. 
PET images were reconstructed using the OSEM iterative algorithm with parameters 
optimized for the head and neck area (i.e., 4 iterations, 16 subsets and 5 mm 3D 
Gaussian filter 17), with correction for photon attenuation. In addition, CT images were 
acquired for anatomical correlation and attenuation correction purposes using 80 mAs, 
130 kV, 3 mm slice width, and intravenous contrast in the venous phase (Optiray, 
Mallinckrodt Inc., Hazelwood, MO, USA).
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18FLT-PET analysis. After reconstruction, SUV-PET images were created with in-house 
developed software correcting for injected dose, decay of the tracer, and patient body 
weight. Subsequently, these SUV-PET images were resliced using the CT format as 
reference. SUV-PET and CT images were imported into Pinnacle3 (version 8.0d; Philips 
Radiation Oncology System, Madison, WI, USA), the radiotherapy planning system  
routinely used at our department. With this software, the consecutive CT and PET scans 
were registered to the first CT-scan using cross-correlation. Two investigators 
delineated the gross tumor volume (GTV) of the primary tumor and the metastatic 
lymph nodes on all registered CT scans (GTVct). Self-written scripts in Pinnacle3 were 
used for the segmentation of the primary tumor and the metastatic lymph nodes from 
the PET images and for the calculation of the mean and maximum standardized uptake 
value (SUVmean and SUVmax) within these volumes.
PET segmentation of primary tumor and metastatic lymph nodes. Two previously 
described methods for segmentation of the primary tumor and the metastatic lymph 
nodes in the PET images were applied 7, 18. Firstly, the 50% isocontour (GTVs0%) was 
based on a fixed percentage of the maximum signal intensity in the primary tumor. 
Secondly, an adaptive threshold delineation based on the signal-to-background ratio 
was performed (GTVsbr; Fig. 8.1) 18.
For this means, the SUVmax was defined as mean uptake of the hottest voxel in the tumor 
or metastatic lymph node and its eight surrounding voxels in one transversal slice. 
Mean background uptake was calculated from a manually defined region of interest in 
the left neck musculature (approximately 10 cm3) at sufficient distance from the 
vertebrae, the primary tumor and lymph node metastases.
PET segmentation of subvolumes with high proliferative activity. Based on the 
18FLT-PET signal, tumor subvolumes with a high density of proliferating tumor cells 
within the GTVct of the primary tumor and metastatic lymph nodes were defined. An 
arbitrary, fixed threshold of the SUVmax was defined that fulfilled the requirement of 
delineating a tumor subvolume in at least the first and second 18FLT-PET scan. This was 
best met using the 80% isocontour (GTVs0%). The absolute GTVs0% and the fraction of 
the GTV80% relative to the GTVct were calculated. The GTVs0% from the third scan was 
not further analyzed, because of a very low 18FLT-uptake in the tumor and thus a 
relatively low SUVmax value within the GTVct. This lead to unsuccessful segmentation of 
PET subvolumes, which were mostly larger than the GTVct and often encompassed the 
entire tonsillar region.
Volumetric and spatial similarity. The absolute volumetric similarity of the gross 
tumor volume on CT (GTVct) and 18FLT-PET (GTVsbr) was assessed at all three time 
points. For this analysis only GTVsbr was used. As it does not adjust for background
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activity, segmentation of the tumor by GTVs0% became increasingly difficult with lower 
18FLT-uptake in the second and third scans.
As measures of volumetric similarity, we calculated the part of the GTVct that was not 
covered by the GTVsbr (simGTVcr) and vice versa: the GTVsbr not enclosed by the GTVct 
(simGTVsBR). As a measure reflecting differences in location more strongly than 
differences in size, the Dice Similarity Coefficient (DSC) was additionally calculated as 
twice the overlap volume divided by the sum of both volumes:
DSC = 2x(GTVctHGTVsbr)/(GTVct+GTVsbr) 19. It is generally accepted that a value of 
DSC>0.7 represents excellent agreement 20. The same calculations were applied to the 
two GTV80% delineated on the first and second 18FLT-PET scans, GTVs0 % 1  and GTVs0%2.
Statistical analysis. Statistical analyses were performed using GraphPad Prism Version 
4.0c for Macintosh (La Jolla, CA). Gaussian distribution was tested using the 
Kolmogorov-Smirnov test. The change in CT and PET volumes was assessed applying 
repeated measures ANOVA and two-tailed paired t-test, and the Friedman test and 
Wilcoxon signed rank test, respectively. The alteration in PET signal intensity was 
assessed using two-tailed paired t-test. The volumetric similarity of the GTVs delineated 
on CT and PET was analyzed using Friedman test and Wilcoxon signed rank test. The 
repeated measures ANOVA and two-tailed paired t-test were applied to the Dice 
Similarity Coefficient. The volumetric change in GTV80% was assessed using the 
Wilcoxon signed rank test. A p-value < 0.05 was regarded statistically significant.
8.3 Results
8.3.1 Patients and tumor characteristics
The patient and tumor characteristics are summarized in Table 8.1. Eight patients were 
treated with radiotherapy alone, two patients with the addition of concomitant 
chemotherapy. The first 18FLT-PET scan was acquired before the start of therapy 
(median 5 days, range 0 -  9 days). The second and third scan were acquired in the 
second and fourth week of treatment (see Table 8.1 for details). All primary tumors and 
lymph node metastases were visualized and subject to further assessment.
8.3.2 Early response monitoring: Reduction of tumor volume
The mean primary tumor volume delineated on CT (GTVct) decreased significantly 
between the second and third CT-scan, but not in the initial phase of treatment: mean 
GTVct (± 1 SD) on subsequent scans 12.7 cm3 (± 9.5 cm3), 11.1 cm3 (± 8.8 cm3) and 5.0 
cm3 (± 4.7 cm3) (Fig. 8.2A).
Although the overall 18FLT signal intensity decreased significantly after the start of 
treatment, the segmented PET volume remained almost unchanged when the SBR 
method was used: mean GTVsbr: 11.8 cm3 (± 8.9 cm3), 11.3 cm3 (± 12.4 cm3) and
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14.1 cm3 (± 10.8 cm3) (Fig. 8.2A), and even increased when the 50% threshold of the 
maximum signal intensity was applied: mean GTVs0% of 18.0 cm3 (± 31.5 cm3), 18.6 cm3 
(± 21.8 cm3) and 40.9 cm3 (± 61.1 cm3). For the two patients treated with concomitant 
radiotherapy and chemotherapy, the decrease in 18FLT-PET signal was similar to that of 
the patients treated with radiotherapy alone. For GTV delineation of the lymph nodes 
the trends were similar as for the primary tumors, i.e., a decrease in GTVct by the end of 
the treatment and no significant change in GTVsbr (Fig. 8.2B). As the 50% method 
resulted in unsatisfactory results in the primary tumors, it was not further applied to 
the metastatic lymph nodes.
Table 8.1 Patient characteristics
Patient Site Gender Age
Clinical
stage
Treatment
Cumulative 
dose 
delivered at 
PET2 (Gy)
Cumulative 
dose 
delivered at 
PET3 (Gy)
1 Tonsil f 67 T3N0M0 RCHT 16 36
2 Soft palate m 66 T2N1M0 RCHT 16 36
3
Base of tongue / 
tonsil
m 60 T2N0M0 RT 12 36
4 Tonsil m 53 T2N2bM0 RT 16 36
5
Base of tongue / 
tonsil
m 69 T2N0M0 RT 12 32
6 Tonsil f 53 T3N0M0 RT 24 36
7
Tonsil / 
hypopharynx
m 64 T2N1M0 RT 16 36
8 Tonsil m 55 T2N2bM0 RT 20 36
9 Tonsil m 70 T2N0M0 RT 10 30
10 Tonsil m 52 T1N2bM0 RT 12 36
f =female; m = male; RT = radiotherapy; RCHT = radiotherapy + chemotherapy.
8.3.3 Early response monitoring: Decrease of standardized uptake value
In the primary tumors, the SUVmax of the second 18FLT-PET-scan was already 
significantly decreased relative to the first scan, and even further in the third [mean 
SUVmax (± 1 SD): 7.6 (± 2.6), 3.1 (± 1.7) and 1.7 (± 0.4); Fig. 8.2C]. The same was 
observed for SUVmean within GTVsbr [mean SUVmean: 4.7 (± 1.6), 2.0 (± 0.9) and 1.3 (±
0.2); Fig. 8.2C]. However, on an individual patient basis, different response patterns 
became apparent (Fig. 8.2E). On average, the relative decrease in SUVmax was 55% 
between the first and second, and 34% between the second and third 18FLT-PET scan.
In the lymph node metastases, similar patterns were observed for SUVmax and SUVmean 
(Fig. 8.2D). The relative decrease in SUVmax between the first and second 18FLT-PET
137
Chapter 8
scan was 44%, and between the second and third 47%, again with individual 
differences (Fig. 8.2F).
Figure 8.1 18FLT-PET-CT images o f a T3N0M0 oropharyngeal tumor obtained prior to radiation 
therapy. The gross tumor volume is delineated on CT (GTVct; red), and after segmentation o f the PET image 
using the signal-to-background method (GTVsbr; green) and the 50% isocontour (GTVsq%; yellow). The 
subvolume o f highest proliferative activity segmented on the PET image using the 80% isocontour (GTVso%) 
is highlighted in pink.
8.3.4 Similarity of CT and 18FLT-PET volume before and during treatment
In order to assess the feasibility of adaptive radiotherapy based on repetitive 18FLT- 
PET-CT scanning, the absolute volumetric similarity and Dice Similarity Coefficient 
(DSC) of the primary gross tumor volumes delineated on CT (GTVct) and PET (GTVsbr) 
were assessed at all time points.
There was a significant decrease in the absolute GTVct volume not covered by GTVsbr at 
the third time point (Fig. 8.3A) indicating an almost complete coverage of the GTVct by 
the GTVsbr. On the other hand, there was a significant increase in the GTVsbr volume not 
enclosed by GTVct indicating a large GTVsbr outside the GTVct that even increased over 
time (Fig. 8.3A). This decrease in volumetric and especially in spatial concordance was 
reflected by a significant decline of the DSC at the second and third PET scan (Fig. 8.3B).
The mean DSC (± 1 SD) was: 0.71 (± 0.08), 0.55 (± 0.21) and 0.29 (± 0.16) on the 
consecutive scans. This decrease in concordance was partly caused by increasing tracer
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uptake in the tonsillar region, especially in the fourth week of treatment, and partly by 
low tracer uptake in the primary tumor hampering the adaptive threshold method.
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Figure 8.2 A and B: Gross tumor volume (in cm3)  delineated on CT (GTVct)  and on PET using the 
signal-to-background method (GTVsbr)  fo r the primary tumor (A) and m etastatic lymph nodes (B). C and D: 
Maximum and mean standardized uptake value (SUVmax and SUVmean) analyzed using the SBR m ethod fo r the 
primary tumor (C) and the m etastatic lymph nodes (D). The volumes and standardized uptake values fo r the 
first (green), second (yellow) and third (blue) scans are shown. n.s. = not significant, *p < 0.01, **p < 0.001, 
***p < 0.0001. E and F: Alteration in SUVmax on an individual patient basis fo r all primary tumors (E) and the 
m etastatic lymph nodes (F). Each patient with cervical lymph node m etastases is highlighted by an identical 
color code.
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Figure 8.3 A: GTVct volume (in cm3)  not covered by GTVsbr (left panel), and GTVsbr not covered by 
GTVct (right panel) fo r the f irs t (green), second (yellow) and third (blue) time points. B: Dice Similarity 
Coefficient (DSC) calculated fo r CT and 18FLT-PET derived volumes a t the three time points. n.s.=not 
significant, * p < 0.01, **p < 0.001, ***p < 0.0001.
8.3.5 Delineation of subvolume with high density of proliferating cells using 
18FLT-PET
For all primary tumors, a GTVs0% within the GTVct could be identified on the first and 
second 18FLT-PET-CT scan (Fig. 8.4). In the third scan, this was hampered by a relatively 
low 18FLT uptake in the tumor relative to the background, leading to unsuccessful 
segmentation and subsequently to PET subvolumes larger than the GTVct, often 
encompassing the entire tonsillar region. The average GTVs0% (± 1 SD) decreased 
slightly between the first and second scan [1.52 cm3 (± 1.76 cm3) and 0.93 cm3 (± 0.94 
cm3), respectively]. Compared to the GTVct, the GTVs0% was relatively small and the 
fraction GTVs0%/GTVct overall did not change during treatment [prior to treatment:
0.12 (± 0.07); second week of treatment: 0.12 (± 0.14)]. On an individual patient basis, 
however, remarkable changes occurred in some cases, e.g., patients 1, 7 and 8 (Fig. 8.4). 
Between the first and second scan, the GTVs0% decreased and displaced (patient 1 and 
7), or substantially increased (patient 8).
In order to assess these changes in size and location of the GTVs0%, the absolute 
volumetric similarity and DSC of GTVs0 % 1 and GTVs0 % 2 (± 1 SD) were calculated. The 
average volume of the GTVs0 % 1 not covered by GTVs0% 2 was 1.12 cm3 (± 1.67 cm3) and
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the average volume of the GTVs0% 2 not encompassed by GTVs0 % 1  was 0.56 cm3 
(± 0.86 cm3). The mean overall DSC was 0.47 (± 0.25), indicating a moderate spatial 
similarity between the first and second tumor subvolume. However, there were large 
inter-individual differences, reflected by a range in DSC from 0.03 to 0.86. For all lymph 
node metastases, a subvolume with a high density of proliferating cells could also be 
identified. The mean absolute overall volume did not significantly change between the 
first and second scan [1.20 cm3 (± 1.13 cm3) and 1.21 cm3 (± 1.25 cm3), respectively], 
nor did the mean fraction of GTVs0% compared to the GTVct [prior to treatment: 0.17 
(± 0.08); second week of treatment: 0.19 (± 0.14)].
8.3.6 Generation of IMRT plan with boost to 18FLT-PET delineated subvolumes
As a proof of principle, an adaptive IMRT treatment plan with SIB and an accelerated 
schedule was generated for a patient with a T3N0M0 oropharyngeal tumor. This plan 
was based on the CT scan acquired prior to treatment taking into account changes in 
proliferative activity occurring during treatment (Fig. 8.5).
With this technique, the neck was treated bilaterally to a dose of 50.3 Gy in fractions of
1.48 Gy, and the gross tumor volume delineated on CT (GTVct) with margin for 
subclinical spread and setup inaccuracy was irradiated to a total dose of 68 Gy in 2 Gy 
fractions. The primary tumor subvolume with highest density of proliferating cells was 
defined twice: based on the 18FLT-PET scan acquired before the initiation of treatment 
(GTV80%1) and on the scan obtained in the second week (GTVs0%2). Subsequently, the 
GTV8 0 % 1 was defined as boost subvolume for the first two weeks of treatment, and the 
GTV8 0% 2 for dose escalation during weeks three and four. From week five, no increased 
dose was delivered to a highly proliferative subvolume. The GTVs0 % 1 and GTVs0 % 2  were 
consecutively irradiated in fractions of 2.3 Gy using the SIB technique resulting in a total 
dose of 74 Gy to the overlapping volume of the GTVs0% 1 and GTVs0%2, and a total dose of 
71 Gy to the areas of GTVs0 % 1  and GTVs0 % 2 mismatch. The volume irradiated to a higher 
dose was small and neither impacted on the dose to the electively treated volume and 
primary tumor volume (PTV> and PTV<, respectively), nor to the dose to normal tissues 
(Table 8.2).
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Figure 8.4 Detail o f CT scans showing the prim ary oropharyngeal tumors (for numerical order see 
Table 8.1). Delineation o f the gross tumor volume defined on CT (GTVct; f irs t CT scan: red, second CT scan: 
orange) and o f the subvolume with highest proliferative activity defined on 18FLT-PET (GTVso%; first PET 
scan: green, second PET scan: skyblue) is shown.
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Figure 8.5 Dose escalation to the tumor subvolumes with highest proliferative activity (GTVbq%1 and 
GTVs0%2)  fo r a T3N0M0 oropharyngeal tumor. Using intensity modulated radiotherapy with integrated 
simultaneous boost technique, the total dose to the bilateral cervical lymph nodes regions was 50.3 Gy (large 
planning target volume, PTV; red) and to the prim ary tumor 68 Gy (small PTV; blue). The GTVbq%i (black) 
and GTV80%2 (green) were consecutively irradiated with 2.3 Gy for 10 fractions resulting in a total dose o f 71 
Gy and a dose o f 74 Gy in the overlapping region. A: Dose distribution for f irs t two weeks o f  treatment, and B: 
dose distribution for week three and four; see legend 1. C: Dose distribution for remaining 14 fractions 
without dose escalation; see legend 2. Dose distribution o f total treatm ent plan in transverse (D) and sagittal 
(E) plane; see legend 3. The parotid glands are delineated in skyblue and the spinal cord in green.
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Table 8.2 Com parison o f  SIB-IM RTdose d istribu tions: classical versus 18FLT-PET 
g u id ed
Parameters Classical 18FLT-PET guided dose escalation
Organs at risk
Left parotid gland (Gy) 25.4 25.4
Right parotid gland (Gy) 24.8 24.8
Dmax spinal cord (Gy) 48.2 48.1
PTV>
Dmean (Gy) 52.2 52.1
D90 (%) 99.5 99.5
D95 (%) 96.7 96.4
PTV<
Dmean (Gy) 68.7 69.0
D90 (%) 99.7 99.6
D95 (%) 96.9 96.8
PTV<<
Dmean 1st subvolume (Gy) n.a. 73.6
Dmean 2nd subvolume (Gy) n.a. 74.5
Dmean overlap subvolumes (Gy) n.a. 74.7
Dmax = maximum dose; Dmean = mean dose; D90 = percentage o f volume receiving 90% o f the prescribed dose; 
D95 = percentage o f volume receiving 95% o f the prescribed dose; PTV> = planning target volume (PTV) 
encompassing electively treated volume, i.e., lymph node regions a t risk o f sub-clinical m etastatic disease; 
PTV< = PTV encompassing primary tumor; PTV<< = PTV for dose escalation defined by repetitive 18FLT-PET 
imaging (see Methods and Materials); n.a. = not available.
8.4 Discussion
Early response measurement
Accelerated tumor cell proliferation is an important mechanism of treatment failure in 
head and neck cancer. A prerequisite for monitoring and early adaptation of treatments 
that counteract this resistance mechanism is visualization and quantification of the 
proliferating tumor cell compartment before and during treatment.
18FLT is the most widely used PET tracer for imaging tumor proliferation. Alterations in 
the standardized uptake value of 18FLT have been used for early response monitoring in 
a variety of human tumors 21-24. Wieder e t  al. studied rectal cancer patients prior to 
treatment, 2 weeks after initiation and 3-4 weeks after completion of treatment 24. 
Although the SUVmean decreased significantly 14 days after the start of chemoradiation, 
this did not correlate with histopathological tumor regression. Herrmann e t  al. assessed 
two groups of patients with non-Hodgkin’s lymphoma undergoing chemotherapy and 
found 18FLT SUVmax to already decrease significantly after 2 days 21. Furthermore, the 
authors were able to detect a significant difference in reduction of tumoral 18FLT uptake
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between patients reaching partial response versus complete response at the end of 
therapy. Finally, two groups studied 18FLT uptake in breast cancer patients 22,23. Kenny 
e t  al. examined patients prior to and one week after neoadjuvant chemotherapy and 
found the 18FLT SUV to decrease significantly discriminating between patients with 
clinical response or stable disease 22. Pio e t  al. found changes in 18FLT uptake after one 
course of chemotherapy to correlate significantly with changes in tumor size detected 
by CT 23. Recently, Menda e t  al. demonstrated in eight head and neck cancer patients 
that initial 18FLT uptake and change early after treatment can be adequately monitored 
by SUV obtained at 45-60 min 25. Furthermore, a study on 15 patients (including six 
head and neck cancer patients) provided evidence that changes in 18FLT-PET SUVmax of 
more than 20-25% are likely to be therapy-related 26. Thus, under the assumption that 
repetitive quantitative 18FLT-PET measurements are sufficiently reproducible, 18FLT- 
uptake quantified by SUV has the potential to monitor changes in the proliferative 
activity of tumors early during treatment.
Based on these assumptions, our study assessed early response in patients with 
oropharyngeal tumors treated with radiotherapy or chemoradiation. Overall, there was 
a significant treatment-induced decrease in 18FLT tracer uptake, both in the primary 
tumor and cervical lymph node metastases as early as after the fifth fraction of 
radiotherapy. This was reflected by a greater than two-fold reduction in standardized 
uptake values in the initial phase of treatment and a further two-fold reduction in the 
fourth week. Clearly, different individual response patterns were also found in this 
study. Some patients showed a moderate decrease in standardized uptake values, whilst 
others even responded with an increase in signal intensity. Longer follow-up and a 
larger patient cohort are necessary in order to assess whether these individual 
differences will be discriminative for ultimate tumor response.
One could hypothesize that the concomitant use of chemotherapy may reduce tumor 
cell proliferation more rapidly compared to radiotherapy alone. However, the two 
patients treated with chemoradiotherapy in this study did not show a more rapid 
decrease in 18FLT-uptake compared to the others. We will further address this issue in a 
subsequent study including a larger number of patients treated with chemotherapy. 
Results of a meta-analysis indicate a survival benefit of concomitant chemotherapy and 
radiotherapy and this has become the standard of care for advanced head and neck 
cancer 27. It is therefore of importance that also the effects of chemotherapy on tumor 
cell proliferation be investigated in future early response studies.
Adaptive radiotherapy based on 18FLT-PET-CT
In current practice, radiotherapy planning is based on a single CT-scan acquired prior to 
the start of treatment. During treatment, however, the tumor and metastatic lymph 
nodes shrink, and the patient may loose weight. As a result, the dose distribution in the
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tumor and organs at risk may change. In addition, as demonstrated in this study, 
biological aspects of the tumor can change even more rapidly and dramatically. 
Adaptation of the target volume based on CT or on functional imaging is a means to 
correct for these treatment-induced alterations. Amongst other PET- 
radiopharmaceuticals, 18FLT is one of the potential tracers for adaptive radiotherapy as 
it specifically visualizes one of the tumor characteristics responsible for treatment 
failure.
In contrast to the early treatment-associated decrease in 18FLT uptake, significant 
changes in gross tumor volume on CT were only detectable in the fourth week (after 15 
to 18 fractions). Analyses of volumetric changes based on 18FLT-PET, however, were not 
successful, possibly due to limitations of the applied PET segmentation techniques. 
During treatment, the signal intensity within the tumor decreased relative to the 
background. This observation might argue against the generally accepted phenomenon 
of accelerated tumor cell repopulation during a course of fractionated radiotherapy. 
However, the decrease in 18FLT-PET signal is caused mainly by a rapid reduction of the 
tumor cell density as a result of the treatment. This does not exclude the possibility that 
the relative number of proliferating tumor cells, i.e., the proliferating fraction, is 
nevertheless increasing. At the same time, 18FLT uptake in the tonsillar region increased 
most likely caused by proliferating inflammatory cells 28. These two phenomena 
hampered PET segmentation based on the fixed threshold of 50%. The adaptive 
threshold delineation based on the signal-to-background ratio performed somewhat 
better, but also failed at the third time point when 18FLT-uptake was very low. As a 
consequence, 18FLT-PET was neither useful for volumetric response monitoring, nor for 
the adaptation of gross tumor volume delineation during treatment. New iterative 
methods are becoming available, but it is questionable whether these can overcome 
these limitations 5,29. The disturbance by increased proliferative activity in the tonsillar 
tissue may be a lesser problem in other head and neck subsites.
Dose escalation to highly proliferative subvolumes
PET may potentially identify parts of the tumor requiring additional radiation doses, 
e.g., areas of high metabolic or proliferative activity, or hypoxic subvolumes. In this 
study, 18FLT-PET was successfully used to identify subvolumes with high proliferative 
activity before and in the second week of therapy in all primary tumors and metastatic 
lymph nodes. It was shown that in a number of patients the subvolumes changed during 
the initial phase of treatment with respect to size and location. Therefore, repetitive 
imaging for proper monitoring of the high proliferative subvolumes is necessary. 
Furthermore, image acquisition at a late time point during treatment, e.g., the fourth 
week, does not lead to useful results due to very low signal intensities. Similar findings 
on temporal changes in hypoxic subvolumes have previously been described, even 
without any treatment 30. Lin e t  al. studied seven head and neck cancer patients
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undergoing serial 18F-fluoromisonidazole (18FMISO) PET scans, separated by 3 days, 
prior to the start of treatment. In four of these patients, significant dissimilarities in the 
hypoxic subvolumes were observed within this short time window.
Various theoretical planning studies applying either uniform dose distribution, dose 
painting or voxel intensity-based IMRT to 18FDG or 18FMISO-PET avid subvolumes have 
been published 8,9,31-34. Schwartz e t  al. escalated the total dose up to 75 Gy in a 
theoretical planning study involving 20 head and neck cancer patients 8. Rajendran e t  al. 
demonstrated that using an IMRT technique, the dose to the 18FMISO-PET detected 
hypoxic subvolume could be escalated by an additional 10 Gy, and Lee e t  al. even 
achieved a dose of 84 Gy in hypoxic areas without exceeding the normal tissue tolerance 
32,33. Recently, the clinical feasibility of 18FDG-PET based dose escalation using a uniform 
dose distribution was demonstrated in a phase I clinical trial on head and neck cancer 
patients 6. With IMRT and simultaneous integrated boost the dose was escalated to 72.5 
Gy and 77.5 Gy achieving high local control rates at 1 year of follow-up.
During the initial four weeks of the current planning study, the radiation dose was 
escalated to 71 Gy in fractions of 2.3 Gy delivered to the highly proliferative subvolumes 
GTV8 0 % 1 and GTVs0%2, resulting in a total dose of 74 Gy in the overlapping volume.
In contrast to 18FDG-PET, which provides a measure of the total viable tumor cell 
density, 18FLT-PET identifies the proliferating cell compartment within the gross tumor 
volume. Although the number of tumor cells is greatly reduced during cytotoxic 
treatment, cells that survive are triggered to repopulate more effectively during the 
intervals between treatments, and this process of repopulation is an important cause of 
treatment failure 10,11,35,36. Randomized trials have convincingly shown that accelerated 
radiotherapy, i.e., delivery of the radiation dose in shorter time, can counteract 
accelerated repopulation and improve the tumor control probability 37,38. Accelerated 
radiotherapy is now considered the standard for head and neck cancer. Delivering a 
higher dose to the most actively proliferating parts of the tumor very early during the 
treatment course might have an additive effect and could further reduce the potential of 
the tumor to recover through accelerated proliferation and repopulation. For elderly 
patients and patients in less good general condition, dose escalation to the highly 
proliferative subvolumes might be an alternative to accelerated radiotherapy. 
Accelerated schedules are accompanied by increased toxicity, in particular early 
mucosal reactions 39. Dose escalation to a relatively small subvolume using IMRT can be 
accomplished with only very limited additional burden to the surrounding normal 
tissues and thus might be better tolerated by these patients. A clinical study will be 
initiated to further explore the feasibility and effectiveness of this approach.
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8.5 Conclusions
18FLT is a promising PET tracer for imaging tumor cell proliferation in head and neck 
carcinomas during treatment. In this study on oropharyngeal tumors, it was shown that 
18FLT-PET signal changes precede volumetric tumor response assessed by CT or PET 
and that the tracer is therefore suitable for early response assessment. Furthermore, 
18FLT-PET can define tumor subvolumes with high proliferative activity, and escalation 
of radiation dose within these regions is technically feasible. Finally, it must be 
concluded that at present, adaptive radiotherapy on the basis of 18FLT-PET volumetric 
changes is not possible with the commonly available segmentation tools.
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PET m ay serve m any pu rp o ses  in rad ia tion  th e ra p y  planning, p a tien t selection for 
ta ilo red  tre a tm e n t and  early  tu m o r response  evaluation. In th e  following paragraphs, 
th e  value of PET for characterization  of head  and  neck tu m o rs  is d iscussed and  fu tu re 
perspectives lead ing  to  individualized rad ia tion  th e ra p y  are  highlighted.
9.1 Tumor characterization
T um or cell hypoxia, accelera ted  tu m o r cell repopu la tion  and  in trin sic  rad io resistance  
are  th e  th ree  m ajo r resis tance  m echanism s adversely  influencing th e rap eu tic  outcom e 
in head  and  neck tu m o rs  1. T rea tm en t m odifications coun terac ting  these  tu m o r featu res 
are  available a t th e  cost of increased  side-effects 2-5. Hence, non-invasive tu m o r 
characteriza tion  p rio r to  and  during  tre a tm e n t is desirab le  aim ed a t im proving  
tre a tm e n t outcom e, w h ils t reducing  side-effects for p a tien ts  n o t profiting.
In th is thesis, d ifferen t m ethods for im aging CA-IX w ere  com pared  (ch ap te r 3), and  18F- 
fluorom isonidazole (18FMISO) and  3’-deoxy-3’-18F-fluorothym idine (18FLT) w ere  
validated  in hum an xenograft tu m o r m odels and  in p rim ary  tu m o r resection  specim en 
ob ta ined  from  head  and  neck  cancer p a tien ts  (chap ters  4-7). It w as d em o n stra ted  th a t 
resu lts  largely depend  on th e  characteristics of th e  trac e r  used, on th e  quantification 
m ethods and  on th e  reso lu tion  of the  im aging techniques. These findings im ply th a t all 
po ten tia l PET trace rs  for tu m o r characteriza tion  as w ell as quantifica tion  m ethods need 
to  be validated  again st h istopathology. Through th is process, th e  s tren g th s  and 
w eaknesses of these  tra c e rs  can be identified  as w ell as po ten tia l pitfalls before th e ir  
in troduction  into clinical studies.
After th e  initial, som ew hat d isappoin ting  resu lts  on 111In-G250, it w as decided to 
tem p o rarily  d iscontinue th e  developm en t and  validation  of a radioactive trac e r  d irec ted  
against CA-IX, until a h igh-reso lu tion  p h osphor im aging device and  an anim al PET 
becam e available. M eanwhile, pre-clinical p ilo t experim ents validating  a 89Zr-F(ab)2- 
cG250 fragm en t d irec ted  against CA-IX have successfully b een  perfo rm ed  using sm all 
anim al PET, au to rad iog raphy  and CA-IX im m unohistochem istry . 89Zr-labeled cG250- 
F(ab ’ ) 2  m icro-PET im aging show ed  rap id  accum ulation in a head  and  neck  xenograft 
m odel, w ith  good co rre la tion  to CA-IX expression  on a m icroregional level (publication 
subm itted). F u rtherm ore , a phase  I clinical tria l validating  124I-cG250 in head  and  neck 
cancer p a tien ts  w as an ticipated . H owever, new  E uropean  legislation has m ade the  
in itia tion  of clinical stud ies involving new  PET tracers  very  cum bersom e.
Based on th e  encouraging experience in the pre-clinical studies, 18FMISO-PET is 
cu rren tly  being validated  aga in st p im onidazole im m unoh istochem istry  in advanced 
p rim ary  head  and  neck tu m o r resection  specim en a t ou r d ep a rtm en t (N CT00159978).
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T here are  several possib ilities to  fu rth e r im prove tu m o r characterization , e.g., by 
in troducing  new  PET tracers, op tim ization  of functional CT- and  MR applications, o r by 
developing new  techn iques su itab le  for m ulti-m odality  imaging.
(1) Several groups have been  developing o ther PET trace rs  po ten tially  su itab le  for 
characteriza tion  of p rim ary  head  and  neck tum ors. Exam ples are: 1-(2’-deoxy-2’-18F- 
fluo roarab inofuranosy l)cy tosine (18FAC) for im aging nucleoside m etabolism , O-2-18F- 
fluoroethyl-L-tyrosine (18FET) for v isualization of p ro te in  synthesis, and  1-11C-acetate 
for im aging non-18FDG avid m alignancies 6-8. Before these  trac e rs  can be used  in the  
clinic they  m u st be te s ted  in preclinical tu m o r m odels and  validated  against estab lished  
m ethods.
F urtherm ore , th e  in troduction  of positron  em itting  rad io-labeled  m onoclonal 
an tibodies, pep tides and  o th e r recep to r-ta rg e tin g  com pounds has b ro ad en ed  the 
horizon  for studying  tu m o r fea tu res and  individualizing trea tm en t. The epiderm al 
g row th  factor recep to r (EGFR) controls num ero u s cellular functions, including tu m o r 
cell p ro liferation , apop tosis and  angiogenesis. Since th e  publication of the  lan d m ark  
phase III tria l on cetuxim ab, a chim eric m onoclonal an tibody  d irected  aga in st EGFR, an 
increasing  nu m b er of head  and  neck cancer p a tien ts  are  undergo ing  com bined 
tre a tm e n t w ith  rad io th erap y  and  th is d rug  9. A dditionally, EGFR expression  in tu m o r 
b iopsies w as show n to be a pred ic tive factor in hyperfrac tionated  accelera ted  
rad io th e rap y  10. Hence, it is of g rea t in te re s t to  non-invasively im age th e  EGFR 
expression  profile. Radionuclide labeled m onoclonal an tibod ies d irec ted  against EGFR 
have been  validated  in tu m o r cell lines and  xenograft tu m o r m odels including squam ous 
cell carcinom as of th e  head  and  neck 11-13. A pprop ria te  sized clinical tria ls  on head  and 
neck cancer p a tien ts  a re  necessary  to  assess th e  p rognostic  and  p red ic tive value of non­
invasive im aging of th e  EGFR status.
(2) The com bination  of functional inform ation  from  PET w ith  th e  h igh-reso lu tion  
anatom ical in form ation  from  CT o r MRI can im prove clinical decision-m aking and 
th e ra p y  p lann ing  14,15. Besides, th e  add ition  of h igh-reso lu tion  functional MRI- (dynam ic 
co n tra s t en hancem en t MRI o r BOLD-MRI) and  CT-studies com bined w ith  d irec t 
m etabolic in form ation  ga thered  by MR spectroscopy  and PET m ay enhance the  
functional tu m o r in form ation  and  th u s  im prove tu m o r characteriza tion  16,17.
(3) In teresting  developm ents regard ing  tu m o r characterization  using gold 
nanopartic les  are  ongoing 18. H um an oral cancer cells overexpressing  EGFR a t th e  cell 
m em brane w ere  found to  align gold nano rods conjugated to  anti-EGFR an tibodies a t the  
cancer cell surface 19. These nano ro d s gave d is tin c t enhanced  spectroscop ic scattering  
sp ec tra  th a t m ay po ten tia lly  serve  as m olecu lar s ignatu re  un ique for cancer. 
A dditionally, these  nanopartic les  m ay be used  for tu m o r charac teriza tion  and  possibly
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9.2 Identification of resistant tumor subvolumes
PET m ay identify  rad io -re s is tan t tu m o r subvolum es requ irin g  h igher doses of 
irrad ia tion . Theoretical p lann ing  stud ies have p roven  th e  feasibility  of th is  approach  for 
18FDG-PET and hypoxic PET trace rs  22-27. A re c e n t clinical phase I tria l on head  and  neck 
cancer p a tien ts  applying dose escalation  to  18FDG avid subvolum es rep o rte d  favorable 
local control ra te s  28. Results from  clinical tria ls  on 18FMISO and 18F-fluoroazom ycin 
arab inoside  (18FAZA) guided dose escalation are  aw aited.
In th e  m eantim e, th e  concepts applied  for dose in tensification  are  sub ject to  in tense  
debate. T here are  concerns ab o u t th e  reso lu tion  of hypoxic PET imaging, ab o u t its 
possib ility  to  de tec t vary ing  levels of hypoxia du rin g  th e  course of trea tm en t, a b o u t the  
dose level req u ired  for elim inating  rad io -re sis tan t tu m o r cells, and  ab o u t its p rognostic  
and  pred ic tive value.
In th is thesis, w e con tribu ted  to the  firs t and  second question  regard ing  th e  reso lu tion  
and  th e  changes in oxygenation sta tu s  (ch ap te r 4 and  5). It w as show n th a t 18FMISO 
identified  hypoxic areas w ith in  th e  xenograft tu m o r lines and  also th e  changes in the  
level of hypoxia. H owever, these  findings largely depended  on th e  underly ing  
m icroarch itec tu re  of th e  xenograft tu m o r line studied. PET im aging has a by far in ferio r 
reso lu tion  com pared  to  au to rad iography . Even though, 18FMISO read ings form  th e  basis 
for dose escalation stud ies e ith e r by applying uniform  doses o r by dose-pain ting  by 
n um bers (the h igher th e  18FMISO up take in a voxel, th e  h igher th e  locally req u ired  
rad ia tion  dose). H owever, as th e  tu m o r m icroarch itectu re  influences th e  18FMISO PET 
readings, caution should  be taken  w hen  study ing  relatively  sm all tu m o r subvolum es.
F urtherm ore , in chap ter 8, th e  feasibility of escalating rad ia tion  dose to  18FLT-PET 
derived  tu m o r subvolum es rep resen ta tiv e  of a high density  of p ro lifera ting  tu m o r cells 
w as successfully addressed . Using IMRT and a SIB technique, th e  to ta l dose to  these 
subvolum es w as escalated  to  74 Gy. Very early  du ring  th e  tre a tm e n t course, delivery  of 
a h igher rad ia tion  dose to  th e  m ost actively p ro lifera ting  p a rts  of th e  tu m o r m igh t have 
an additive effect. It could reduce th e  pro liferative co m p artm en t of th e  tum or, th e reby  
reducing  th e  capacity of accelera ted  p ro life ra tion  and  rep opu la tion  w ith  p rogression  of 
trea tm en t. For elderly  p a tien ts  and  p a tien ts  w ith  substan tia l co-m orbidity, dose 
escalation to  th e  highly pro liferative subvolum es m igh t be an a ttrac tive  a lte rna tive  to 
accelera ted  rad io therapy . A clinical study  will be in itia ted  to  fu rth er explore the  
feasibility and  effectiveness of th is approach.
also for treatment response monitoring by means of microscopic imaging, CT or MRI
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As d iscussed in p arag rap h  9.1, new  trace rs  and  im aging techn iques are  cu rren tly  being 
developed th a t m ay fu rth e r serve th e  identification  of rad io -re s is tan t tu m o r 
subvolum es. A dditionally, developm ents in th e  field of au to rad iog raphy  and  PET 
im aging m ay im prove validation  and  delineation  accuracy. The spatial reso lu tion  for 
hum an PET-scanners is in th e  o rd e r of 5-7 mm, com pared  to  1-3 m m  for sm all anim al 
scanners. New developm ents regard ing  th e  size of th e  d e tec to r crystal, th e  coincidence- 
tim ing  w indow  and signal p rocessing  have achieved a reso lu tion  of 2 m m  for th e  hum an  
application  (p ro d u c t in form ation  Siem ens). Consequently, th e  characteriza tion  of tu m o r 
subvolum es becom es feasible, and  th e ir  delineation  for rad io th erap y  p lann ing  purposes 
m ore accurate.
Before th e  concep t of escalating  th e  dose to  tu m o r subvolum es can be in troduced  in 
ro u tin e  clinical practice, it is of u tm o st im portance to  balance th e  benefit in te rm s of 
local contro l and  disease-free survival against th e  add itional m orb id ity  in clinical trials. 
Especially in elderly  o r m ulti-m orb id  p a tien ts  un fit for tre a tm e n t m odifications (i.e., 
carbogen and  n ico tinam ide coun terac ting  hypoxia o r accelera ted  rad io th e rap y  
com pensating  for accelera ted  tu m o r cell repopu la tion ) dose escalation to  sm all volum es 
m ay be an e legan t alternative.
9.3 Early treatment response monitoring and adaptive 
radiotherapy planning
T rea tm en t m odifications coun teracting  tu m o r cell hypoxia and  accelera ted  
repopu la tion  have been  successfully  developed 2-5. H owever, they  increase  th e  severity  
and  du ra tio n  of acute side-effects 29,30. Hence, it is desirab le  to  non-invasively 
characterize th e  tu m o r p rio r to  th e rap y  for individualized tre a tm e n t selection and  to 
m on ito r response  early  du ring  tre a tm e n t facilitating adap ta tions of th e  trea tm en t.
In chap ter 8 of th is thesis, th e  value of 18FLT-PET for early  tre a tm e n t resp o n se  
m onito ring  during  rad io th erap y  w as ad d ressed  in o ropharyngeal cancer patien ts. 
Overall, 18FLT-PET signal in tensities as m easu red  by th e  s tan d ard ized  up take value 
(SUV) already  decreased  m ore th an  tw o-fold in th e  second week, and  even fu rth e r  in 
th e  fou rth  w eek  of trea tm en t. On an individual basis, d ifferen t response  p a tte rn s  
becam e apparen t. Some p a tien ts  only show ed  a m o d est reduction  in SUV, w h ils t o thers  
even re sp o n d ed  w ith  an increase. It is to  be aw aited, w h e th e r these  in ter-ind iv idual 
d iscrepancies will have d iscrim inative pow er for tu m o r response  assessm ent.
The coh o rt d iscussed w as p a r t  of a la rger clinical tria l on 52 p a tien ts  w ith  advanced 
stage head  and  neck cancer undergo ing  repetitive  18FLT-PET-CT im aging during  the  
course of rad io th erap y  o r chem orad iation  (N CT00163176). This study  w as closed 
Sep tem ber 2008  and th e  resu lts  w ith  re sp ec t to  th e  p rognostic  pow er of 18FLT-PET are 
expected to  be pub lished  in th e  au tum n  of 2010.
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As m en tioned  in p arag rap h  9.1, EGFR activation  influences th e  tu m o r’s pro liferative 
activity. T herefore, ou r group  is cu rren tly  assessing  early  trea tm en t-in d u ced  changes of 
th e  18FLT-PET signal in head  and  neck p a tien ts  undergo ing  rad io th erap y  com bined w ith  
cetuxim ab. W ith th is study, w e aim to u n d ers tan d  m ore  ab o u t th e  tu m o r resp o n se  to 
cetuxim ab alone and  ab o u t th e  add itional value of com bined trea tm en t. F urtherm ore , 
w e investigate w h e th e r 18FLT-PET can distinguish  p a tien ts  benefiting  from  th e  add ition  
of cetuxim ab from  those  only experiencing its side-effects and  th u s  guide ta ilo red  
trea tm en t.
A dditionally, th e  feasibility  of adaptive im age-guided rad io th erap y  using 18FLT-PET w as 
add ressed  in chap ter 8. Earlier, in a p roo f of princip le study, Geets e t  al. assessed  the  
concep t of adaptive im age-guided rad io th erap y  in head  and  neck  cancer p a tien ts  31. 
R adiation tre a tm e n t p lanning  based  on repetitive  18FDG-PET scanning  and  volum e 
adap ta tion  progressively  reduced  th e  irrad ia ted  volum es com pared  to  trad itional CT- 
based  tre a tm e n t p rio r  to  irrad ia tion .
In ou r study  (chap ter 8), a significant reduction  in CT derived  gross tu m o r volum es w as 
only observed  in th e  fou rth  w eek  of trea tm en t. 18FLT-uptake decreased  m uch m ore 
rapidly, b u t a lim itation  w as that, w ith  p rogression  of trea tm en t, it  w as increasingly  
difficult to segm en t trac e r  up take in th e  tu m o r from  th e  background. This w as caused 
by th e  decreased  18FLT signal and  increased  trac e r  up take in th e  to nsilla r region, m ost 
likely caused by p ro life ra ting  inflam m atory  cells. As a resu lt, accurate  tu m o r delineation  
and  adap ta tion  of th e  tre a tm e n t p lan  du ring  irrad ia tion  w as n o t possible. The value of 
18FLT-PET for adaptive rad io th e rap y  p lanning  in o th e r head  and  neck subsites is y e t to 
be assessed.
T here are  new  developm ents regard ing  tu m o r segm en tation  th a t m ay con tribu te  to 
adaptive rad io th e rap y  planning. Our group  has been  involved in th e  developm ent and 
validation  of an itera tive  backg round-sub trac ted  re la tive-th resho ld  level (RTL) 
m ethod  32. Geets e t  al. have validated  a g rad ien t-based  segm en tation  too l based  on 
w ate rsh ed  tran sfo rm  and  h ierarch ical c luster analysis 33. These segm en tation  m ethods 
will sho rtly  be te sted  on th e  p a tie n t cohort. However, it rem ains to  be seen w h e th e r 
these  tw o new  segm entation  tools can solve th e  en coun tered  difficulties.
The tu m o r m icroenv ironm en t is a highly dynam ic system  w ith  con tinuous cell tu rn o v er 
occuring bo th  w ith  o r w ith o u t tre a tm e n t 34,35. In o rd e r to  accurately  assess these  
changes, it is com pulsory  to repetitively  im age th e  tu m o r during  the  course of therapy . 
This m ay be facilitated  by th e  developm ent of specific PET trace rs  w ith  a sh o rte r  half­
life com pared  to  18F. Using com pounds labeled w ith  11C (half-life 21 m in) and  15O w a te r 
(2 m in), th e  acquisition  of tw o PET scans w ith in  a sh o rt tim e span  becom es feasible, e.g., 
for im aging m ultip le tu m o r characteristics a t one day o r for in s ta n t tu m o r response
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evaluation afte r tre a tm e n t m odification (e.g., a fte r carbogen breath ing). Besides, double 
trac e r  techn iques com bining a sh o rte r  and  a longer half-life rad iopharm aceu tica l 
becom e attainable.
9.4 Final remark
Since th e  discovery  of x-rays and  n a tu ra l rad ioactiv ity  ju s t over one h u n d red  years ago, 
th e  th ree  disciplines R adiation Oncology, N uclear M edicine and  Radiology have 
gradually  evolved. In th e  field of oncology, these  th ree  specia lties are  m oving closer 
toge ther, e .g ., by com bining anatom ical and  functional im aging devices for tu m o r 
characteriza tion  and  tre a tm e n t planning. The increasing  ro le  of PET for ta ilo r-m ade 
rad io th e rap y  is b e s t highlighted by the  em ergence of PET-CT scanners into 
R adio therapy  D epartm ents.
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Chapter 10
Several aspects of visualizing and quantifying the biological tumor characteristics tumor 
cell hypoxia and proliferation by means of PET were discussed in this thesis. In 
chapter 2, an introductory overview regarding the role of 18FDG-PET for radiotherapy 
planning purposes was given and more specific tracers were put forward.
10.1 Tumor cell hypoxia
The value of 111In-G250, a radio-labeled antibody directed against the hypoxia-related 
marker CA-IX, was assessed in chapter 3. 111In-G250 biodistribution was compared 
with pimonidazole and CA-IX immunohistochemistry in a panel of human head and 
neck carcinoma xenograft lines. It was concluded that different methods of CA-IX 
quantification resulted in different findings. Furthermore, the immunohistochemical 
staining pattern of CA-IX relative to pimonidazole differed between tumor lines of 
similar origin. Therefore, the role of CA-IX as a marker of tumor hypoxia was disputed.
In chapter 4  and 5, 18FMISO was validated in human xenograft tumor lines. First, 
18FMISO autoradiography was compared with pimonidazole immunohistochemistry 
using pixel-by-pixel analysis, mean signal intensities and hypoxic fraction (chapter 4). 
Overall, a weak but significant correlation between hypoxic fractions based on 
pimonidazole binding and the mean 18FMISO signal intensity was observed. However, 
for tumors with a ribbon-like microregional distribution pattern of hypoxia the 
correlation was much stronger. This indicates that 18FMISO accumulation depends on 
the underlying microregional distribution of hypoxia.
In a subsequent study including three xenograft tumor lines (chapter 5), the level of 
hypoxia was altered by clamping of the tumor and by carbogen breathing. Again, a 
significant, but tumor line dependent correlation between the hypoxic fractions and the 
mean signal intensities of pimonidazole and 18FMISO was observed. The hypoxic 
fraction based on pimonidazole staining significantly increased and decreased in all 
xenograft tumors. However, an increased 18FMISO signal after tumor clamping was only 
observed in two of the three lines, and there was no reduction of the 18FMISO signal 
after carbogen breathing.
It was concluded that 18FMISO can be used for the detection of tumor cell hypoxia and 
for monitoring treatment-induced changes in the level of hypoxia. However, caution 
must be taken when studying relatively small tumor subvolumes as 18FMISO 
accumulation depends on the tumor microarchitecture.
10.2 Tumor cell proliferation
In chapter 6 and 7, 18FLT-PET was validated for the characterization of primary oral 
cavity tumors and for the detection of cervical lymph node metastases. Seventeen 
patients with oral cavity tumors underwent an 18FLT-PET scan prior to tumor resection,
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and iododeoxyuridine was intravenously administered shortly before the surgery 
(chapter 6). There was a significant correlation between the 18FLT-PET standardized 
uptake values and iododeoxyuridine optical densities. Unexpectedly, expression of 
TK-1, the principal enzyme in 18FLT phosphorylation, did not correlate with 18FLT- 
uptake. This was probably the result of differences in biomarker characteristics, 
resolution and quantification methods.
In ten patients with squamous cell carcinoma of the head and neck undergoing a lymph 
node dissection, the value of 18FLT-PET for identifying metastatic deposits was assessed 
(chapter 7). In PET positive lymph nodes, abundant Ki-67 and iododeoxyuridine 
staining of B-lymphocytes was found in germinal centers. Therefore, it was concluded 
that due to the high rate of false positive findings, 18FLT-PET is not suitable for 
assessment of the pre-therapeutic lymph node status.
In chapter 8, various aspects of repetitive 18FLT-PET-CT imaging were addressed in ten 
advanced stage oropharyngeal cancer patients. 18FLT-PET-CT scans were acquired 
before the start of (chemo)radiation and in the second and fourth week of treatment. 
Changes in 18FLT-PET standardized uptake values were found to precede volumetric 
tumor changes on CT. Tumor subvolumes with a high density of proliferating cells were 
successfully identified on 18FLT-PET, and the technical feasibility of dose escalation to 
these regions was shown. A limitation is that, with progression of treatment, it was 
increasingly difficult to segment tracer uptake in the tumor from the background due to 
the decrease of the 18FLT signal and increased uptake in nearby tonsillar tissue.
Chapter 9 provides a general discussion of the presented findings and highlights future 
perspectives.
10.3 Conclusions
Several PET tracers to image biological tumor characteristics reflecting radiation 
resistance mechanisms are available and offer potential for tailored radiation therapy. 
In this thesis, validation of imaging with tracers visualizing tumor cell hypoxia (111In- 
G250 and 18FMISO) and proliferation (18FLT) was performed in human xenograft 
tumors and in primary head and neck resection specimen. Furthermore, the value of 
18FLT-PET for early treatment reponse measurement, adaptive image-guided 
radiotherapy planning and focal dose escalation was assessed.
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11.1 Hoofd- halskanker
Kanker in het hoofd- halsgebied (vaak een zogenaamd plaveiselcelcarcinoom afkomstig 
van het slijmvlies) wordt jaarlijks bij ongeveer 2400 in Nederland wonende mensen 
vastgesteld. Veelal hebben patiënten in het verleden gerookt of alcohol geconsumeerd, 
maar er is ook in toenemende mate onderbouwing dat een virus, het humaan 
papillomavirus (HPV), vooral bij jonge mensen kanker in het gebied van de amandelen, 
het zachte gehemelte of de tongbasis kan veroorzaken. De klachten van patiënten zijn 
meestal vaag en daarom presenteren zij zich veelal met een gevorderd stadium van de 
ziekte. Zij hebben dan grote primaire tumoren en uitzaaiingen (metastasen) naar 
lymfklieren in de hals. Hoofd- halskanker is in eerste instantie een locale ziekte die een 
locale behandeling vereist: chirurgische verwijdering van de primaire tumor en de 
lymfkliermetastasen, bestraling (radiotherapie) van de tumor en (potentieel) 
aangedane lymfklieren, chemotherapie ter verbetering van het effect van de bestraling, 
of een combinatie van deze behandelmogelijkheden. Radiotherapie is door het 
orgaanbehoud in de meeste gevallen de belangrijkste pijler van de behandeling. In de 
jaren 90 van de vorige eeuw heeft de radiotherapie een belangrijke ontwikkeling 
doorgemaakt met de introductie van “intensiteitgemoduleerde radiotherapie” (IMRT). 
Met deze techniek kan de tumor tot een hoge bestralingsdosis behandeld worden met 
gelijktijdige sparing van omliggend gezond weefsel. Echter, om deze methode toe te 
kunnen passen is het van groot belang de exacte tumoruitbreiding te kennen.
11.2 Afbeelding van hoofd- halstumoren
Het in kaart brengen van een tumor in het hoofd- halsgebied begint met een grondig 
lichamelijk onderzoek: inspectie van mond- en keelholte (indien nodig tevens onder 
algehele narcose) en aftasten van de hals op zoek naar vergrote lymfklieren. Daarnaast 
worden beeldvormende technieken toegepast om de tumor en halslymfklieren in kaart 
te brengen (anatomische beeldvorming): computertomografie (CT) en magnetische 
resonantie (MR). CT kan aantasting van kraakbeen of bot aantonen (voornamelijk voor 
kanker van het strottenhoofd), MR geeft een hoog wekedelen contrast teneinde 
onderscheid te kunnen maken tussen bijvoorbeeld diepe tongspieren en tumor 
(geschikt voor tumoren van mondholte, tong, amandelen, zacht gehemelte en 
tongbasis). Beide beeldvormende modaliteiten kunnen ook gebruikt worden om de 
reactie van de tumor op behandeling in kaart te brengen. Echter, zij hebben nadelen: (1) 
het kan moeilijk zijn onderscheid te maken tussen tumor en omliggend normaal 
weefsel, (2) verkleining van het tumorvolume is vaak pas in een late fase van de 
bestraling meetbaar, en (3) na de behandeling kan de anatomie veranderd zijn, 
enerzijds als reactie op nog aanwezige kwaadaardige ziekte of anderzijds door volledig 
verdwijnen van de tumor. Daarom zijn recent verschillende “functionele
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beeldvormende technieken” geïntroduceerd, die informatie geven over biologische 
eigenschappen van het afgebeelde weefsel.
Positron emissie tomografie (PET) is een relatief nieuwe functionele beeldvormende 
techniek. Hiermee kan van buiten af (niet-invasief) een radioactief gemarkeerde stof 
afgebeeld en gekwantificeerd worden. Met de meest gebruikte radioactieve stof, 18F- 
fluorodeoxyglucose (18FDG; radioactief fluor gekoppeld aan een variant van suiker), 
kan het energieverbruik van verschillende weefsels in kaart worden gebracht. 
Betreffende de bestralingsplanning zou 18FDG-PET belangrijke aanvullende informatie 
over de tumoruitbreiding kunnen geven. Vaak gaan hoofd- halstumoren echter gepaard 
met locale ontstekingsreacties rond de tumor en met opgezette “reactieve” lymfklieren. 
Omdat 18FDG ook in gebieden van ontstekingen wordt opgenomen, is de waarde van 
deze markerstof voor deze specifieke tumoren dus slechts beperkt. Naast het afbeelden 
en afgrenzen van tumoren kan PET ook worden gebruikt voor het karakteriseren 
daarvan. Dit is de doorlopende vraagstelling van dit proefschrift.
11.3 Ongunstige tumoreigenschappen voor radiotherapie
Er zijn drie belangrijke tumoreigenschappen die de uitkomst van een 
bestralingsbehandeling nadelig beïnvloeden: zuurstofgebrek (hypoxie), versnelde 
deling (proliferatie) van tumorcellen tijdens de bestraling (geaccelereerde repopulatie) 
en de tumoreigen gevoeligheid voor bestraling die per tumor verschilt (intrinsieke 
radioresistentie). “Acute hypoxie” ontstaat door het willekeurig en kortdurend sluiten 
van slecht gevormde tumorbloedvaten die de zuurstoftoevoer en -spanning doen 
variëren. “Chronische hypoxie” is het gevolg van een te grote afstand van de tumorcel 
naar het dichtstbijzijnde bloedvat, met als gevolg een constant tekort aan zuurstof en 
voedingsstoffen. Geaccelereerde repopulatie is een vaak optredende reactie van hoofd- 
halstumoren om het celverlies, dat tijdens de bestraling ontstaat, tegen te gaan. Hoe 
langer de totale bestralingsbehandeling duurt, hoe slechter de uiteindelijke 
behandeluitkomst. De tumoreigen gevoeligheid voor bestraling wordt onder andere 
bepaald door factoren zoals de celeigen capaciteit om bestralingsschade aan het DNA te 
herstellen.
Er zijn verschillende behandelingsmogelijkheden om deze ongunstige 
tumoreigenschappen tegen te gaan. Door verkorten van de totale behandelduur wordt 
de versnelde deling van tumorcellen tegengegaan. Dit wordt in de praktijk gerealiseerd 
door twee maal per dag te bestralen of door ook gedurende de weekenden te 
behandelen. Ook hypoxie kan op verschillende manieren worden tegengegaan: er zijn 
geneesmiddelen, zogenaamde “hypoxische sensitizers”, die zuurstofarme cellen 
gevoeliger maken voor bestraling, en men kan patiënten tijdens de behandeling extra 
zuurstof laten inademen. Recent is een door het UMC St Radboud gecoördineerde
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landelijke klinische studie bij patiënten met strottenhoofdkanker afgerond. Patiënten 
werden versneld bestraald, ademden carbogeen (98% zuurstof en 2% koolstofdioxide) 
en namen een geneesmiddel voor verwijding van de bloedvaten in om acute hypoxie 
tegen te gaan (Accelerated Radiotherapy with CarbOgen breathing and Nicotinamide, 
ARCON). Uitkomsten van deze studie worden in 2010 verwacht.
11.4 Invasieve methoden voor tumorkarakterisering
Zuurstofgebrek kan gemeten worden met behulp van een optische sensor, die in de 
hoofd- halstumor of lymfkliermetastase wordt ingebracht. Daarnaast kan men zowel 
hypoxie als ook celdelingactiviteit van een tumor op speciaal gekleurde weefselcoupes 
microscopisch aantonen (immunohistochemie). Beide methoden hebben echter 
beperkingen: zij zijn invasief, beelden maar een gedeelte van de tumor af, en kunnen 
zonder narcose alleen toegepast worden bij makkelijk toegankelijke tumoren. Hierdoor 
is het herhaaldelijk analyseren van tumorkarakteristieken tijdens de behandeling 
slechts mogelijk bij een deel van de tumoren. Niet-invasieve methoden, zoals PET, 
kunnen een tumor in zijn geheel (macroscopisch) voor en ook tijdens de bestraling in 
kaart brengen.
11.5 Tumorkarakterisering met PET
In hoofdstuk 2 van dit proefschrift werden onder andere de verschillende PET 
markerstoffen besproken, die specifiek zuurstofgebrek en celdelingactiviteit in tumoren 
kunnen afbeelden (paragraaf 2.3).
11.5.1 Zuurstofgebrek
Verschillende methoden om carbonische anhydrase IX (CA-IX), een lichaamseigen aan 
hypoxie gerelateerd enzym aan te tonen, werden in hoofdstuk 3 vergeleken. Hiervoor 
werden op de flank van naakte muizen biopten van menselijke tumoren geïmplanteerd 
en tot groei gebracht (xenografts). Na injectie van 111In-G250, een radioactief 
antilichaam tegen CA-IX, werden weefselcoupes van deze tumoren met autoradiografie 
(afbeelding van radioactiviteit op een fosforplaat) en immunohistochemie afgebeeld en 
de 111In-G250 opname in de weefsels (“biodistributie”) kwantitatief bepaald. De 
belangrijkste conclusies van dit onderzoek waren dat CA-IX niet zonder meer als een 
vervanger van de als standaard gebruikte hypoxie marker pimonidazole beschouwd 
mag worden en dat verschillende methoden om CA-IX te meten niet direct vergelijkbaar 
zijn.
18F-fluoromisonidazole (18FMISO) is een markerstof voor PET die in cellen met zuurstof 
gebrek wordt opgenomen. Met behulp van 18FMISO kunnen hypoxische delen van de 
tumor worden geïdentificeerd. Voorts is het theoretisch mogelijk, deze delen middels
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speciale IMRT technieken te bestralen. Echter, er zijn nog een aantal onduidelijkheden 
betreffende de waarde van 18FMISO-PET. In dit proefschrift werd 18FMISO in 
weefselcoupes met behulp van autoradiografie opgespoord en de verdeling hiervan 
vergeleken met middels immunohistochemie aangetoonde hypoxie (gebruikte 
markerstof pimonidazole).
In hoofdstuk 4  werden weefselcoupes van tien verschillende menselijke hoofd- 
halstumor xenografts met behulp van beide beeldvormende technieken in kaart 
gebracht. Vastgesteld werd dat de verdeling van 18FMISO afhankelijk is van het hypoxie 
patroon op microregionaal niveau. Verder werd slechts in vijf tumoren, allen met 
dezelfde microscopische opbouw, een overeenkomst tussen de signaalintensiteiten van 
beide beeldvormende technieken gevonden. De conclusie van dit onderzoek is dat 
weergave van hypoxie door 18FMISO-PET afhankelijk is van het onderliggend 
microregionaal hypoxie patroon. Hiermee dient rekening te worden gehouden indien 
men 18FMISO-PET wil gebruiken voor identificatie van hypoxische tumorvolumina ten 
behoeve van IMRT.
Daarnaast onderzochten wij in hoofdstuk 5 in drie verschillende xenograft tumorlijnen 
of veranderingen in de mate van hypoxie ook middels 18FMISO autoradiografie 
aangetoond konden worden. Pimonidazole immunohistochemie was opnieuw de 
standaard waarmee vergeleken werd. In één groep werd de mate van hypoxie verhoogd 
door mechanische onderbinding van de bloedtoevoer (clamping); in een andere groep 
werd de hypoxie verminderd door inademen van carbogeen. De bevindingen waren dat 
18FMISO de toename van hypoxie in twee van de drie onderzochte xenografts kon 
aantonen, maar dat de afname niet detecteerbaar was. Verder werd voor twee van de 
drie tumorlijnen een significante samenhang tussen de hypoxische fractie en de 
signaalintensiteiten van pimonidazole en 18FMISO aangetoond.
11.5.2 Tumor cel proliferatie en repopulatie
3’-deoxy-3’-18F-fluorothymidine (18FLT) is een PET markerstof die delende cellen 
opspoort. In theorie is dit juist voor tumoren in het hoofd- halsgebied een bij uitstek 
geschikte marker. Voordat deze in de klinische praktijk geïntroduceerd kan worden is 
echter het vaststellen in welke mate 18FLT op betrouwbare wijze proliferatie weergeeft 
(validatie) noodzakelijk.
Hiervoor werd in hoofdstuk 6 bij zeventien hoofd- halspatiënten een 18FLT-PET scan 
vervaardigd alvorens zij een chirurgische verwijdering van de tumor zouden 
ondergaan. De informatie van het PET signaal werd vergeleken met microscopische 
bevindingen in weefselcoupes van de verwijderde tumor (gebruikte markerstof 
iododeoxyuridine: standaard proliferatiemarker bij immunohistochemie). Er was 
slechts een zwakke maar wel statistisch significante samenhang tussen het 18FLT-PET 
signaal en de signaalintensiteit van iododeoxyuridine. Deze bevindingen waren
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waarschijnlijk het gevolg van verschillen in beeldresolutie en van specifieke kenmerken 
van beide merkstoffen.
De waarde van 18FLT-PET voor het opsporen van halskliermetastasen werd in 
hoofdstuk 7 onderzocht. Bij tien hoofd- halspatiënten die een verwijdering van de 
halsklieren ondergingen werd eveneens een 18FLT-PET scan gemaakt. Vervolgens 
werden de PET bevindingen vergeleken met de celdelingactiviteit in weefselcoupes van 
verwijderde lymfklieren. Verrassend genoeg werd het 18FLT-PET signaal foutief 
beïnvloed door delende ontstekingscellen in de halslymfklieren. Derhalve werd 
geconcludeerd dat 18FLT-PET (evenals 18FDG-PET) bij deze tumorsoort geen 
toegevoegde waarde heeft voor het opsporen van uitzaaiingen naar de lymfklieren.
In hoofdstuk 8 werden bij tien patiënten met hoofd- halskanker de veranderingen van 
het 18FLT-PET-CT volume en signaal bestudeerd voor en tijdens bestraling, met of 
zonder chemotherapie (2e en 4e week). De veranderingen in het 18FLT-PET signaal 
waren al in de tweede week van de behandeling (na minimaal 5 bestralingen) duidelijk 
meetbaar en liepen vooruit op volumeveranderingen op CT. Verder kon een 
tumorgebied gedefinieerd worden, waarbinnen de celdelingactiviteit zeer hoog was. 
Een theoretische planningstudie slaagde erin om dit tumorvolume met een extra hoge 
dosis te bestralen zonder omliggend gezond weefsel te schaden.
11.6 Conclusies
Radiotherapie is bij patiënten met hoofd- halskanker veelal de behandeling van keuze, 
al of niet in combinatie met chirurgie of chemotherapie. Naast lichamelijk onderzoek en 
anatomische beeldvorming heeft functionele beeldvorming met PET tot nu toe geen 
toegevoegde waarde voor het vinden van de tumor of lymfklieruitzaaiingen. Het gebruik 
van PET voor het definiëren van de tumoruitbreiding ten behoeve van 
bestralingsplanning is nog onderwerp van onderzoek. Sommige PET markerstoffen 
kunnen biologische eigenschappen van de tumor voor en tijdens de behandeling 
gedetailleerd in kaart brengen op basis waarvan mogelijk de behandeling verder 
geïndividualiseerd kan worden. Daarnaast komen er aanwijzingen dat op basis van deze 
biologische eigenschappen tumorgebieden aangetoond kunnen worden waarvoor het 
wellicht zinvol kan zijn een hogere bestralingsdosis toe te dienen om zo de 
genezingskans te vergroten. Voordat deze PET markerstoffen echter klinisch toepast 
kunnen worden, moeten de bevindingen gevalideerd worden. De ontwikkeling van 
nieuwe markerstoffen en de technische vooruitgang van PET zullen de nauwkeurigheid 
en individualisatie van radiotherapie waarschijnlijk doen toenemen met uiteindelijk als 
resultaat een betere controle van de tumor en een beperking van bijwerkingen.
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